Charakterisierung beteiligter Proteine an der Lipidhomöostase von Pseudomonas aeruginosa und Agrobacterium tumefaciens by Groenewold, Maike Kathrin
  
 
 
Characterization of proteins involved in  
lipid homeostasis of Pseudomonas aeruginosa  
and Agrobacterium tumefaciens 
 
 
 
Von der Fakultät für Lebenswissenschaften 
der Technischen Universität Carolo-Wilhelmina zu Braunschweig 
zur Erlangung des Grades  
einer Doktorin der Naturwissenschaften 
(Dr. rer. nat.) 
genehmigte 
D i s s e r t a t i o n 
 
 
 
 
 
 
 
 
 
 
 
 
von  Maike Kathrin Groenewold 
aus  Leer (Ostfriesland) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Referent:  Professor Dr. Dirk Heinz 
2. Referent:  Professor Dr. Dieter Jahn 
eingereicht am: 09.06.2017 
mündliche Prüfung (Disputation) am: 21.08.2017 
 
Druckjahr 2017  
  
 
Vorveröffentlichungen der Dissertation 
 
Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für 
Lebenswissenschaften, vertreten durch den Mentor der Arbeit, in folgenden 
Beiträgen vorab veröffentlicht: 
 
 
Publikationen 
 
Hebecker, S., Krausze, J., Hasenkampf, T., Schneider, J., Groenewold, M., 
Reichelt, J., Jahn, D., Heinz, D. W. and Moser, J. Structures of two bacterial 
resistance factors mediating tRNA-dependent aminoacylation of 
phosphatidylglycerol with lysine or alanine. Proc Natl Acad Sci U S A 112(34): 
10691-10696 (2015). 
 
Groenewold, M. K., Massmig, M., Hebecker, S., Magnowska, Z., Nimtz, M., 
Jahn, D., Heinz, D. W., Jänsch, J. and Moser, J. Identification of a Phosphatidic 
Acid Binding Protein Responsible for the Adaptation of Pseudomonas 
aeruginosa to Anaerobic Biofilm Conditions. In revision. 
 
 
Tagungsbeiträge 
 
Groenewold, M., Krüger, S. and Zegenhagen, L.: Attack and defense – All 
against one. 6. Public Retreat of the Helmholtz International Graduate School 
for Infection Research, Braunschweig (2015). 
 
Groenewold, M. and Moser, J.: Lipid modification in Pseudomonas aeruginosa. 
Protein Crystallography Summer School, St. Andrews, Scotland (2015). 
 
Groenewold, M. and Moser, J.: Lipid homeostasis in Pseudomonas aeruginosa. 
Lehrstuhl für Biologie der Mikroorganismen, Prof. Dr. Narberhaus, Bochum 
(2016). 
 
Groenewold, M., Krüger, S. and Schinner, S.: Lung pathogens: Think big, 
because they do. 7. Public Retreat of the Helmholtz International Graduate 
School for Infection Research, Goslar-Hahnenklee (2016). 
 
 
Posterbeiträge 
 
Groenewold, M., Moser, J. and Heinz, D. W.: PA3911 – a  potential lipid carrier 
protein in Pseudomonas aeruginosa PAO1. 5. Public Retreat of the Helmholtz 
International Graduate School for Infection Research, Goslar-Hahnenklee 
(2014) 
 
Groenewold, M., Wolf, A.-K., Magnowska, Z., Jänsch, L., Heinz, D. W. and 
Moser, J.: PA3911 – a potential lipid carrier protein in Pseudomonas 
aeruginosa. VAAM und DGHM Jahrestagung, Dresden (2014) 
 
  
 
Groenewold, M., Massmig, M., Wolf, A.-K., Jänsch, L., Heinz, D. W. and 
Moser, J.: Characterization of a putative lipid binding protein from 
Pseudomonas aeruginosa. 8. PhD Symposium of the Helmholtz Centre for 
Infection Research, Braunschweig (2014) 
 
Groenewold, M., Massmig, M., Wolf, A.-K., Jänsch, L., Heinz, D. W. and 
Moser, J.: Characterization of a putative lipid binding protein from 
Pseudomonas aeruginosa. VAAM Jahrestagung, Marburg (2015) 
 
Groenewold, M., Massmig, M., Wolf, A.-K., Jänsch, L., Heinz, D. W. and 
Moser, J.: Towards the function of the lipid binding protein PA3911 from 
Pseudomonas aeruginosa. 9. PhD Symposium of the Helmholtz Centre for 
Infection Research, Braunschweig (2015) 
 
Groenewold, M., Massmig, M., Wolf, A.-K., Jänsch, L., Heinz, D. W. and 
Moser, J.: Towards the function of the lipid binding protein PA3911 from 
Pseudomonas aeruginosa. VAAM Jahrestagung, Jena (2016) 
 
 
 I 
 
Table of contents 
 
Abbreviations ........................................................................................................... VII 
1. Introduction ...................................................................................................... 1 
1.1 Composition of bacterial cell envelopes ..................................................... 1 
1.1.1 Glycerophospholipid biosynthesis .............................................................. 1 
1.1.2 Structure and function of bacterial glycerophospholipids ............................ 4 
1.2 Modification of phosphatidylglycerol by aminoacylation .............................. 5 
1.2.1 Synthesis of aminoacylated phosphatidylglycerol in P. aeruginosa ............ 6 
1.2.2 Biochemical characterization of protein PA0919 ........................................ 6 
1.2.3 Model for phosphatidylglycerol modification in P. aeruginosa ..................... 9 
1.2.4 Homologous A-PGH proteins in bacteria ...................................................10 
1.2.5 Introduction to two model organisms containing modified 
glycerophospholipids – characteristics and impact ....................................12 
1.3 Relevance of P. aeruginosa infection in cystic fibrosis patients .................14 
1.4 Proteomics studies ....................................................................................15 
1.4.1 Comparative P. aeruginosa membrane proteomics study .........................16 
1.5 Lipid carrier proteins ..................................................................................18 
1.6 Aim of this study ........................................................................................19 
2. Materials and methods ...................................................................................21 
2.1 Instruments, chemicals and materials .......................................................21 
2.1.1 Instruments ...............................................................................................21 
2.1.2 Chemicals and materials ...........................................................................22 
2.2 Bacterial strains, plasmids and oligodeoxynucleotides ..............................24 
2.2.1 Bacterial strains ........................................................................................24 
2.2.2 Plasmids ...................................................................................................24 
2.2.3 Oligodeoxynucleotides ..............................................................................28 
2.2.4 Synthetic genes ........................................................................................29 
2.3 Sterilization, growth media and media additives ........................................31 
2.3.1 Sterilization ...............................................................................................31 
2.3.2 Media ........................................................................................................31 
2.3.2.1 Luria Bertani medium ................................................................................31 
2.3.2.2 AB medium ...............................................................................................31 
2.3.2.3 Yeast Extract Broth ...................................................................................32 
2.3.2.4 Media for Arabidopsis seedling infection ...................................................32 
2.3.2.5 Medium for protein labeling with L(+)-selenomethionine ............................33 
2.3.3 Additives ...................................................................................................33 
2.4 Microbiological techniques ........................................................................34 
 II 
 
2.4.1 Cultivation of bacterial cells ...................................................................... 34 
2.4.2 Determination of cell density .................................................................... 34 
2.4.3 Storage of bacteria ................................................................................... 34 
2.4.4 Cultivation of E. coli for recombinant protein production ........................... 35 
2.4.5 Monitoring of P. aeruginosa growth behavior ........................................... 35 
2.5 Molecular biological techniques ................................................................ 35 
2.5.1 Preparation of competent cells ................................................................. 35 
2.5.1.1 CaCl2 method for competent E. coli cells .................................................. 35 
2.5.1.2 RbCl method for competent E. coli cells ................................................... 35 
2.5.1.3 CaCl2 method for competent A. tumefaciens cells .................................... 36 
2.5.2 Transformation of competent cells............................................................ 36 
2.5.2.1 E. coli cells ............................................................................................... 36 
2.5.2.2 A. tumefaciens cells ................................................................................. 36 
2.5.3 Preparation of plasmid DNA ..................................................................... 36 
2.5.4 Determination of DNA concentration ........................................................ 37 
2.5.5 Amplification of DNA by polymerase chain reaction ................................. 37 
2.5.6 Agarose gel electrophoresis ..................................................................... 38 
2.5.7 Restriction of DNA .................................................................................... 38 
2.5.8 Dephosphorylation of vector DNA ............................................................ 39 
2.5.9 Purification of PCR products .................................................................... 39 
2.5.10 Ligation of DNA ........................................................................................ 39 
2.5.11 In-Fusion® HD cloning .............................................................................. 39 
2.5.12 Site-directed mutagenesis ........................................................................ 39 
2.5.13 Construction of vectors ............................................................................. 40 
2.5.14 Sequencing .............................................................................................. 42 
2.5.15 Diparental mating with P. aeruginosa ....................................................... 43 
2.5.16 Construction of a markerless P. aeruginosa deletion mutant .................... 43 
2.6 Protein biochemical methods ................................................................... 43 
2.6.1 Recombinant protein production ............................................................... 43 
2.6.1.1 Production of A-PGH protein variants ....................................................... 43 
2.6.1.2 Production of L(+)-selenomethionine labeled A-PGH protein ................... 44 
2.6.1.3 Production of AcvB protein and derivatives .............................................. 44 
2.6.1.4 Production of PA3911 protein and mutant variants ................................... 45 
2.6.2 Cell disruption .......................................................................................... 45 
2.6.2.1 Isolation of the periplasmic fraction (A-PGH and AcvB protein) ................ 45 
2.6.2.2 PA3911 protein variants ........................................................................... 45 
2.6.3 Protein purification by affinity chromatography ......................................... 46 
2.6.3.1 Purification of A-PGH and AcvB protein variants ...................................... 46 
 III 
 
2.6.3.2 Purification of GST-tagged PA3911 protein ...............................................47 
2.6.3.3 Purification of His6- or thioredoxin-His6-S-tagged PA3911 protein .............47 
2.6.4 Dialysis .....................................................................................................48 
2.6.4.1 A-PGH protein variants .............................................................................48 
2.6.4.2 AcvB protein variants ................................................................................48 
2.6.4.3 PA3911 protein variants ............................................................................48 
2.6.5 Protein concentration ................................................................................48 
2.7 Protein characterization.............................................................................49 
2.7.1 Determination of protein concentration ......................................................49 
2.7.2 Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis49 
2.7.3 Protein transfer via blotting ........................................................................50 
2.7.4 Immunochemical detection of StrepII-tagged® proteins .............................51 
2.7.5 Amino acid sequence determination..........................................................52 
2.7.6 Native molecular mass determination by gel permeation chromatography 52 
2.7.7 Determination of molecular mass by electrospray ionization mass 
spectrometry .............................................................................................52 
2.7.8 Thermal Shift Assay ..................................................................................53 
2.7.9 Determination of selenomethionine incorporation by mass spectrometry ..53 
2.7.10 Small-angle X-ray scattering .....................................................................54 
2.7.11 Protein-lipid overlay assay ........................................................................54 
2.8 Lipid analysis ............................................................................................55 
2.8.1 Lipid extraction ..........................................................................................55 
2.8.2 Lipid analysis by thin-layer chromatography ..............................................55 
2.8.3 Liquid scintillation counting ........................................................................56 
2.8.4 Quantification of phosphatidic acid in P. aeruginosa cells .........................56 
2.9 Determination of in vitro A-PGS activity .....................................................56 
2.10 In vitro activity assay for AcvB and VirJ .....................................................57 
2.10.1 Confirmation of P. aeruginosa mutant strain PW7609 ...............................58 
2.10.2 Standard phenotype assays ......................................................................58 
2.10.2.1 Twitching motility .......................................................................................58 
2.10.2.2 Swimming motility .....................................................................................58 
2.10.2.3 Swarming motility ......................................................................................58 
2.10.2.4 Biofilm assay .............................................................................................58 
2.10.3 Phenotype Microarray™ analyses .............................................................59 
2.11 Localization of protein PA3911 in P. aeruginosa .......................................59 
2.11.1 Cultivation for localization studies .............................................................59 
2.11.2 Isolation of the periplasmic and cytoplasmic fraction .................................60 
2.11.3 Isolation of the total membrane fraction .....................................................60 
 IV 
 
2.11.4 Sample preparation and analysis ............................................................. 61 
2.12 Localization of AcvB and VirJ in A. tumefaciens ....................................... 61 
2.12.1 Localization of AcvB and VirJ via alkaline phosphatase fusions ............... 61 
2.12.1.1 Cultivation for localization studies............................................................. 61 
2.12.1.2 Isolation of the periplasmic and cytoplasmic fraction ................................ 62 
2.12.1.3 Determination of alkaline phosphatase activity ......................................... 62 
2.12.1.4 Plate-based assay for the determination of alkaline phosphatase activity in 
whole cells ............................................................................................... 63 
2.12.1.5 Determination of malate dehydrogenase activity ...................................... 63 
2.12.2 Localization of AcvB and VirJ via Western Blot ........................................ 63 
2.12.2.1 Cultivation for localization studies............................................................. 63 
2.12.2.2 Isolation of the soluble cell fractions ......................................................... 64 
2.12.2.3 Analysis of the fractionation efficiency ...................................................... 64 
2.12.2.4 Isolation of the total membrane fraction .................................................... 64 
2.12.2.5 Sample preparation and analyses ............................................................ 65 
2.13 A. tumefaciens infection assays ............................................................... 65 
2.13.1 Potato disc infection assay ....................................................................... 65 
2.13.2 Infection of Arabidopsis seedlings with Agrobacterium ............................. 65 
2.14 Protein crystallization ............................................................................... 66 
2.14.1 Preparation of crystals from A-PGH protein or variants ............................ 66 
2.14.2 Crystal soaking......................................................................................... 67 
2.14.3 Data collection and structure determination .............................................. 67 
2.14.4 Bioinformatical analyses ........................................................................... 68 
2.15 Bioinformatic tools .................................................................................... 69 
3. Results and Discussion ................................................................................ 71 
3.1 Identification of A-PGS amino acids involved in tRNA interaction ............. 71 
3.2 Towards the structure of protein A-PGH from P. aeruginosa .................... 73 
3.2.1 Production and purification of native A-PGH protein ................................. 73 
3.2.2 Production and purification of a selenomethionine derivative ................... 74 
3.3 Thermal Shift Assays ............................................................................... 76 
3.4 Structure determination of protein A-PGH ................................................ 77 
3.4.1 Crystallization of native A-PGH ................................................................ 77 
3.4.2 Crystallization of SeMet-A-PGH ............................................................... 79 
3.4.3 Soaking of native A-PGH crystals with heavy metals................................ 81 
3.4.4 Structure determination, refinement and validation ................................... 82 
3.4.5 Structure description ................................................................................ 86 
3.5 Dali search ............................................................................................... 88 
3.6 Strategies to solve the structure of the C-terminal part of A-PGH ............. 89 
 V 
 
3.6.1 Production and purification of the C-terminal part of protein A-PGH or 
mutant variants .........................................................................................90 
3.6.2 Crystallization experiments for protein A-PGHtrunc or mutant variants ........92 
3.7 Determination of the A-PGH solution structure by small-angle X-ray 
scattering ..................................................................................................92 
3.8 Role of AcvB and VirJ in the lipid homeostasis of A. tumefaciens .............95 
3.8.1 AcvB and VirJ are A-PGH homologs .........................................................95 
3.8.2 Production and purification of AcvB variants and VirJ ...............................95 
3.8.3 In vitro activity assays with AcvB variants and VirJ ....................................96 
3.8.4 Membrane alterations in A. tumefaciens ΔlpiA and ΔacvB strains .............98 
3.9 Localization of AcvB and VirJ in A. tumefaciens ........................................99 
3.9.1 Prediction of signal sequences and transmembrane helices .....................99 
3.9.2 Localization studies using cellular fractions of A. tumefaciens ................. 100 
3.9.3 Protein localization analyses via alkaline phosphatase fusions ............... 101 
3.9.4 Determination of alkaline phosphatase activity in whole cells .................. 104 
3.10 A. tumefaciens infection assays .............................................................. 105 
3.10.1 Tumorigenesis studies on potato discs .................................................... 105 
3.10.2 T-DNA transfer from A. tumefaciens into plant cells ................................ 106 
3.10.2.1 T-DNA transfer assay using β-glucuronidase as a reporter ..................... 106 
3.11 Protein PA3911 is upregulated under anaerobic biofilm conditions ......... 113 
3.12 Orthologous PA3911 sequences and operon prediction .......................... 113 
3.13 Phenotypic characterization .................................................................... 114 
3.13.1 P. aeruginosa PA3911 mutant strain ....................................................... 114 
3.13.2 Growth behavior in complex and minimal medium .................................. 115 
3.13.3 Phenotype Microarray™ analyses ........................................................... 115 
3.13.4 Motility and biofilm formation assays ....................................................... 117 
3.13.4.1 Motility assays ......................................................................................... 117 
3.13.4.2 Biofilm formation ..................................................................................... 118 
3.14 Localization of the PA3911 protein in P. aeruginosa ............................... 119 
3.14.1 Prediction of signal sequences and transmembrane helices ................... 119 
3.14.2 Localization of protein PA3911 in cellular fractions .................................. 119 
3.15 Production and purification of protein PA3911 ......................................... 121 
3.16 Protein-lipid overlay assays ..................................................................... 123 
3.17 Characterization of the potential lipid binding pocket of PA3911 ............. 124 
3.18 Comparative lipid analyses ..................................................................... 128 
3.19 Phosphatidic acid quantification assay .................................................... 128 
4. Summary ....................................................................................................... 133 
5. Outlook .......................................................................................................... 135 
 VI 
 
6. References ................................................................................................... 137 
7. Appendix ...................................................................................................... 151 
Danksagung ............................................................................................................ 155 
 
 
 
  
 
 
  
 
 VII 
 
Abbreviations 
 
A ampere 
A-PG alanyl-phosphatidylglycerol 
A-PGH alanyl-phosphatidylglycerol hydrolase 
A-PGS alanyl-phosphatidylglycerol synthase 
aa amino acid(s) 
aaPG aminoacyl-phosphatidylglycerol 
aaPGS aminoacyl-phosphatidylglycerol synthase(s) 
ACP acyl carrier protein 
ALA 5-aminolevulinic acid 
Anr anaerobic regulation of arginine deiminase and nitrate reduction 
Ap ampicillin 
Apr ampicillin resistance 
AP alkaline phosphatase 
APS ammonium persulfate 
AS acetosyringone  
ATP adenosine triphosphate  
BCIP 5-bromo-4-chloro-3-indolyl phosphate 
BLAST basic local alignment search tool 
bp base pair(s) 
BSA bovine serum albumin 
CAI Codon Adaptation Index 
CAMP cationic antimicrobial peptide 
Cb carbenicillin 
CDC Centers for Disease Control and Prevention 
CDNB 1-chloro-2,4-dinitrobenzene 
CDP-DAG cytidine diphosphate-diacylglycerol 
CF cystic fibrosis 
CFTR cystic fibrosis transmembrane conductance regulator 
Cm chloramphenicol 
CMP cytidine monophosphate 
CoA coenzyme A 
CTP cytidine triphosphate 
CV column volume(s) 
DAG diacylglycerol 
DESY Deutsches Elektronen-Synchrotron 
DMPE dimethyl-phosphatidylethanolamine 
dNTP deoxynucleotide triphosphate 
DOOR2 Database of prOkaryotic OpeRons2 
DPG diphosphatidylglycerol 
ESI-MS electrospray ionization mass spectrometry 
ESRF European Synchrotron Radiation Facility  
FRT Flp recombinase target 
G3P glycerol-3-phosphate 
Gm gentamicin 
GPC gel permeation chromatography 
GST glutathione S-transferase 
GUS β-glucuronidase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG isopropyl-β-D-galactopyranoside 
 VIII 
 
iTRAQ isobaric Tags for Relative and Absolute Quantitation 
Kan kanamycin 
L-PG lysyl-phosphatidylglycerol 
L-PGS lysyl-phosphatidylglycerol synthase 
LB Luria Bertani 
LBP lipid binding protein(s) 
LC liquid chromatography 
LPA lysophosphatidic acid 
MALDI-TOF  matrix-assisted laser desorption ionization-time of flight 
MD malate dehydrogenase 
MES 2-(N-morpholino)ethanesulfonic acid 
MIC minimal inhibitory concentration 
MMPE monomethyl-phosphatidylethanolamine 
MPD 2-methyl-2,4-pentanediol 
MS mass spectrometry 
MWCO molecular weight cut-off 
NaOH sodium hydroxide 
NBT nitrotetrazolium blue 
No. number  
ODxxx  optical density at a wavelength of xxx nm 
orf  open reading frame 
ori origin of replication 
PA phosphatidic acid 
PBS Phosphate Buffered Saline 
PC phosphatidylcholine 
PCR polymerase chain reaction 
PDB Protein Data Bank 
PE phosphatidylethanolamine 
PEG polyethylene glycol 
PG phosphatidylglycerol 
PGP phosphatidylglycerol phosphate  
PI phosphatidylinositol 
PLD phospholipase D 
Pmt phospholipid N-methyltransferase(s) 
PS phosphatidylserine 
psi pounds per square inch 
PVDF polyvinylidene difluoride 
rmsd root-mean-square deviation 
RNase A ribonuclease A 
rpm rounds per minute 
RT room temperature 
SAD single-wavelength anomalous dispersion 
SAH S-adenosylhomocysteine 
SAM S-adenosylmethionine 
SAXS small-angle X-ray scattering 
SCP sterol carrier protein  
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SeMet L(+)-selenomethionine 
SER Surface Entropy Reduction 
 IX 
 
SLS Swiss Light Source 
Spc spectinomycin 
Str streptomycin 
T4SS type IV secretion system 
TAE Tris-acetate-EDTA 
T-DNA transfer-DNA 
TEMED N,N,N’,N’-tetramethylethylene diamine 
Tet tetracycline 
Ti Tumor inducing 
Tic ticarcillin 
TLC thin-layer chromatography 
TM melting temperature(s) 
tRNA transfer RNA 
V volt 
(v/v) volume per volume 
(w/v) weight per volume 
x g gravity   
X-Gluc 5-bromo-4-chloro-3-indolyl-β-D-glucuronide 
YEB Yeast Extract Broth 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
1. Introduction 
 
1.1 Composition of bacterial cell envelopes 
The bacterial cytoplasmic membrane is composed of a glycerophospholipid 
bilayer containing embedded or associated proteins. On the one hand this 
membrane separates the cytoplasm from the surroundings, on the other hand it 
allows the exchange of compounds and signals with the environment, thereby 
functioning as a permeability barrier (1). 
The cell envelope is different in Gram-positive and Gram-negative bacteria (2). 
In Gram-positives the cytoplasmic membrane is surrounded by a thick 
peptidoglycan layer containing teichoic acids. By contrast, a thin peptidoglycan 
layer covered by an additional outer membrane is present in Gram-negatives. 
This outer membrane is composed of glycerophospholipids in the inner leaflet 
and of lipopolysaccharides in the outer leaflet (3, 4). The cytoplasmic 
membrane and the outer membrane enclose a concentrated gel-like matrix, the 
periplasm (5). 
Continuous adaptation to changing environmental conditions is essential for 
bacterial survival. One mechanism is to adjust the glycerophospholipid 
composition which significantly influences the biophysical properties of 
membranes (1). Therefore, the types of fatty acids in glycerophospholipids are 
modified or the ratio of unsaturated to saturated fatty acids is altered, 
influencing the membrane fluidity and permeability. Furthermore, the 
glycerophospholipid head groups can be modified to modulate the membrane 
surface charge leading e.g. to an increase in the bacterial resistance to 
antimicrobial peptides (6). 
 
1.1.1 Glycerophospholipid biosynthesis 
The biosynthesis of glycerophospholipids proceeds by a common biosynthetic 
pathway that takes place on/within the inner leaflet of the cytoplasmic 
membrane (7). To initiate this pathway in bacteria the central precursor 
molecule phosphatidic acid (PA) has to be generated. Therefore, 
glycerol-3-phosphate (G3P) is acylated at the sn1- and sn2-position by 
acyltransferases. Initially one fatty acid is transferred from a thioester of either 
acyl-coenzyme A (acyl-CoA) or acyl-acyl carrier protein (acyl-ACP) to the 
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sn1-position of G3P by PlsB (8) or PlsX and PlsY (9) yielding lysophosphatidic 
acid (LPA). Afterwards the sn2-position is acylated by PlsC resulting in PA, a 
universal glycerophospholipid precursor (6). Glycerophospholipids mostly 
possess saturated fatty acids at the sn1-position and unsaturated fatty acids at 
the sn2-position due to the substrate specificities of the acyltransferases (10). 
Besides the de novo synthesis, PA can be generated by the recycling of already 
existing phospholipids. One possibility is the phosphorylation of the sn3-position 
of diacylglycerol (DAG) by DAG kinases like the integral membrane kinase 
DgkA (11) in Gram-negative bacteria or the soluble kinase DgkB (12) in 
Gram-positive bacteria. Furthermore, PA can be formed by the hydrolysis of a 
glycerophospholipid headgroup by phospholipase D (PLD) (13).  
PA is coupled to diverse headgroup moieties which results in a diversity of 
different glycerophospholipids. An overview is presented in figure 1. 
At first, PA is converted by the cytidine diphosphate diglyceride-synthase CdsA 
with cytidine triphosphate (CTP) to the activated intermediate cytidine 
diphosphate-diacylglycerol (CDP-DAG) (14). CDP-DAG represents the 
branching point in the biosynthetic pathways to either anionic 
glycerophospholipids like phosphatidylglycerol (PG), diphosphatidylglycerol 
(DPG, also named cardiolipin), phosphatidylinositol (PI) and phosphatidylserine 
(PS) or zwitterionic glycerophospholipids like phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC) (15). 
The formation of the zwitterionic glycerophospholipids PE and PC starts with 
the condensation of L-serine and CDP-DAG coupled to the release of cytidine 
monophosphate (CMP) by the PS synthase PssA which results in the formation 
of PS (16). The decarboxylation of the serine headgroup of PS by the 
PS decarboxylase Psd leads to the formation of PE (17). Finally, PE can be 
converted to PC by phospholipid N-methyltransferases (Pmt) catalyzing the 
successive methylation using S-adenosylmethionine (SAM) as a methyl donor 
(18). PC can also be obtained by a reaction catalyzed by the PC synthase Pcs 
condensing CDP-DAG with choline (19). In the literature the presence of PC in 
at least 15% of the organisms from the domain Bacteria was estimated (20). 
In prokaryotes like actinomycetes, myxobacteria and Treponema PI is present 
and comprises up to 25% of the total membrane lipids. For PI formation 
CDP-DAG and myo-inositol are condensed by a PI synthase (21). 
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Figure 1: Overview of glycerophospholipid biosynthesis pathways in bacteria 
according to Geiger et al. (2010) (22)  
The basis for glycerophospholipid biosynthesis is the molecule glycerol-3-phosphate 
(G3P). G3P is coupled to two fatty acids resulting in phosphatidic acid (PA). PA is the 
precursor for cytidine diphosphate-diacylglycerol (CDP-DAG), an important branching 
point for the synthesis of the zwitterionic glycerophospholipids phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) or the anionic glycerophospholipids 
phosphatidylserine (PS), phosphatidylglycerol (PG), diphosphatidylglycerol (DPG) and 
phosphatidylinositol (PI). Glycerophospholipid synthesizing or modifying enzymes are 
depicted in bold font. aa: amino acid, aaPG: aminoacyl-phosphatidylglycerol, ACP: acyl 
carrier protein, CMP: cytidine monophosphate, CoA: coenzyme A, CTP: cytidine 
triphosphate, LPA: lysophosphatidic acid, PGP: phosphatidylglycerol phosphate, Pi: 
inorganic phosphate, PPi: inorganic pyrophosphate, SAH: S-adenosylhomocysteine, 
SAM: S-adenosylmethionine, tRNA: transfer RNA 
 
The anionic glycerophospholipid PG is formed in a two-step reaction. Initially, 
the CMP moiety of CDP-DAG is substituted by G3P by the phosphatidylglycerol 
phosphate synthase PgsA. Then, the obtained phosphatidylglycerol phosphate 
(PGP) is dephosphorylated to PG by the PGP phosphatase PgpA (23). The 
condensation of two PG molecules by the cardiolipin synthase Cls results in 
DPG formation (24). Apart from being a precursor for DPG, PG can be modified 
in certain bacteria by aminoacyl-phosphatidylglycerol synthases (aaPGS). 
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These enzymes transfer an amino acid (e.g. alanine, arginine or lysine) in a 
transfer RNA (tRNA)-dependent reaction to PG yielding 
aminoacyl-phosphatidylglycerol (aaPG) (25). 
Most bacterial membranes are comprised of PE, PG and DPG as the major 
constituents. For Escherichia coli the following membrane composition was 
described: 70-80% PE, 15-20% PG and up to 5% DPG (26). 
Pseudomonas aeruginosa membranes contain similar amounts of the major 
constituents (~73% PE, ~17% PG, ~5% DPG) but additionally the zwitterionic 
glycerophospholipid PC (~4%) (27). PC is present in high amounts in 
Agrobacterium tumefaciens membranes (~22%) and also the DPG content 
(~15%) is significantly increased when compared to E. coli or P. aeruginosa 
membranes. PE together with PG accounts for ~45% of the total 
glycerophospholipid content. Additionally, A. tumefaciens membranes contain 
~15% of monomethyl-PE (MMPE) and 4% of dimethyl-PE (DMPE) (28). 
 
1.1.2 Structure and function of bacterial glycerophospholipids 
Glycerophospholipids represent the major component of bacterial cell 
membranes and consist of a glycerol backbone coupled to a modifiable 
phosphate group (head) and two fatty acids (tails). Due to the hydrophilic head 
and the hydrophobic tail region glycerophospholipids possess an amphipathic 
character resulting in spontaneous bilayer or micelle formation in aqueous 
environments (29). 
Anionic (e.g. PS, PG, DPG and PI) or zwitterionic (e.g. PE and PC) 
glycerophospholipids are able to significantly influence the surface charge of the 
cell membrane. Therefore, the lipid composition has to be balanced in an 
optimal way to maintain the integrity of the cell membrane and the correct 
topology of integral membrane proteins (15). Within bilayers a rapid lateral 
diffusion of glycerophospholipids occurs which allows the formation of lipid 
domains, e.g. DPG-rich domains in the septal and on the polar membrane 
regions of E. coli cells (30). In recent years, it was shown that this lipid domain 
formation can recruit proteins with specific functions to their place of action, e.g. 
enzymes involved in the glycerophospholipid biosynthesis are septally localized 
(31). Additionally, glycerophospholipids are involved in several other cellular 
processes. Anionic glycerophospholipids for instance can stimulate continuous 
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rounds of DNA replication initiation (32), are necessary for protein membrane 
translocation (33) or play an important role in ice nucleation (34). For 
zwitterionic glycerophospholipids the involvement in several solute transport 
systems was described (35). Furthermore, they play a role in proper membrane 
protein folding (36), in the bacterial symbiosis with host plants (37) and in 
virulence (38). 
 
1.2 Modification of phosphatidylglycerol by aminoacylation 
Lipid composition analyses revealed the presence of aminoacylated PG 
derivatives in some bacteria. This modification of PG with different amino acids 
was first described for certain Gram-positives in the 1960s (39–41). In the last 
decades several bacteria containing aaPG were identified and the physiological 
relevance of this lipid modification was explored (42). 
The most abundant aminoacylated PG variants contain a lysine or alanine 
moiety but also the modification with arginine, glycine or ornithine was 
described (42). The structures of lysyl-phosphatidylglycerol (L-PG) and 
alanyl-phosphatidylglycerol (A-PG) are presented in figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structures of the PG derivatives lysyl-phosphatidylglycerol (A) and 
alanyl-phosphatidylglycerol (B) 
The PG derivatives L-PG and A-PG are depicted. R1 and R2 represent fatty acid side 
chains. 
 
The general mechanism for the aminoacylation of PG is the transfer of a 
specific amino acid from the corresponding tRNA onto the 2’ or 3’ hydroxyl 
group of PG by an aaPGS (43, 44). Depending on the utilized amino acid 
glycerophospholipids with zwitterionic (e.g. A-PG) or positive (e.g. L-PG) net 
charges are generated (figure 2). It was proposed that membrane properties 
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like surface charge, fluidity, molecular packing and permeability or 
intermolecular lipid-lipid interactions are modulated by the presence of aaPG 
(45, 46, 43). 
 
1.2.1 Synthesis of aminoacylated phosphatidylglycerol in P. aeruginosa 
Several bacteria that are associated with eukaryotes as pathogens, symbionts 
or commensals contain aaPG in their cell membrane(s) (22). In our laboratory a 
PG-modifying system in the opportunistic pathogen P. aeruginosa was 
discovered and characterized (43, 47–49). The aminoacylation of PG with 
L-alanine is catalyzed under acidic pH conditions by the 
alanyl-phosphatidylglycerol synthase (A-PGS) that is encoded by the open 
reading frame (orf) PA0920 in P. aeruginosa. The N-terminal domain anchors 
the A-PGS in the cytoplasmic membrane, whereas the C-terminal domain faces 
the cytoplasm and catalyzes the transfer of L-alanine from the corresponding 
tRNA to a hydroxyl group of PG resulting in A-PG (47). 
In other aaPGS a flippase function was ascribed to the N-terminal domain 
resulting in the translocation of the respective aaPG into the outer leaflet of the 
cytoplasmic membrane (50, 51). A similar mechanism was proposed for 
P. aeruginosa. 
A-PG synthesis results in an increased resistance of P. aeruginosa in the 
presence of the heavy metal CrCl3, the β-lactam antibiotic cefsulodin, the 
cationic antimicrobial peptide (CAMP) protamine sulphate and the osmolyte 
sodium lactate (43). 
 
1.2.2 Biochemical characterization of protein PA0919 
In a recent study performed in our laboratory the gene product of orf PA0919, 
adjacent to orf PA0920 which encodes for the A-PGS, was biochemically 
characterized. The results of Arendt et al. (2013) (49) are summarized in the 
following chapter. 
Growth analyses revealed a significant phenotype of the P. aeruginosa 
ΔPA0919 deletion mutant in the stationary growth phase under acidic cultivation 
conditions (pH 5.3) when compared to the P. aeruginosa wild type. Moreover, 
the deletion mutant and the wild type strain were cultivated under acidic 
conditions and their lipid composition was analyzed by two-dimensional 
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thin-layer chromatography (TLC). The deletion mutant contains twice as much 
A-PG as the wild type. Wild type growth and lipid composition were restored by 
a chromosomal complementation of the ΔPA0919 mutant. Accordingly, a 
functional role of protein PA0919 in the regulation of the cellular A-PG content 
in P. aeruginosa was proposed. 
A hypothetical promoter region was identified within 430 base pairs (bp) 
upstream of orf PA0919. It is located within orf PA0920. Several promoter 
fragment-reporter gene fusions (430, 206 or 140 bp upstream of orf PA0919 
fused to the reporter gene lacZ) were constructed and the respective promoter 
activity was determined under neutral and acidic growth conditions. The 
analyses revealed that only the activity of the 430 bp promoter fragment was 
significantly induced under acidic growth conditions in the stationary phase 
indicating the presence of a pH-controlled promoter in this region. 
Sequence analyses revealed that protein PA0919 contains a characteristic 
LIPASE_SER motif that is typically found in lipases (52). Based on a sequence 
alignment of PA0919 homologs conserved serine and histidine residues 
(Ser240, Ser307 and His401) were identified and a functional role of protein 
PA0919 in A-PG hydrolysis was proposed. 
To get insight into a potential catalytic function, protein PA0919 and mutant 
variants were heterologously produced in E. coli cells and purified by affinity 
chromatography. Gel permeation chromatography (GPC) analyses revealed 
that purified PA0919 is a monomer and spectroscopic analyses did not indicate 
the presence of a cofactor. Artificial p-nitrophenol derivatives, mostly 
p-nitrophenol esters of amino acid derivatives or aliphatic acid compounds, 
were employed in an in vitro activity assay to monitor the potential hydrolysis 
activity of purified PA0919. Only 4-nitrophenyl esters containing an amino acid 
moiety e.g. alanine, glycine or lysine were accepted by PA0919. The 
determined specific activities were in the same magnitude for all the employed 
amino acid p-nitrophenyl esters suggesting that the amino acid side chain is of 
minor importance for substrate recognition. In contrast, artificial substrates 
lacking an amino group were not hydrolyzed by PA0919 which highlights the 
importance of the amino group for substrate recognition. Based on these 
findings a specific cleavage of the aminoacyl bond in the putative native 
substrate A-PG was proposed. 
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The purified PA0919 mutant proteins S240A, S307A and H401A were also 
analyzed in the in vitro activity assay using the L-alanine 4-nitrophenyl ester 
(similar to the putative natural substrate A-PG) as a substrate. The S240A 
protein variant showed a significantly reduced specific activity of 45% when 
related to the wild type protein. However, no substrate hydrolysis was detected 
for the mutant proteins S307A and H401A which implies that the amino acids 
Ser307 and His401 are of prime importance for PA0919 catalysis. 
To proof whether protein PA0919 is able to hydrolyze the putative natural 
substrate A-PG an in vitro activity assay using radioactively labeled A-PG was 
employed. Therefore, [1-14C]-A-PG was synthesized by the purified A-PGS in 
an in vitro system (47). The polar lipids were extracted, solubilized by 
Triton™ X-100 and incubated with the purified PA0919 protein variants. The 
reaction products were separated by one-dimensional TLC and detected by 
autoradiography. For the wild type protein and the S240A variant the hydrolysis 
product [1-14C]-L-alanine (identical migration to a L-alanine reference sample) 
was observed, whereas it was absent in the experiments using the S307A or 
H401A mutant protein. These results emphasize that protein PA0919 is able to 
hydrolyze A-PG in vitro and functions as an alanyl-phosphatidylglycerol 
hydrolase (A-PGH). Moreover, the amino acids Ser307 and His401 were clearly 
identified as the key residues of A-PGH catalysis. 
To corroborate the physiological relevance of protein A-PGH a localization 
study was performed. P. aeruginosa ΔPA0919 cells containing a 
plasmid-encoded PA0919 gene fused to a Strep-tag® II sequence were 
separated into their soluble (periplasm and cytoplasm) and insoluble (inner and 
outer membrane) fractions. The analyses of the respective cellular fractions 
clearly indicated the presence of A-PGH in the inner membrane of 
P. aeruginosa and it was concluded that the protein is anchored by an 
N-terminal transmembrane helix. The C-terminal protein domain was proposed 
to be directed towards the periplasm based on a previous localization study 
using an alkaline phosphatase (AP) fusion screen (53). This localization permits 
the specific interaction of protein A-PGH with A-PG molecules in the inner 
membrane of P. aeruginosa. 
In recent studies it was shown that the presence of aaPG molecules in the cell 
membrane(s) of different organisms reduces their susceptibility against several 
 9 
 
antimicrobial agents (54, 43, 55). For Staphylococcus aureus a ‘charge 
repulsion’ mechanism for the interaction with CAMPs was proposed (54, 56). 
Anionic glycerophospholipids like PG cause a negatively charged membrane 
surface and their anionic head groups interact with the positively charged 
CAMPs which disorders the membrane structure. In contrast, the presence of 
L-PG results in a more positively charged membrane surface which leads to the 
repulsion of CAMPs and causes resistance. 
The deletion of orf PA0919 resulted in artificially elevated A-PG levels in 
P. aeruginosa. Accordingly, the susceptibility of this strain was analyzed in the 
presence of selected antimicrobial compounds. However, for all the tested 
compounds a reduction instead of the expected increase of the minimal 
inhibitory concentration (MIC) compared to the wild type strain was determined 
indicating the importance of a fine-tuned cellular membrane composition for 
P. aeruginosa resistance. 
 
1.2.3 Model for phosphatidylglycerol modification in P. aeruginosa 
In recent years, research in our laboratory contributed to a comprehensive 
understanding of PG modification in P. aeruginosa (43, 47–49, 57). 
The two enzymes A-PGS and A-PGH responsible for A-PG synthesis and 
hydrolysis, respectively, were discovered and biochemically characterized. 
From the obtained results a model for PG modification under acidic conditions 
in P. aeruginosa was proposed (58) which is presented in figure 3. 
The transmembrane protein A-PGS catalyzes the transfer of the amino acid 
alanine from its Ala-tRNAAla to a hydroxyl group of PG by its C-terminal, 
catalytic domain which is located in the cytoplasm (47). It was proposed, in 
analogy to other aaPGS (50, 51), that A-PG is transferred from the inner to the 
outer leaflet of the cytoplasmic membrane by a flippase function of the 
N-terminal domain. A-PG is subsequently translocated into the inner leaflet of 
the outer membrane by a so far unknown mechanism. The A-PGH protein is 
anchored in the cytoplasmic membrane by one transmembrane helix and is 
localized in the periplasm (49). For A-PG hydrolysis an enzymatic mechanism 
according to lipases was postulated (58). The ester bond between PG and 
alanine is attacked by the hydroxyl group of Ser307 and a covalent 
enzyme-substrate intermediate is formed. The PG moiety is liberated and 
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alanine is released into the periplasm. The participation of key amino acid 
His401 was proposed.  
Biochemical studies highlighted the relevance of an accurately fine-tuned 
cellular A-PG level for the resistance of P. aeruginosa against several 
antimicrobial compounds (43, 58). Dysbalancing the lipid homeostasis 
increased the susceptibility of P. aeruginosa against CAMPs and antimicrobials. 
Based on these findings, the A-PGS/A-PGH system was proposed as a 
promising target for the development of specific inhibitors in order to overcome 
the high antibiotic resistance of P. aeruginosa. 
 
 
Figure 3: Proposed model for PG modification in P. aeruginosa (modified 
according to Arendt (2013) (58)) 
The amino acid alanine is transferred from the corresponding tRNA to a hydroxyl group 
of the glycerophospholipid PG (dark grey-colored lipid). This reaction is catalyzed by 
the C-terminal, catalytic domain of the A-PGS. The N-terminal transmembrane domain 
was shown to be responsible for aaPG flipping across the cytoplasmic membrane in 
several organisms (50, 51). An analogous mechanism was proposed for P. aeruginosa. 
The alanine moiety of A-PG is hydrolyzed by the N-terminally anchored A-PGH 
containing the key residues Ser307 and His401. 
 
1.2.4 Homologous A-PGH proteins in bacteria 
The A-PGH encoding orf PA0919 is located downstream of orf PA0920 which 
encodes for the A-PGS. Sequence alignments revealed that this sequential 
arrangement is conserved in several Gram-negatives (e.g. Agrobacterium 
tumefaciens, Burkholderia phymatum, Ralstonia pickettii and Rhizobium tropici) 
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and A-PGH homologous sequences were identified in α-, β- and 
γ-proteobacteria as well as enterobacteria (49). By contrast, no A-PGH 
homologous sequences were detected in Gram-positives which is in agreement 
with the presence of an N-terminal signal peptide and a previous localization 
study which indicated that the C-terminal part of protein A-PGH faces the 
periplasm (53). 
Some A-PGH homologous proteins are already described in the literature like 
AtvA (acid tolerance and virulence protein A) of R. tropici as well as AcvB 
(Agrobacterium chromosomal virulence protein B) and VirJ of A. tumefaciens. 
For an atvA transposon mutant in R. tropici prolonged generation times under 
acidic cultivation conditions were observed and it was demonstrated that AtvA is 
required for nodulation competitiveness (52). Moreover, a LIPASE_SER motif 
was detected within the AtvA protein sequence. An exchange of the active site 
serine against alanine in the wild type strain resulted in a growth phenotype as 
observed for the atvA transposon mutant. Accordingly, amino acid Ser313 was 
proposed as a key residue for the so far unknown protein function and AtvA was 
proposed to belong to a new family of lipolytic enzymes (52) that might 
down-modulate the L-PG amounts in R. tropici membranes (59). 
A transposon insertion in the acvB gene resulted in an avirulent A. tumefaciens 
strain, but virulence could be restored by a plasmid-encoded acvB gene (60). In 
addition, a paralogous acvB version with a sequence identity of 52% was 
identified in A. tumefaciens strains containing an octopine-type Tumor inducing 
(Ti)-plasmid (61). The VirJ protein corresponds to the C-terminal part of AcvB 
and a plasmid-encoded virJ gene was also able to restore wild type virulence 
for the A. tumefaciens acvB transposon mutant (61). Localization studies 
indicated a periplasmic localization of AcvB and VirJ (62, 63) and a potential 
function as periplasmic chaperones involved in the translocation of 
transfer-DNA (T-DNA) and effector proteins into the plant cell was postulated 
(64, 65). 
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1.2.5 Introduction to two model organisms containing modified 
glycerophospholipids – characteristics and impact 
In the following chapter two bacterial species containing modified 
glycerophospholipids in their cell membranes will be introduced: A. tumefaciens 
as a plant pathogen and P. aeruginosa as an opportunistic human pathogen. 
 
A. tumefaciens: A model organism for the investigation of the type IV 
secretion system 
A. tumefaciens is a ubiquitous rod-shaped, Gram-negative bacterium belonging 
to the class of α-proteobacteria and is present in the soil microflora (66). 
Several Agrobacterium strains cause neoplastic diseases on plants like ‘hairy 
root’ by A. rhizogenes, ‘cane gall’ by A. rubi or ‘crown gall’ by A. tumefaciens 
(67). The broad-host-range phytopathogenic bacterium A. tumefaciens is able 
to initiate tumors on dicotylic and some monocotylic plant species (68). The 
formation of crown galls was first described in 1853 (69) and was connected to 
A. tumefaciens as the causal agent in 1907 (70). 
Researchers became interested in the ‘tumor inducing principle’ (71) altering 
normal host cells into tumor cells. In the 1970s, it was demonstrated that the 
transfer and subsequent genomic integration of the T-DNA region from the 
Ti-plasmid of virulent Agrobacterium species is responsible for the formation of 
crown gall tumors in plants (72). The mechanism of Agrobacterium-mediated 
transformation of host cells was intensively studied in the last decades and so 
Agrobacterium was established as an important model system to study 
host-pathogen interaction. 
Initially, A. tumefaciens cells sense signal molecules (e.g. phenolic or sugar 
compounds) in the soil which were released by wounded plants (73). Upon 
these stimuli the two-component regulatory system VirA/VirG activates the 
transcription of the Ti plasmid-encoded virulence operons (vir genes) (74). The 
respective Vir proteins form the VirB complex, a prototypical type IV secretion 
system (T4SS), which is responsible for the translocation of the T-strand in 
complex with several Vir proteins (referred to as T-complex) and other effector 
proteins from an attached Agrobacterium cell into the plant cell (75). The 
formation of a super-T-complex, additionally containing plant proteins, in the 
plant cytoplasm was postulated by Gelvin (2010) (76). After the 
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super-T-complex is targeted into the nucleus, associated proteins are removed 
from the T-strand prior to its genomic integration (76). Subsequently, the 
infected plant cells produce enzymes which are involved in the syntheses of the 
plant hormones auxin and cytokinin whose activity leads to tumor 
formation (77). Moreover, enzymes involved in opine syntheses are produced. 
Opines are amino acid and sugar phosphate derivatives and serve as a nutrient 
source for A. tumefaciens (78). 
 
P. aeruginosa: A model organism for the investigation of antimicrobial 
resistance 
P. aeruginosa is a ubiquitous, facultative anaerobic Gram-negative bacterium 
belonging to the class γ-proteobacteria. It is highly abundant worldwide but 
especially found in soil, marshes, coastal areas and on tissues of plants and 
animals (79). P. aeruginosa can grow or survive under anaerobic conditions 
using nitrate or nitrite as a terminal electron acceptor or by the fermentation of 
arginine or pyruvate, respectively, and is thus well adapted for the survival 
under microaerobic and anaerobic conditions (80). 
As an opportunistic human pathogen P. aeruginosa can cause serious 
infections e.g. in burn wounds and the urinary or respiratory tract (79). It is one 
of the major nosocomial pathogens and primarily infects immunocompromised 
and cystic fibrosis (CF) patients (81). 
In 2013, the Centers for Disease Control and Prevention (CDC) of the United 
States classified multidrug resistant P. aeruginosa strains as a serious threat. 
From the estimated 51’000 healthcare-associated infections reported to the 
CDC per year about 8% are caused by P. aeruginosa. From the estimated total 
number of P. aeruginosa infections 13% were attributed to multidrug resistant 
strains. Multidrug resistance is one of the major problems in the treatment of 
P. aeruginosa infections and leads to a threefold higher in-hospital mortality rate 
of ~27% when compared to the infection with susceptible organisms (82). 
Besides a high intrinsic resistance against several structurally diverse 
antibiotics, P. aeruginosa is capable of acquiring and developing additional 
resistance mechanisms (83). P. aeruginosa resistance is caused by, inter alia, 
the low permeability of the outer membrane, very efficient and constitutively 
active multidrug efflux systems or/and the enzymatic inactivation or degradation 
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of antibiotics (84, 83). 
Furthermore, P. aeruginosa is able to form biofilms on various surfaces in the 
environment, tissues and medical devices such as catheters (79, 85). Several 
factors were demonstrated to be important for the establishment and 
differentiation of such P. aeruginosa biofilms, e.g. bacterial motility provided by 
functional type IV pili (86), signaling molecules like the second messenger cyclic 
diguanosine-5’-monophosphate (87) or the quorum sensing molecule 
N-(3-oxododecanoyl)-L-homoserine lactone (88) and the production of 
exopolysaccharides (89). 
The existing concentration gradients (e.g. nutrients, oxygen and signaling 
molecules) within a biofilm lead to bacterial cells in different physiological states 
that are adapted to the respective local microenvironment (90, 91). 
P. aeruginosa cells growing in biofilms are protected from diverse 
environmental factors and are up to 1’000 times more resistant against 
antimicrobials than planktonic bacteria (92, 93). Therefore, this lifestyle allows 
for a long-term colonization of surfaces and additionally impedes the eradication 
of P. aeruginosa infections (94). 
 
1.3 Relevance of P. aeruginosa infection in cystic fibrosis patients 
The human genetic disorder CF is caused by mutations in the gene encoding 
for the CF transmembrane conductance regulator (CFTR) which result in a 
defective chloride channel in epithelial cells (95). This defect affects the function 
of different organs like the pancreas, the liver, the gastrointestinal tract and in 
particular the respiratory system (96). In the latter case the airway mucus 
dehydrates and becomes viscous because of an impaired CFTR-mediated 
chloride secretion into the airways and the excessive reabsorption of sodium 
and water at the same time (97). Furthermore, goblet cells hypersecrete mucins 
to the apical surface which leads to plaque generation (98). Plaque 
accumulation results in a reduced mucociliary transport, an important innate 
defense mechanism to clear bacteria, viruses and foreign substances (95). 
If bacteria invade a CF lung they will be trapped in a thick viscous mucus layer 
with a dramatically reduced oxygen tension forming a ‘steep hypoxic gradient’ 
(99). It was demonstrated that infected CF lungs are colonized by a diverse 
bacterial community comprised of more than 15 species, also including 
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facultative and obligate anaerobic species (100). P. aeruginosa is well adapted 
for such microaerophilic to anaerobic conditions (80) and represents the main 
pathogen leading to chronic infections in CF patients (101). 
During the colonization of a CF lung P. aeruginosa undergoes diverse genetic, 
morphological and physiological changes. For instance, the bacterial cells 
switch from the non-mucoid to a mucoid cell type during the progression from 
an intermittent to a chronic infection (99). Mucoid strains produce a matrix 
(biofilm) containing the exopolysaccharide alginate that protects against 
antibiotics, reactive oxygen species and phagocytosis (101, 96). Furthermore, 
the mutation rate is increased resulting in a partial or complete loss of function 
of genes encoding for e.g. virulence factors or multidrug efflux pumps (102, 
103). Besides this the production of virulence factors by P. aeruginosa is 
decreased or stopped resulting in a reduced immune recognition by the host 
and serving as a survival strategy in chronic infections (104). 
Such chronic infections lead to a bacterial bronchitis that evolves into a 
syndrome of bronchiectasis, bronchiolectasis and finally respiratory failure and 
the death of the patient (98). 
The current therapies (mainly antibiotic treatment) only alleviate the symptoms 
of a chronic infection, thereby improving the quality of life and the life 
expectancy of the patients but until today an eradication of the colonizing 
organisms is almost impossible (101). 
 
1.4 Proteomics studies 
The gene expression under defined conditions can be easily analyzed by 
microarray approaches. However, on the translational level further regulation 
mechanisms are involved and so the transcription profile does not directly 
reflect the proteomic pattern (105). Therefore, proteomics studies provide 
complementary information allowing for a detailed understanding of bacterial 
adaptation. 
In the last decades, most proteomics studies focused on the analyses of 
cytoplasmic proteins, primarily due to technical difficulties. However, up to 30% 
of all bacterial genes are encoding for membrane proteins (106). Proteins 
embedded or associated with membranes play important roles in energy and 
signal transduction, metabolism, motility, growth and transport (105). Especially 
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for pathogenic bacteria the cell envelope represents the initial contact point to 
host cells which contains several virulence factors and mediates antibiotic 
resistance (107). Therefore, it is of great interest to also explore bacterial 
pathogenicity by membrane proteomics studies to discover potential biomarkers 
or to develop antimicrobial drugs and vaccines (108). 
For proteomic approaches either gel-based (one- or two-dimensional) or 
non-gel based techniques are employed. Two-dimensional gel-based 
techniques are frequently used to separate mainly soluble proteins by 
isoelectric focusing in the first dimension and a sodium dodecyl sulfate (SDS) 
gel separation in the second dimension (109, 110). After gel staining, the 
respective spots are picked and digested before the peptides are identified by 
mass spectrometry (MS) analyses. 
Since gel-based techniques are not suitable to analyze the membrane 
proteome, non-gel based techniques are used. For this, the entire protein 
mixture is digested and peptides are analyzed by one- or two-dimensional liquid 
chromatography (LC) coupled to MS analyses (105). 
Bioinformatical analyses revealed that the P. aeruginosa genome encodes for 
~2’000 known or putative proteins containing at least one transmembrane 
domain (111). The large-scale proteomics study of Blonder et al. (2004) (111) 
focused on the analysis of the P. aeruginosa PAO1 membrane subproteome by 
using a LC-MS/MS approach. This study was able to detect ~17% of the 
estimated P. aeruginosa membrane proteins involved in e.g. susceptibility, 
adaptation processes or antibiotic resistance. Further development of non-gel 
based techniques will facilitate the identification of more membrane proteins 
and the analyses of post-translational modifications, topology and orientation of 
membrane proteins in membranes (112). 
 
1.4.1 Comparative P. aeruginosa membrane proteomics study 
A recent proteomics study focused on the comparative analysis of the 
P. aeruginosa PAO1 membrane proteome under aerobic and anaerobic biofilm 
conditions which mimic the metabolic changes during CF infection progression 
(113). 
In the study P. aeruginosa biofilms were grown on artificial sputum medium 
agar plates under aerobic and anaerobic conditions. Cells were disrupted by a 
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French Press® and membrane proteins were enriched and separated into the 
inner and outer membrane fraction by an isopycnic gradient centrifugation. 
Integral or strongly associated proteins were precipitated from the two 
membrane fractions and proteolytically digested. The obtained peptides were 
labeled with isobaric Tags for Relative and Absolute Quantitation (iTRAQ), a 
method that allows a simultaneous and relative quantification of peptides in a 
pooled sample via MS analyses (114, 115). The samples were fractionated by 
strong cation exchange chromatography and analyzed by LC-MS/MS. Protein 
identification was performed via Mascot database search and protein regulation 
(aerobic vs. anaerobic biofilm growth) was validated using the in-house 
bioinformatics tool iTRAQassist (116). Approximately 1’000 robustly regulated 
proteins were identified and ranked according to their regulation reliability. 
This proteomics study identified 3’043 proteins which are associated with the 
membrane of P. aeruginosa PAO1. During biofilm cultivation 695 membrane 
proteins (571 and 124 identified proteins in the inner and outer membrane 
fraction) were detected which corresponds to ~35% of the estimated number 
(111) of proteins containing at least one transmembrane domain. 
In general, P. aeruginosa adapted to anaerobic CF lung-like conditions via the 
upregulation of proteins involved in the denitrification pathway, for example Nar, 
Nir, Nor and Nos proteins which are necessary for the assembly of the nitrate, 
nitrite, nitric oxide or nitrous oxide reductase, respectively. Furthermore, 
proteins embedded in the outer membrane functioning as virulence factors, 
receptors or transporters were downregulated. Similar findings were described 
in the literature as a survival strategy of P. aeruginosa during chronic CF 
infections (104). 
The conserved hypothetical proteins PA3913, PA3912 and PA3911 were 
detected among the top 20 upregulated proteins in the inner membrane fraction 
under anaerobic biofilm conditions and are encoded by a putative operon as 
described by Filiatrault et al. (2006) (117). 
The gene expression of operon PA3913-PA3912-PA3911 is upregulated under 
reduced oxygen concentrations of 2% or 0.4% (118) and under anaerobic 
conditions in the presence of nitrate as a terminal electron acceptor (119, 118). 
Gene expression of PA3912 or PA3913 was induced under oxygen limited 
conditions in response to nitrate and nitrite (120) or under anaerobic conditions 
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with nitrate (121), respectively. Furthermore, gene expression was upregulated 
for all three genes during the cultivation in enhanced synthetic sputum medium 
(122). 
Growth of PA3912 and PA3913 transposon mutants was significantly impaired 
or abolished under anaerobic conditions with nitrate as the electron acceptor. 
Also the presence of nitrite or arginine did not allow for anaerobic growth of both 
transposon mutants which indicates the general requirement of PA3912 and 
PA3913 for anaerobic growth (117). These findings are supported by the 
identification of a binding site for the major anaerobic transcriptional regulator 
Anr (anaerobic regulation of arginine deiminase and nitrate reduction) in the 
promoter region of PA3913 (119, 117). 
The genes PA3913 and PA3912 encode for potential proteases with a 
peptidase family U32 signature, whereas gene PA3911 encodes for a 
conserved hypothetical protein with homology to lipid carrier proteins of the 
sterol carrier protein (SCP)-2 sterol transfer family (117). A transposon mutant 
of PA3912 revealed impaired swarming and swimming motility, whereas the 
biofilm formation was increased compared to the PAO1 wild type (123). By 
contrast, no functional role for proteins PA3913 and PA3911 is described in the 
literature to date. 
 
1.5 Lipid carrier proteins 
The comparative proteomics study described in chapter 1.4.1 identified protein 
PA3911 as the second-most significantly upregulated protein under anaerobic 
biofilm conditions mimicking the situation during a CF infection (113). In the 
literature PA3911 is described as a conserved hypothetical protein which 
shares homology with lipid carrier proteins of the SCP-2 family (117). 
Research in the field of soluble fatty acid binding proteins and lipid binding 
proteins (LBP) facilitating the intracellular transport, metabolism and storage of 
these poorly soluble ligands started in the early 1970s with the investigation of 
the mammalian fatty acid binding protein (124). Since then a variety of soluble 
LBP was studied which led to the discovery of a very prominent domain in LBP, 
the SCP-2 domain. This domain can be found in stand-alone form or fused with 
other domains in bacteria, archaea and eukaryotes. Due to diverse 
architectures in multidomain proteins SCP-2 might have multiple functions in 
 19 
 
various cellular contexts (125). 
Although the sequence homology of LBP is very low nearly all possess a 
hydrophobic cavity to accommodate specific ligands (126). In case of the 
mammalian SCP-2 in vitro binding studies revealed a broad ligand spectrum 
(e.g. fatty acids, fatty acyl CoA esters, cholesterol and phospholipids) and the 
protein is, therefore, also known as the non-specific lipid transfer protein (127). 
The 58 kDa multidomain protein SCP-X is composed of an N-terminal 
3-ketoacyl CoA thiolase and a C-terminal SCP-2 domain which can be cleaved 
off post-translationally (128). Cytosolic SCP-2 plays a role in the cellular uptake 
of cholesterol and fatty acids as well as in the intracellular cholesterol transport 
to the plasma membrane, whereas peroxisomal SCP-2 takes part in the 
β-oxidation of fatty acids (127). 
From all branches of life three-dimensional structures of proteins containing a 
SCP-2 domain are available. SCP-2 domains have an α/β fold consisting of a 
five-stranded β-sheet surrounded by five α-helices (126). The secondary 
structure elements and their spatial orientation are highly conserved as 
demonstrated by the superposition of 22 three-dimensional structures 
containing SCP-2 domains (125). Most SCP-2 domains contain an internal 
cavity which is large enough to accommodate bulky hydrophobic ligands, but 
their size and shape can differ widely (126, 129, 130). Another characteristic of 
SCP-2 domains is a surface patch with a positive electrostatic potential which is 
predominantly located at the opening for ligand access/exit (125). This patch is 
proposed to interact with membranes via electrostatic interactions (125). 
Despite several decades of research the functional diversity of proteins 
containing SCP-2 domains still has to be discovered, particularly for SCP-2 
proteins from bacteria or plants. 
 
1.6 Aim of this study 
In bacteria, aminoacylation of the glycerophospholipid PG represents an 
adaptation strategy to various stress conditions and was demonstrated to 
increase the resistance against several antimicrobials. In the opportunistic 
pathogen P. aeruginosa PG is modified with L-alanine, yielding A-PG, under 
acidic conditions (43). In recent studies the enzymes A-PGS and A-PGH 
responsible for A-PG synthesis and hydrolysis were biochemically characterized 
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(43, 47–49). It was demonstrated that a fine-tuned cellular A-PG content is 
critical for the bacterial susceptibility in the presence of antimicrobials. To get 
insight into the underlying molecular principle of A-PG hydrolysis in 
P. aeruginosa it was intended to elucidate the three-dimensional structure of 
protein A-PGH by X-ray crystallography. 
 
The sequential arrangement of orthologous A-PGS and A-PGH genes is 
conserved in several Gram-negatives (49). The proteins LpiA or AcvB and VirJ 
of A. tumefaciens were identified as homologous A-PGS and A-PGH proteins, 
respectively, and a functional role in L-PG synthesis or hydrolysis was 
proposed. To elucidate the biochemical function of these proteins in vitro activity 
assays using purified wild type protein or active site mutants had to be 
performed. Furthermore, the localization of AcvB and VirJ in A. tumefaciens had 
to be analyzed. In cooperation with Prof. Franz Narberhaus and 
Dr. Meriyem Aktas from Ruhr-University Bochum A. tumefaciens ΔlpiA or 
ΔacvB mutants had to be characterized concerning their growth behavior and 
lipid composition. Besides this, the physiological relevance of LpiA and AcvB in 
tumorigenesis of the phytopathogenic bacterium A. tumefaciens had to be 
investigated. 
 
A comparative proteomics study identified the conserved hypothetical protein 
PA3911 as the second-most significantly upregulated protein under anaerobic 
CF lung-like conditions (113). For phenotypical characterization a P. aeruginosa 
PA3911 transposon mutant had to be analyzed with respect to growth, lipid 
composition, motility, biofilm formation and antimicrobial susceptibility. 
Furthermore, the cellular localization of PA3911 in P. aeruginosa PAO1 had to 
be studied. Protein PA3911 shares homology with lipid carrier proteins of the 
SCP-2 family (117). Accordingly, the lipid binding capability of the purified wild 
type protein and of protein variants had to be explored. 
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2. Materials and methods 
 
2.1  Instruments, chemicals and materials 
 
2.1.1 Instruments  
 
Table 1: List of instruments used in this study 
instrument model manufacturer 
agarose gel electrophoresis 
chamber 
Mini-Sub
®
 Cell GT Bio-Rad 
agarose gel documentation DeVision G system Science Tec 
autoclave LVSA 50/70 Zirbus 
blot machine Trans-Blot
®
 Turbo™ Bio-Rad 
blue-light transilluminator Flu-O-Blu Biozym Scientific GmbH 
centrifuge Avanti
®
 J-30I Beckman Coulter GmbH 
Avanti
®
 J-E Beckman Coulter GmbH 
Megafuge
®
 1.0R Heraeus
®
 
MiniSpin
®
 Eppendorf 
Optima™ L-90K ultracentrifuge Beckman Coulter GmbH  
Biofuge
®
 fresco Heraeus
®
 
cell disruptor FastPrep
®
-24 MP Biomedicals 
clean bench HERAsafe
®
 Heraeus
®
  
FPLC ÄKTAexplorer™ GE Healthcare 
ÄKTApurifier™ GE Healthcare 
French Press
® 
French
®
 Pressure Cell Press Polytec 
French Press
® 
cell 
French
®
 Pressure Cell 
Thermo Electron 
Corporation 
gel scanner BIO-5000 Plus VIS gel scanner Serva 
magnetic stirrer IKAMAG
® 
KMO-1 IKA
®
 
VARIOMAG
®
 Multipoint HP15 Thermo Scientific 
mass spectrometer Orbitrap Fusion™ Thermo Scientific 
microplate incubator OmniLog
® 
Biolog 
microplate reader Model 680 Bio-Rad 
Varioskan
®
 Flash Thermo Scientific 
pH determination CG 842 Schott 
photometer 
Ultrospec 2000 
Amersham Pharmacia 
Biotech 
Libra S22 Biochrom 
pipettes 0.5-10 µl Research
®
 Eppendorf 
10-100 µl Research
 ® Eppendorf 
100-1’000 µl Research
®
 Eppendorf  
10 ml Research plus ABI Med 
5-100 µl Xplorer
®
, 8 channels Eppendorf 
50-1’200 µl Xplorer
®
, 8 channels Eppendorf 
power supply 
electrophoresis 
PowerPac™ Basic 300 V Bio-Rad 
real-time PCR  C1000™ Thermal Cycler with 
CFX96™ real-time system 
Bio-Rad 
rocker PMR-30 Grant 
roller mixer  RM5 Assistent 
scales BL1500 Sartorius 
BP61S Sartorius 
SBA52 Scaltec 
scintillation counter Tri-Carb
®
 2900TR PerkinElmer 
SDS-PAGE system Mini-PROTEAN
®
 Tetra Cell Bio-Rad 
shakers 305/3020 GFL
®
 
CH-4103 Infors HT 
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instrument model manufacturer 
spectrophotometer  
NanoDrop™ ND-1000 
PEQLAB Biotechnologie 
GmbH 
Speed Vac
®
 SPD101B Savant 
thermocycler Tpersonal Biometra 
C1000™ Thermal Cycler Bio-Rad 
thermomixer  Thermomixer compact Eppendorf 
TLC plate heater TLC plate heater III CAMAG
®
 
UV-VIS spectrophotometer V-650 Jasco 
vortex Vortex-Genie
®
 2 Scientific Industries™ 
water purification system  Milli-Q
®
 system Merck Millipore 
X-ray generator MicroMax™-007 HF Rigaku 
 
2.1.2 Chemicals and materials 
 
Table 2 summarizes the chemicals and materials used in this study. Chemicals 
not specifically listed were purchased from the following manufacturers: Fluka®, 
Merck, Riedel-de Haën®, Roche, Roth® and Sigma-Aldrich® (quality grade p.a.). 
 
Table 2: List of utilized chemicals and materials 
application product manufacturer 
antibodies and 
detection reagents 
5-bromo-4-chloro-3-indolyl phosphate  Roth
®
 
Anti-mouse IgG (Fc-specific)-alkaline 
phosphatase antibody produced in goat 
Sigma-Aldrich
®
 
nitrotetrazolium blue  Roth
®
 
Penta-His mouse monoclonal IgG antibody 
BSA-free 
QIAGEN 
Strep-Tactin
®
 AP conjugate iba 
blotting Immobilon-P membrane, polyvinylidene 
difluoride, pore size 0.45 µm 
Merck Millipore 
blotting paper, 150 x 150 mm, 550 g/m² neoLab
® 
chemicals avidin Calbiochem
®
 
Bradford reagent Sigma-Aldrich
®
 
[1-
14
C]-L-alanine  Moravec Biochemicals 
1-chloro-2,4-dinitrobenzene Sigma-Aldrich
®
 
chloramphenicol Roth
®
 
crystal violet Merck 
D-desthiobiotin iba 
deoxynucleotide triphosphate mixture New England BioLabs
®
 
GelStar
®
 Nucleic Acid Gel Stain Lonza 
InstantBlue™ Expedeon 
isopropyl-β-D-galactopyranoside  GERBU Biotechnik  
minocycline hydrochloride Sigma-Aldrich
®
 
Nafcillin sodium salt Sigma-Aldrich
®
 
oligodeoxynucleotides  
Biomers, Invitrogen, 
Eurofins Genomics  
OptiPhase HighSafe 2 PerkinElmer 
oxacillin sodium salt monohydrate Sigma-Aldrich
®
 
polymyxin B Sigma-Aldrich
® 
L(+)-selenomethionine ACROS Organics™ 
Sodium chloride (NaCl) Fisher Chemical 
Strep-Tactin
®
 regeneration buffer  iba 
SYPRO
®
 Orange Protein Gel Stain  Thermo Fisher Scientific 
thiamphenicol Sigma-Aldrich
®
 
crystallization CrystalCap-T™ Cap/Vial HR 8-116 with 
loops 
Hampton Research 
CrystalClear Manco
®
 Inc. 
 23 
 
application product manufacturer 
Crystalgen 24 Well SuperClear™ Plate 
(REF 23-252)  
Jena Bioscience 
INTELLI-PLATE
®
, 96-well 
(REF 102-0001-03) 
Art Robbins Instruments 
NeXtal crystallization screens QIAGEN 
enzymes Antarctic Phosphatase New England BioLabs
®
 
Benzonase
®
  Merck Millipore 
Phusion
®
 High-Fidelity DNA Polymerase New England BioLabs
®
 
restriction endonucleases New England BioLabs
®
 
T4 DNA Ligase New England BioLabs
®
 
kits In-Fusion
®
 HD Cloning Kit Clontech
®
 Laboratories 
QIAprep Spin Miniprep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
QuikChange Site-Directed Mutagenesis Kit Agilent Technologies 
markers  Gel Filtration Markers Kit for Protein 
Molecular Weights 12’000-200’000 Da 
Sigma-Aldrich
®
 
GeneRuler™ DNA Ladder Mix  Thermo Fisher Scientific 
MassRuler™ DNA Ladder Mix  MBI Fermentas  
PageRuler™ Prestained Protein Ladder Thermo Fisher Scientific 
Unstained Protein Molecular Weight Marker Thermo Fisher Scientific 
microplate 
appliance 
Breathe-Easy™ sealing membrane Diversified Biotech 
microplate, 96-well flat bottom  
(REF 82.1581.001) 
Sarstedt 
microplate, 96-well round bottom, 
polypropylene  
Nunc™ 
Phenotype 
microarray™ 
IF-0 medium Biolog 
IF-10 medium  Biolog 
MicroPlates™ PM9 to PM20 Biolog 
Redox Dye Mix A Biolog 
protein purification, 
concentration and 
dialysis 
Amicon
®
 Ultra-0.5 device (molecular weight 
cut-off (MWCO): 10 kDa) 
Merck Millipore 
Chelating Sepharose™ Fast Flow GE Healthcare 
dialysis tubing membrane visking  
(MWCO: 14 kDa)  
Roth
®
  
illustra NAP-5 GE Healthcare 
Poly-Prep
®
 Chromatography Column  
(0.8 x 4 cm) 
Bio-Rad 
Protino
®
 Glutathione Agarose 4B Macherey-Nagel  
Strep-Tactin
®
 Superflow
®
  iba 
Strep-Tactin
®
 Superflow
®
 high capacity iba 
Superdex™ 200 Increase 5/150 GL GE Healthcare 
Superdex™ 200 HR 10/30 GE Healthcare 
TALON
® 
metal affinity resin Clontech
®
 Laboratories 
Vivaspin
®
 Turbo 4 Sartorius stedim biotech 
others cuvette (REF 67.742) Sarstedt 
pH indicator test stripes (pH Fix 4.5-10.0)  Macherey-Nagel  
silica glass cuvette type 115F-QS Hellma
® 
sterile filters Filtropur S (Ø 0.2 or 0.45 µm) 
or Filtropur BT50 (Ø 0.22 µm), 500 ml 
Sarstedt 
Membrane Lipid Strips™ P-6002 Echelon Biosciences 
thermal shift assay Microseal
®
 ‘B’ seal Bio-Rad 
Multiplate™ PCR plates 96-well, clear Bio-Rad 
thin-layer 
chromatography  
TLC plate Alugram
®
 SIL G/UV254 Macherey-Nagel 
molybdatophosphoric acid Roth
® 
Molybdenum Blue spray reagent  Sigma-Aldrich
®
 
ninhydrin spray solution Merck 
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2.2  Bacterial strains, plasmids and oligodeoxynucleotides  
 
2.2.1 Bacterial strains  
 
The bacterial strains used in this work are listed in table 3. 
 
Table 3: Overview of the bacterial strains used in this study 
strain genotype reference 
Agrobacterium tumefaciens 
C58 wild type C. Baron (Montreal, Canada) 
C58 ΔacvB markerless deletion mutant of orf 
Atu2522 from A. tumefaciens C58 
M. Aktas, Ruhr-University 
Bochum, unpublished 
C58 ΔlpiA markerless deletion mutant of orf 
Atu2521 from A. tumefaciens C58 
M. Aktas, Ruhr-University 
Bochum, unpublished 
Escherichia coli 
BL21(λDE3) B F
-
 dcm ompT hsdS(rB
-
 mB
-
) gal 
λ(DE3)  
Stratagene, (131) 
DH10B F
-
 araD139 Δ(ara, leu)7697 ΔlacX74 
galU galK rpsL deoR Φ80dlacZΔM15 
endA1 nupG recA1 mcrA 
Δ(mrr hsdRMS mcrBC), Str
r
 
Invitrogen, (132) 
Rosetta™ (DE3) 
pLysS 
F
-
 ompT hsdSB(rB
- 
mB
-
) gal dcm (DE3) 
pLysSRARE, Cm
r
 
Novagen 
ST18 S17 λpir ΔhemA (133) 
Stellar™ F
-
, endA1, supE44, thi-1, recA1, relA1, 
Φ80d lacZΔ M15, ΔmcrA, 
Δ(lacZYA-argF) U169, λ–, phoA, 
Δ(mrr hsdRMS mcrBC), gyrA96  
Clontech
®
 Laboratories 
Pseudomonas aeruginosa 
PAO1 wild type (79) 
PAO1 pUCP20T-
PPA3911-PA3911 
PAO1 containing vector 
pUCP20T-PPA3911-PA3911, Cb
r
 
this work 
MPAO1 wild type of transposon mutant bank  (134) 
PW7609 PA3911-C03::ISphoA/hah, Tet
r
 (134) 
 
2.2.2 Plasmids 
 
The plasmids used in this work are listed in table 4. Correct integration of the 
insert sequence into the respective vector was verified by sequencing. 
 
Table 4: List of plasmids used in this study 
plasmid description reference 
pET22b(+) vector for recombinant protein production in 
E. coli, provides a T7 promoter, an 
N-terminal pelB secretion signal sequence 
and a C-terminal His6-tag, Ap
r
 
Novagen, 
Merck 
pET22b(+)Strep pET22b(+) derivative providing a C-terminal 
Strep-tag
®
 II, cloned into HindIII/XhoI sites, 
Ap
r
 
(49) 
pET22b(+)PA0919-Strep  pET22b(+)Strep derivative encoding amino 
acids 34-427 of orf PA0919 from 
P. aeruginosa cloned into NcoI/HindIII sites, 
employed for production of A-PGH fused to 
an N-terminal pelB sequence and a 
C-terminal Strep-tag
®
 II, Ap
r
 
(49) 
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plasmid description reference 
pET22b(+)PA0919trunc-Strep pET22b(+)Strep derivative encoding amino 
acids 203-427 of orf PA0919 from 
P. aeruginosa cloned into NcoI/HindIII sites, 
employed for production of A-PGHtrunc fused 
to an N-terminal pelB sequence and a 
C-terminal Strep-tag
®
 II, Ap
r 
(135) 
pET22b(+)PA0919trunc-
Strep/AAK 
pET22b(+)PA0919trunc-Strep derivative,  
amino acids E176EK were changed to AAK, 
Ap
r
 
this work 
pET22b(+)PA0919trunc-
Strep/AAA 
pET22b(+)PA0919trunc-Strep derivative, 
amino acids E176EK were changed to AAA, 
Ap
r
 
this work 
pET22b(+)Strep_pelB_acvB
ΔAS1-24 
pET22b(+)Strep derivative encoding amino 
acids 25-456 of orf Atu2522 from 
A. tumefaciens, employed for production of 
AcvB fused to an N-terminal pelB sequence 
and a C-terminal Strep-tag
®
 II, Ap
r
 
(136) 
pET22b(+)Strep_pelB_acvB
ΔAS1-24-S269A 
pET22b(+)Strep_pelB_acvBΔAS1-24 
derivative, amino acid serine 269 of AcvB 
was changed to alanine, Ap
r
 
(137) 
pET22b(+)Strep_pelB_acvB
ΔAS1-24-S336A 
pET22b(+)Strep_pelB_acvBΔAS1-24 
derivative, amino acid serine 336 of AcvB 
was changed to alanine, Ap
r
 
(137) 
pET22b(+)Strep_pelB_acvB
ΔAS1-24 H433A 
pET22b(+)Strep_pelB_acvBΔAS1-24 
derivative, amino acid histidine 433 of AcvB 
was changed to alanine, Ap
r
 
(137) 
pET22b(+)Strep_pelB_acvB
ΔAS1-24-H433N 
pET22b(+)Strep_pelB_acvBΔAS1-24 
derivative, amino acid histidine 433 of AcvB 
was changed to asparagine, Ap
r
 
(137) 
pET22b(+)Strep_pelB_virJ 
ΔAS1-21 
pET22b(+)Strep derivative containing the 
codon-optimized sequence of virJ (amino 
acids 22-255) from A. tumefaciens, 
employed for production of VirJ fused to an 
N-terminal pelB sequence and a C-terminal 
Strep-tag
®
 II, Ap
r
 
(136) 
pET28b(+) vector for recombinant protein production, 
PT7, oripBR322, lacI, N-terminal His6-tag, Kan
r
 
Novagen 
pET28b(+)PA0903 derivative of pET28b(+) encoding orf 
PA0903 (alanyl-tRNA synthetase) from 
P. aeruginosa inserted into the NdeI/BamHI 
sites; production of protein PA0903 fused to 
an N-terminal His6-tag, Kan
r
       
(47) 
pET28b(+)-PA3911 derivative of pET28b(+) containing the 
codon-optimized sequence of orf PA3911 
from P. aeruginosa inserted into the 
NcoI/XhoI sites; production of protein 
PA3911 fused to an N-terminal His6-tag, 
Kan
r
  
this work  
pET32a(+) vector for recombinant protein production, 
PT7, oripBR322, lacI, N-terminal 
thioredoxin-His6-S-tag, C-terminal His6-tag, 
Ap
r
 
Novagen 
pET32a(+)/PA3911opt 
ΔAS1-19 
derivative of pET32a(+) encoding amino 
acids 20-171 of orf PA3911 
(codon-optimized sequence) from 
P. aeruginosa inserted into the SacI/NotI 
sites; production of protein PA3911 fused to 
an N-terminal thioredoxin-His6-S-tag, 
PreScission™ protease specific cleavage 
site, Ap
r
 
(138) 
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plasmid description reference 
pET32a(+)-PA3911 derivative of pET32a(+)/PA3911opt ΔAS 
1-19 containing the codon-optimized 
sequence of orf PA3911 from P. aeruginosa 
(synthetic fragment) inserted into the 
EcoRI/NotI sites; production of protein 
PA3911 fused to an N-terminal 
thioredoxin-His6-S-tag, Ap
r
 
this work 
pET32a(+)-PA3911-L56R derivative of pET32a(+)-PA3911, amino 
acid leucine 56 of PA3911 was changed to 
arginine, Ap
r
 
(139) 
pET32a(+)-PA3911-L56W derivative of pET32a(+)-PA3911, amino 
acid leucine 56 of PA3911 was changed to 
tryptophan, Ap
r
 
(139) 
pET32a(+)-PA3911-L58R derivative of pET32a(+)-PA3911, amino 
acid leucine 58 of PA3911 was changed to 
arginine, Ap
r
 
(139) 
pET32a(+)-PA3911-L58W derivative of pET32a(+)-PA3911, amino 
acid leucine 58 of PA3911 was changed to 
tryptophan, Ap
r
 
(139) 
pET32a(+)-PA3911-V69R derivative of pET32a(+)-PA3911, amino 
acid valine 69 of PA3911 was changed to 
arginine, Ap
r
 
(139) 
pET32a(+)-PA3911-V69W derivative of pET32a(+)-PA3911, amino 
acid valine 69 of PA3911 was changed to 
tryptophan, Ap
r
 
(139) 
pET32a(+)-PA3911-F95R derivative of pET32a(+)-PA3911, amino 
acid phenylalanine 95 of PA3911 was 
changed to arginine, Ap
r
 
(139) 
pET32a(+)-PA3911-F95W derivative of pET32a(+)-PA3911, amino 
acid phenylalanine 95 of PA3911 was 
changed to tryptophan, Ap
r
 
(139) 
pET32a(+)-PA3911-L114R derivative of pET32a(+)-PA3911, amino 
acid leucine 114 of PA3911 was changed to 
arginine, Ap
r
 
(139) 
pET32a(+)-PA3911-L114W derivative of pET32a(+)-PA3911, amino 
acid leucine 114 of PA3911 was changed to 
tryptophan, Ap
r
 
(139) 
pEX18Ap gene replacement vector, oriT
+
, sacB
+
, Ap
r
  (140) 
pEX18Ap-ΔPA3911 pEX18Ap derivative with 460 bp upstream 
sequence of orf PA3911, gentamicin 
resistance cassette of pPS858 (flanked by 
BamHI sites) and 649 bp downstream of orf 
PA3911, inserted into KpnI/HindIII sites, 
Ap
r
, Gm
r 
 
this work 
pFLP2 source of Flp recombinase, Ap
r
 (140) 
pFU84 pSC101* vector backbone with phoA gene 
from E. coli inserted into SalI/NotI sites, Ap
r
 
(141) 
pFU84_QC pFU84 derivative with silent mutation in the 
codon of amino acid 298 of the phoA gene 
to eliminate the NcoI restriction site, Ap
r
 
(142) 
pGEX-6P-1 vector for recombinant protein production, 
Ptac, oripBR322, N-terminal glutathione 
S-transferase (GST)-tag, PreScission™ 
protease specific cleavage site, Ap
r
 
GE Healthcare 
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plasmid description reference 
pGEX-6P-1/PA3911opt 
ΔAS1-19 
derivative of pGEX-6P-1 encoding amino 
acids 20-171 of orf PA3911 
(codon-optimized sequence) from 
P. aeruginosa inserted into the EcoRI/NotI 
sites; production of protein PA3911 fused to 
an N-terminal GST-tag, PreScission™ 
protease specific cleavage site, Ap
r
 
(138) 
pGEX-6P-1-PA3911 derivative of pGEX-6P-1/PA3911opt 
ΔAS 1-19 containing the codon-optimized 
sequence of orf PA3911 from P. aeruginosa 
inserted into the EcoRI/NotI sites; 
production of protein PA3911 fused to an 
N-terminal GST-tag, Ap
r
 
this work 
pPS858 source of gentamicin resistance cassette, 
Ap
r
, Gm
r
  
(140) 
pTrc200 trc promoter production vector, lacI
q
, Spc
r
, 
Str
r
 
(143) 
pTrc200 ‘phoA pTrc200 derivative encoding amino acids 
34-471 of phoA gene (signal sequence 
removed, silent mutation in the codon of 
amino acid 298 to eliminate the NcoI 
restriction site) from E. coli cloned into 
NcoI/HindIII sites, Spc
r
, Str
r
 
(142) 
pTrc200 phoA pTrc200 derivative containing the phoA 
gene (silent mutation in the codon of amino 
acid 298 to eliminate the NcoI restriction 
site) from E. coli cloned into NcoI/HindIII 
sites, Spc
r
, Str
r
  
(142) 
pTrc200 leader acvB ‘phoA pTrc200 derivative containing a synthetic 
fragment encoding for the acvB leader 
sequence (amino acids 1-24) and amino 
acids 34-471 of phoA gene (signal 
sequence removed), cloned via In-Fusion
®
 
HD Cloning, Spc
r
, Str
r
 
(142) 
pTrc200 leader virJ ‘phoA pTrc200 derivative containing a synthetic 
fragment encoding for virJ leader sequence 
(amino acids 1-22) and amino acids 34-471 
of phoA gene (signal sequence removed), 
cloned via In-Fusion
®
 HD Cloning, Spc
r
, Str
r
 
(142) 
pTrc200_acvB_Strep pTrc200 derivative encoding for orf Atu2522 
from A. tumefaciens, employed for 
production of AcvB fused to a C-terminal 
Strep-tag
®
 II, Spc
r
, Str
r
 
 
S. Hebecker, 
unpublished 
pTrc200_acvB_Strep-S269A pTrc200_acvB_Strep derivative, amino acid 
serine 269 of AcvB was changed to alanine, 
Spc
r
, Str
r
 
this work 
pTrc200_acvB_Strep-S336A pTrc200_acvB_Strep derivative, amino acid 
serine 336 of AcvB was changed to alanine, 
Spc
r
, Str
r
 
this work 
pTrc200_acvB_Strep-H433A pTrc200_acvB_Strep derivative, amino acid 
histidine 433 of AcvB was changed to 
alanine, Spc
r
, Str
r
 
this work 
pTrc200_acvB_Strep-H433N pTrc200_acvB_Strep derivative, amino acid 
histidine 433 of AcvB was changed to 
asparagine, Spc
r
, Str
r
 
this work 
pTrc200_virJ_Strep pTrc200 derivative containing a synthetic 
fragment encoding for the virJ gene from 
A. tumefaciens, employed for production of 
VirJ fused to a C-terminal Strep-tag
®
 II, 
cloned via In-Fusion
®
 HD Cloning, Spc
r
, Str
r
 
S. Hebecker, 
unpublished 
 28 
 
plasmid description reference 
pUCP20T E. coli-P. aeruginosa shuttle vector, Cb
r
 (144) 
pUCP20T-PPA3911-PA3911 pUCP20T derivative containing the putative 
promoter (500 bp upstream of orf PA3911), 
orf PA3911 and the Strep-tag
®
 II sequence, 
cloned into XbaI/BamHI sites, Cb
r
  
this work 
 
2.2.3 Oligodeoxynucleotides 
 
In table 5 oligodeoxynucleotides are listed that were used for cloning purposes 
in this work. They were purchased from Biomers (Ulm, Germany), Invitrogen 
(Carlsbad, CA, USA) or Eurofins Genomics (Ebersberg, Germany). 
 
Table 5: Oligodeoxynucleotides utilized for cloning 
Restriction sites are underlined and exchanged nucleotides for site-directed 
mutagenesis are highlighted in bold font. Oligodeoxynucleotides highlighted 
superscript derived from: 1(135), 2(142), 3(145), 4(139), 5(134). No., number. 
 
No. name sequence (5’ – 3’) 
1
1
 APGHtrunc_fw CCGGCGATGGCCATGGACGTGCTCGCCCATCAGTTG 
2
1
 APGHtrunc_rv AAGCGCTGAGAAGCTTGGCGTCGGGAGCGTTCTC 
3 
A-PGH EEK-AAK fw GCATCTATGGCGCCGCAGCAAAGGACGAAAGCGGCT
G 
4 A-PGH EEK-AAK rv CAGCCGCTTTCGTCCTTTGCTGCGGCGCCATAGATGC 
5 A-PGH EEK-AAA fw_2 GCATCTATGGCGCCGCAGCAGCGGACGAAAGCGCTG 
6 A-PGH EEK-AAA rv_2 CAGCCGCTTTCGTCCGCTGCTGCGGCGCCATAGATGC 
7
2
 CAT zu CAC-fw CCGAAAGCAACGTACCACGGCAATATCGATAAG  
8
2
 GTA zu GTG-rv CTTATCGATATTGCCGTGGTACGTTGCTTTCGG  
9
2
 
NcoI phoA fw  AGGAAACAGACCATGGTGAAACAAAGCACTATTGCACT
GGC  
10
2
 
NcoI ‘phoA fw  AGGAAACAGACCATGGCTCAGGGCGATATTACTGCAC
C  
11
2
 
‘phoAHindIII-rv  CAAAACAGCCAAGCTTTTATTTCAGCCCCAGAGCGGCT
TTC  
12
3
 pTrc200_acvB fw GTAGCCATGGCGGTGATCTAT 
13
3 pTrc200_acvB rv_XmaI GTTACCCGGGTTATTTTTCGAACTGCG 
14
4 L56R_fw GCTGGAAGGTCGTTGGCGCCGTCTGGAAGTTCGTGAT
CTGGG 
15
4 L56R_rv GATCACGAACTTCCAGACGGCGCCAACGACCTTCCAG
CAG 
16
4 L56W_fw GCTGGAAGGTCGTTGGTGGCGTCTGGAAGTTCGTGAT
CTGGG 
17
4 L56W_rv GATCACGAACTTCCAGACGCCACCAACGACCTTCCAG
CAG 
18
4 L58R_fw GGAAGGTCGTTGGCTGCGTCGCGAAGTTCGTGATCTG
GG 
19
4 L58R_rv CCCAGATCACGAACTTCGCGACGCAGCCAACGACCTT
CC 
20
4
 
L58W_fw GGAAGGTCGTTGGCTGCGTTGGGAAGTTCGTGATCTG
GG 
21
4 L58W_rv CCCAGATCACGAACTTCCCAACGCAGCCAACGACCTT
CC 
22
4
 V69R_fw GGGTGTGGGTTGGTGTCGCACCCGTGTTCCGGGTGG 
23
4 V69R_rv CCACCCGGAACACGGGTGCGACACCAACCCACACCC 
24
4 V69W_fw GGGTGTGGGTTGGTGTTGGACCCGTGTTCCGGGTGG 
25
4 V69W_rv CCACCCGGAACACGGGTCCAACACCAACCCACACCC 
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No. name sequence (5’ – 3’) 
26
4 F95R_fw CGTGGTGATTGGCGTGATCGCCTGCTGCTGGCAAGCC
G 
27
4 F95R_rv GACGGCTTGCCAGCAGCAGGCGATCACGCCAATCACC
ACGAATGG 
28
4 F95W_fw CGTGGTGATTGGCGTGATTGGCTGCTGCTGGCAAGCC
G 
29
4 F95W_rv GACGGCTTGCCAGCAGCAGCCAATCACGCCAATCACC
ACGAATGG 
30
4 L114R_fw CCCTGTTTTTTCGTCGTCGTCGCGTTATTGAAGGTGAT
ACCGAAC 
31
4 L114R_rv GTTCGGTATCACCTTCAATAACGCGACGACGACGAAAA
AACAGGG 
32
4 L114W_fw CCCTGTTTTTTCGTCGTCGTTGGGTTATTGAAGGTGAT
ACCGAAC 
33
4 L114W_rv GTTCGGTATCACCTTCAATAACCCAACGACGACGAAAA
AACAGGG 
34 
pPA3911_fw XbaI CACTCTAGAGTATTCCTGGGGCATGCGCCGCTGGATT
C 
35 
PA3911_nativ rev 
compl. BamHI 
ATACGGATCCTCAGTCGACCTTTTCGAACTGCGGGTGG
CTCCAGAGCTCGCCGCCCCGCGCGCCCTGGACCGGC 
36 P1 fw 3911 KpnI CGTCAAGGTACCTCTCCGGCAAGCTGC 
37 P2 rv 3911 BamHI GCATTCGGATCCAGCCCTGCCTCCTC 
38 P3 fw 3911 BamHI CGTCAAGGATCCGGTCGGTGGAAAGGG 
39 P4 rv 3911 HindIII GCATATAAGCTTGGCGCACTGCGCAGG 
40
5 PAO1 PA3911 fw GCTTCAGGGAATACACCCAA 
41
5 PAO1 PA3911 rv CCAGCAGTATCCCGAAGGTA 
42
5 Hah-138 CGGGTGCAGTAATATCGCCCT 
 
Oligodeoxynucleotides used for sequencing are listed in table 6. 
 
Table 6: Oligodeoxynucleotides applied for sequencing reactions 
If not stated otherwise, standard oligodeoxynucleotides from GATC Biotech 
(Konstanz, Germany) were used for sequencing. Oligodeoxynucleotides 
highlighted superscript were taken from: 1(142). No., number. 
 
No. name sequence (5’ – 3’) 
A
 
pET-RP CTAGTTATTGCTCAGCGG 
B
1 
pFU84 phoA fw  CAGTTGGTGAGCGATGCTGC  
C
 
pBR1  CGAAAAGTGCCACCTGAC 
D
 
pTI2-1-1 GGCAAATATTCTGAAATGAGC  
E pTI2-1-2  GCGTTTCACTTCTGAGTTCG  
F pTrcHis-RP CTGATTTAATCTGTATCAGG 
G T7 TAATACGACTCACTATAGGG 
H pGEX3-RP TCAAGAATTATACACTCCG 
I pET30er-FP TCATCATTCTTCTGGTCTG 
J PAO1 PA3911 rv CCAGCAGTATCCCGAAGGTA 
 
2.2.4 Synthetic genes 
 
Synthetic genes used in this study were purchased as GeneArt® Strings™ DNA 
fragments from Life Technologies GmbH (Carlsbad, CA, USA) and are listed in 
table 7. 
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Table 7: Synthetic gene sequences 
Restriction sites are underlined and leader sequences are highlighted in bold 
font. Specifically labeled sequences derived from: 1(142), 2S. Hebecker, 
unpublished. 
 
name 
codon 
usage  
sequence (5’ – 3’) 
AcvB_leader_phoA
1 
native 
AGGAAACAGACCATGGTGAAACGCAATCTGATAGGGGCATTCATTG
CCGCTTCGACGCTACTCTCCTCGTCTGTCGCCTTTTCCGCTCAGGGC
GATATTACTGCACCCGGCGGTGCTCGCCGTTTAACGGGTGATCAGAC
TGCCGCTCTGCGTGATTCTCTTAGCGATAAACCTGCAAAAAATATTAT
TTTGCTGATTGGCGATGGGATGGGGGACTCGGAAATTACTGCCGCAC
GTAATTATGCCGAAGGTGCGGGCGGCTTTTTTAAAGGTATAGATGCC
TTACCGCTTACCGGGCAATACACTCACTATGCGCTGAATAAAAAAACC
GGCAAACCGGACTACGTCACCGACTCGGCTGCATCAGCAACCGCCT
GGTCAACCGGTGTCAAAACCTATAACGGCGCGCTGGGCGTCGATATT
CACGAAAAAGATCACCCAACGATTCTGGAAATGGCAAAAGCCGCAGG
TCTGGCGACCGGTAACGTTTCTACCGCAGAGTTGCAGGATGCCACGC
CCGCTGCGCTGGTGGCACATGTGACCTCGCGCAAATGCTACGGTCC
GAGCGCGACCAGTGAAAAATGTCCGGGTAACGCTCTGGAAAAAGGC
GGAAAAGGATCGATTACCGAACAGCTGCTTAACGCTCGTGCCGACGT
TACGCTTGGCGGCGGCGCAAAAACCTTTGCTGAAACGGCAACCGCT
GGTGAATGGCAGGGAAAAACGCTGCGTGAACAGGCACAGGCGCGTG
GTTATCAGTTGGTGAGCGATGCTGCCTCACTGAATTCGGTGACGGAA
GCGAATCAGCAAAAACCCCTGCTTGGCCTGTTTGCTGACGGCAATAT
GCCAGTGCGCTGGCTAGGACCGAAAGCAACGTACCACGGCAATATC
GATAAGCCCGCAGTCACCTGTACGCCAAATCCGCAACGTAATGACAG
TGTACCAACCCTGGCGCAGATGACCGACAAAGCCATTGAATTGTTGA
GTAAAAATGAGAAAGGCTTTTTCCTGCAAGTTGAAGGTGCGTCAATCG
ATAAACAGGATCATGCTGCGAATCCTTGTGGGCAAATTGGCGAGACG
GTCGATCTCGATGAAGCCGTACAACGGGCGCTGGAATTCGCTAAAAA
GGAGGGTAACACGCTGGTCATAGTCACCGCTGATCACGCCCACGCC
AGCCAGATTGTTGCGCCGGATACCAAAGCTCCGGGCCTCACCCAGG
CGCTAAATACCAAAGATGGCGCAGTGATGGTGATGAGTTACGGGAAC
TCCGAAGAGGATTCACAAGAACATACCGGCAGTCAGTTGCGTATTGC
GGCGTATGGCCCGCATGCCGCCAATGTTGTTGGACTGACCGACCAG
ACCGATCTCTTCTACACCATGAAAGCCGCTCTGGGGCTGAAATAAAA
GCTTGGCTGTTTTG 
PA3911_full-length E. coli 
GAATTCATGCTGAATCGTCAGCGTCTGCTGCTGGGTGTTGCAGGTCG
CCTGCTGCCGCTGGCAGCCAAAGTTCCGCGTGGTCTGCAGCATCTG
GTTCTGCAGCGTGTTGCAAATCGTCTGTTTGCACAGCCGCTGGAAGA
AGGTGCATTTGATCTGCTGGAAGGTCGTTGGCTGCGTCTGGAAGTTC
GTGATCTGGGTGTGGGTTGGTGTGTTACCCGTGTTCCGGGTGGCCT
GCGCCTGGTTGAACGTCCGCGTGCAAGCGTTACCATTCGTGGTGATT
GGCGTGATTTCCTGCTGCTGGCAAGCCGTCATGAAGATCCGGATACC
CTGTTTTTTCGTCGTCGTCTGGTTATTGAAGGTGATACCGAACTGGGT
CTGGCAGTTAAAAACCTGCTGGATAGCCTGGACCCTGAACATCTGCC
TCCGTGGCTGTGGAATGCAGTTGAACGTGCAGGTCGTGCAGTTCAAG
AGGAACGTGGTGAAGCACCGCAGGGTCCGGTTCAGGGTGCACGTGG
TGGTTAAGCGGCCGC 
VirJ_Strep
2
 E. coli 
AGGAAACAGACCATGGCCATTAAACTGGTTCTGATCCTGGTTTTTAC
CCTGTTTCTGGCAGCAGATGCAGCCTATGCAAATGATCGTGCAAATG
GTGTTATGTGGTCAAATGGTGGTGAAGCCGGTGTTCGTCTGCCGCTG
CGTGTTTTTAATGCAAAACCGGCAAAAAATACCGTGGCCATTATCTAT
AGCGGTGATGCAGGTTGGCAGAATATTGATGAAGTTATTGGCACCTA
TCTGCAGACCGAAGGTATTCCGGTTATTGGTGTTAGCAGCCTGCGTT
ATTTTTGGAGCGAACGTAGCCCGAGCGAAACCGCAAAAGATCTGGGT
CATATTATTGACGTGTACACCAAACATTTTGGCGTTCAGAATGTTCTG
CTGATCGGTTATAGCTTTGGTGCAGATGTTATGCCTGCCAGCTTTAAT
CGTCTGACCCTGGAACAGAAAAATCGCGTTAAACAAATTAGCCTGCT
GGCACTGAGCCATCAGGTTGATTATGTTGTTAGCTTTCGTGGTTGGCT
GCAGCTGGAAACCGAAGGCAAAGGTGGTAATCCGCTGGATGATCTG
CGTTTTATTGATCCGGCAATTGTTCAGTGTATGTATGGTCGTGAAGAT
CGTAATAATGCATGTCCGAGCCTGCGTCAGACCGGTGCAGAAGTGAT
TGGTTTTAGCGGTGGTCATCATTTTGGCAACGATTTCAAAAAACTGAG
CACCCGTGTTGTGAGCGGTCTGGTTGCACGTCTGAGTCATCAGTATA
GCAGCGGTCCGGCTCCGCTGAAGCTTCTCAGCGCTTGGAGCCACCC
GCAGTTCGAAAAATAACCCGGGGATCCTCTAG 
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name 
codon 
usage  
sequence (5’ – 3’) 
VirJ_leader_phoA
1 
native 
AGGAAACAGACCATGGCGATAAAATTGGTATTGATACTCGTATTTAC
ACTGTTTCTCGCGGCAGACGCTGCCTATGCGGCTCAGGGCGATATTA
CTGCACCCGGCGGTGCTCGCCGTTTAACGGGTGATCAGACTGCCGC
TCTGCGTGATTCTCTTAGCGATAAACCTGCAAAAAATATTATTTTGCTG
ATTGGCGATGGGATGGGGGACTCGGAAATTACTGCCGCACGTAATTA
TGCCGAAGGTGCGGGCGGCTTTTTTAAAGGTATAGATGCCTTACCGC
TTACCGGGCAATACACTCACTATGCGCTGAATAAAAAAACCGGCAAAC
CGGACTACGTCACCGACTCGGCTGCATCAGCAACCGCCTGGTCAAC
CGGTGTCAAAACCTATAACGGCGCGCTGGGCGTCGATATTCACGAAA
AAGATCACCCAACGATTCTGGAAATGGCAAAAGCCGCAGGTCTGGCG
ACCGGTAACGTTTCTACCGCAGAGTTGCAGGATGCCACGCCCGCTGC
GCTGGTGGCACATGTGACCTCGCGCAAATGCTACGGTCCGAGCGCG
ACCAGTGAAAAATGTCCGGGTAACGCTCTGGAAAAAGGCGGAAAAGG
ATCGATTACCGAACAGCTGCTTAACGCTCGTGCCGACGTTACGCTTG
GCGGCGGCGCAAAAACCTTTGCTGAAACGGCAACCGCTGGTGAATG
GCAGGGAAAAACGCTGCGTGAACAGGCACAGGCGCGTGGTTATCAG
TTGGTGAGCGATGCTGCCTCACTGAATTCGGTGACGGAAGCGAATCA
GCAAAAACCCCTGCTTGGCCTGTTTGCTGACGGCAATATGCCAGTGC
GCTGGCTAGGACCGAAAGCAACGTACCACGGCAATATCGATAAGCCC
GCAGTCACCTGTACGCCAAATCCGCAACGTAATGACAGTGTACCAAC
CCTGGCGCAGATGACCGACAAAGCCATTGAATTGTTGAGTAAAAATG
AGAAAGGCTTTTTCCTGCAAGTTGAAGGTGCGTCAATCGATAAACAG
GATCATGCTGCGAATCCTTGTGGGCAAATTGGCGAGACGGTCGATCT
CGATGAAGCCGTACAACGGGCGCTGGAATTCGCTAAAAAGGAGGGT
AACACGCTGGTCATAGTCACCGCTGATCACGCCCACGCCAGCCAGAT
TGTTGCGCCGGATACCAAAGCTCCGGGCCTCACCCAGGCGCTAAATA
CCAAAGATGGCGCAGTGATGGTGATGAGTTACGGGAACTCCGAAGA
GGATTCACAAGAACATACCGGCAGTCAGTTGCGTATTGCGGCGTATG
GCCCGCATGCCGCCAATGTTGTTGGACTGACCGACCAGACCGATCTC
TTCTACACCATGAAAGCCGCTCTGGGGCTGAAATAAAAGCTTGGCTG
TTTTG 
 
2.3  Sterilization, growth media and media additives 
 
2.3.1 Sterilization 
 
Heat-resistant media and items were steam pressure sterilized at 121 °C and 
1 bar excess pressure for 20 min. Sterilization of temperature sensitive 
solutions was performed by filtration (pore size 0.2 µm). 
 
2.3.2 Media 
 
2.3.2.1 Luria Bertani medium 
 
Luria Bertani (LB) medium (146) was used as a standard medium to cultivate 
the bacterial strains unless indicated otherwise. To obtain solid medium 
1.5% (w/v) agar-agar was added before sterilization.  
 
 LB medium tryptone 10 g/l 
  yeast extract 5 g/l 
  NaCl 5 g/l 
 
2.3.2.2 AB medium 
 
Modified AB medium was used as a minimal medium for the cultivation of 
P. aeruginosa PAO1 strains. Therefore, AB medium (147) was prepared without 
sodium citrate and supplemented with glucose and FeSO4. The pH of the 
modified AB medium was adjusted by varying the ratio of phosphate buffer 
components. Depending on the utilized A10 solution (e.g. pH 5.0 or 7.0) the pH 
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value of the resulting AB medium is increased by 0.3 units (e.g. pH 5.3 or 7.3) 
(43). 
All media components were prepared as stock solutions. Sterilization of A10, 
MgCl2 and CaCl2 solution was performed by autoclaving and glucose, FeSO4 
and trace element solution by filtration (pore size 0.2 µm). 
 
 AB medium A10 solution  100 ml/l 
  1 M D(+)-glucose 20 ml/l 
  trace elements 1 ml/l 
  1 M MgCl2 1 ml/l 
  FeSO4·7 H2O (14 mg/ml)  0.5 ml/l 
  1 M CaCl2 0.1 ml/l 
 
 trace elements CaSO4·2 H2O 200 mg/l 
  FeSO4·7 H2O 200 mg/l 
  MnSO4·H2O  20 mg/l 
  CuSO4·5 H2O 20 mg/l 
  ZnSO4·7 H2O 20 mg/l 
  NaMoO4·H2O 10 mg/l 
  H3BO3 5 mg/l 
 
 A10 solution pH 5.0 (NH4)2SO4 20 g/l 
  Na2HPO4 20 mM 
  KH2PO4 430 mM 
 
 A10 solution pH 7.0 (NH4)2SO4 20 g/l 
  Na2HPO4 300 mM 
  KH2PO4 150 mM 
 
2.3.2.3 Yeast Extract Broth 
 
A. tumefaciens was cultivated in Yeast Extract Broth (YEB) (148). Solid medium 
was obtained by the addition of 2% (w/v) agar-agar previous to sterilization. 
 
 YEB medium beef extract 5 g/l 
  yeast extract 1 g/l 
  peptone 5 g/l 
  D(+)-sucrose 5 g/l 
  MgSO4 2 mM 
 
2.3.2.4 Media for Arabidopsis seedling infection 
 
Arabidopsis thaliana seedlings were infected with different A. tumefaciens 
strains according to the AGROBEST method (149). 
 
 MS medium Murashige & Skoog salt  2.17 g/l 
  D(+)-sucrose 5 g/l 
 adjusted to pH 5.7 with potassium hydroxide, but pH 5.5 after autoclaving 
 
For AB-MES pH 5.5 medium all media components were prepared as stock 
solutions. Sterilization was performed by autoclaving, except for glucose and 
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FeSO4 solution which were sterilized by filtration (pore size 0.2 µm). 
 
 AB-MES pH 5.5 medium K2HPO4 17.2 mM 
  NaH2PO4 8.3 mM 
  NH4Cl 18.7 mM 
  KCl 2 mM 
  MgSO4 1.25 mM 
  CaCl2 100 µM 
  FeSO4 10 µM 
  MES 50 mM 
  D(+)-glucose 2% (w/v) 
 adjusted to pH 5.5 with HCl 
 
 Infection medium MS medium 500 ml/l 
  AB-MES pH 5.5 medium 500 ml/l 
  acetosyringone (AS) 200 µM 
 
2.3.2.5 Medium for protein labeling with L(+)-selenomethionine 
 
For incorporation of L(+)-selenomethionine (SeMet; ACROS Organics™, Geel, 
Belgium) into proteins during heterologous production in E. coli cells a minimal 
medium supplemented with SeMet and the respective antibiotic(s) was used for 
the cultivation (150). 
 
 SeMet minimal medium NH4Cl 20.8 mM 
  KH2PO4 pH 7.0 24.5 mM 
  Na2HPO4 pH 7.0 24.9 mM 
 
 SeMet nutrients D(+)-glucose 1.11 M 
  MgSO4 24.7 mM 
  thiamine HCl 332 µM 
  Fe2(SO4)3 260 µM 
 
 amino acids with SeMet L-lysine 100 mg/l 
  L-phenylalanine 100 mg/l 
  L-threonine 100 mg/l 
  L-isoleucine 50 mg/l 
  L-leucine 50 mg/l 
  L-valine 50 mg/l 
  SeMet 60 mg/l 
 
The components for the minimal medium and the nutrients were prepared as 
stock solutions whereof all solutions were autoclaved except from D(+)-glucose, 
thiamine HCl and Fe2(SO4)3 which were sterilized by filtration (pore size 
0.2 µm). The amino acid mixture containing SeMet was dissolved in 14 ml 
sterile dH2O before use. 
 
2.3.3 Additives 
 
Concentrated stock solutions of antibiotics and media additives dissolved in 
water, unless indicated otherwise, were sterilized by filtration (pore size 0.2 µm). 
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Table 8 shows an overview of the utilized additives with the corresponding 
concentrations for usage. 
 
Table 8: Antibiotics and media additives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4  Microbiological techniques 
 
2.4.1 Cultivation of bacterial cells 
 
Bacterial cells were cultivated at 37 °C (E. coli and P. aeruginosa) or 30 °C 
(A. tumefaciens) under vigorous shaking (200 rpm). 
To generate pre-cultures, 5-50 ml of the desired medium containing the 
respective antibiotic(s) in test tubes or baffled flasks was inoculated with a 
single colony from a plate culture or with cell material from a glycerol stock and 
was cultivated overnight.   
For plate cultures a bacterial cell suspension (5-250 µl) was plated with a 
Drigalski spatula or cell material was streaked with an inoculating loop on sterile 
agar plates and incubated at the respective temperature overnight. 
 
2.4.2 Determination of cell density 
 
To determine cell densities of liquid bacterial cultures the optical density (OD) at 
a wavelength of 578 nm was measured photometrically. An OD578 of 1 
corresponds to a cell density of ~1·109 cells/ml (146). 
 
2.4.3 Storage of bacteria 
 
Glycerol stocks were prepared for long-term storage of bacteria. Bacterial 
overnight cultures were, therefore, mixed with sterile glycerol to result in a final 
concentration of 20% (w/v) and stored at -80 °C (146).  
 
 
Additive 
Stock solution 
(solvent) 
Final concentration 
E. coli A. tumefaciens P. aeruginosa 
5-aminolevulinic acid 
(ALA) 
50 mg/ml 50 µg/ml - - 
acetosyringone (AS) 39.24 mg/ml 
(DMSO) 
- 200 µM - 
ampicillin (Ap) 100 mg/ml 100 µg/ml - - 
carbenicillin (Cb) 50 mg/ml - - 250 µg/ml 
chloramphenicol (Cm) 34 mg/ml  
(100% EtOH) 
34 µg/ml - - 
gentamicin (Gm) 10 mg/ml 10 µg/ml - 50 µg/ml 
isopropyl-β-D-galacto-
pyranoside (IPTG) 
1 M 25-300 µM 15 µM - 
kanamycin (Kan) 100 mg/ml 100 µg/ml - - 
potassium nitrate 2 M - - 50 mM 
spectinomycin (Spc) 50 mg/ml 50 µg/ml 300 µg/ml - 
streptomycin (Str) 75 mg/ml - 100 µg/ml - 
tetracycline (Tet) 10 mg/ml  
(70% EtOH) 
- - 60 µg/ml 
ticarcillin (Tic) 100 mg/ml - 100 µg/ml - 
D(+)-sucrose 50% (w/v) - - 5% (w/v) 
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2.4.4 Cultivation of E. coli for recombinant protein production 
 
For the heterologous production of recombinant proteins in E. coli 
500 ml LB medium supplemented with the respective antibiotic in baffled flasks 
was inoculated in a ratio of 1:100 (v/v) with an overnight pre-culture. Cultivation 
was performed at 37 °C and 200 rpm until an OD578 of 0.5-0.6 was reached. 
After the induction of protein production by IPTG addition the cultivation was 
preceded at 17 °C overnight.  
 
2.4.5 Monitoring of P. aeruginosa growth behavior 
 
To determine the growth behavior of P. aeruginosa strains, pre-cultures in 
LB medium were inoculated with a single colony from a plate culture (2.4.1) and 
were incubated at 37 °C and 200 rpm overnight. 
For aerobic main cultures LB medium (2.3.2.1) or AB medium pH 5.3 or 7.3 
(2.3.2.2) in baffled flasks was inoculated with the respective pre-culture to an 
OD578 of 0.05. Cultivation was performed at 37 °C and 200 rpm for 24 h, 
meanwhile measuring the OD578 at certain time points. 
For anaerobic main cultures LB medium or AB medium pH 7.3 supplemented 
with 50 mM potassium nitrate in anaerobic culture flasks was inoculated to an 
OD578 of 0.3 using a pre-culture of the respective P. aeruginosa strain. During 
cultivation at 37 °C and 100 rpm for 24 h the optical densities were monitored 
on a regular basis. 
 
2.5  Molecular biological techniques 
 
2.5.1 Preparation of competent cells 
 
2.5.1.1 CaCl2 method for competent E. coli cells 
 
100 ml LB medium in a 500 ml baffled flask was inoculated 1:100 (v/v) with an 
overnight pre-culture of the desired E. coli strain and incubated at 37 °C and 
200 rpm until an OD578 of 0.6-0.8 was reached. Cells were sedimented by 
centrifugation (3’000 x g, 4 °C, 10 min), washed with 10 ml ice-cold CaCl2 
solution, gently resuspended in 1 ml ice-cold CaCl2 solution and stored in 
aliquots at -80 °C (146). 
 
 CaCl2 solution CaCl2 100 mM 
  Glycerol 10% (w/v) 
   
2.5.1.2 RbCl method for competent E. coli cells 
 
Overnight pre-cultures of the desired E. coli strain were used to inoculate 
500 ml LB medium in a 1 l baffled flask in a ratio of 1:100 (v/v). After cultivation 
at 37 °C and 200 rpm to an OD578 of 0.5-0.6 the cells were harvested by 
centrifugation (3’000 x g, 4 °C, 10 min). The received cell sediment was 
suspended in 100 ml of ice-cold TFB-I buffer and incubated on ice for 5 min. 
Cells were centrifuged (4’500 x g, 4 °C, 10 min) and subsequently resuspended 
in twice as much ice-cold TFB-II buffer referring to the cell sediment volume 
(~2-3 ml). After incubation on ice for 1 h cells were divided into aliquots and 
stored at -80 °C (151). 
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 TFB-I CaCl2 10 mM 
  potassium acetate  30 mM 
  MnCl2 50 mM 
  RbCl 100 mM 
  glycerol 15% (w/v) 
 adjusted to pH 5.8 with acetic acid, sterilized by filtration 
 
 TFB-II piperazine-N,N’-bis(2-ethanesulfonic 
  acid)-HCl pH 6.5 10 mM 
  RbCl 10 mM 
  CaCl2 75 mM 
  glycerol 15% (w/v) 
 adjusted to pH 6.5 with KOH, sterilized by filtration 
 
2.5.1.3 CaCl2 method for competent A. tumefaciens cells 
 
50 ml YEB medium in a baffled flask was inoculated 1:25 (v/v) with an overnight 
pre-culture of the desired A. tumefaciens strain and incubated at 30 °C and 
250 rpm until an OD578 of 0.5-1.0 was reached. The cell suspension was chilled 
on ice for 5 min. The cells were sedimented by centrifugation (3’000 x g, 4 °C, 
5 min), washed with 10 ml of an ice-cold 20 mM CaCl2 solution, gently 
resuspended on ice in 1 ml of 20 mM ice-cold CaCl2 solution and stored in 
aliquots at -80 °C (152). 
 
2.5.2 Transformation of competent cells 
 
2.5.2.1 E. coli cells 
 
For transformation purposes 25-100 µl of CaCl2 or RbCl competent E. coli cells 
(2.5.1.1 and 2.5.1.2) were mixed with 1-10 µl plasmid DNA solution (50 µg/ml). 
The mixture was incubated on ice for 20 min and afterwards a heat shock of the 
cells at 42 °C for 45 sec was performed. Following another incubation step on 
ice for 2 min, the cells were gently resuspended in 500 µl LB medium and 
incubated for 1 h at 37 °C and 300 rpm in a thermomixer. To select transformed 
clones 10-250 µl of the cell suspension was plated on LB agar plates 
supplemented with the respective antibiotic(s) and incubated overnight at 37 °C  
(146). 
 
2.5.2.2 A. tumefaciens cells   
 
To transform A. tumefaciens cells 1-1.5 µg of plasmid DNA was mixed with 
100 µl CaCl2 competent A. tumefaciens cells (2.5.1.3). The reaction tube 
containing the cell suspension was incubated for 5 min in warm water (37 °C) 
and subsequently 150 µl of YEB medium were added. The mixture was 
incubated for 3 h at 28 °C and 300 rpm in a thermomixer. Afterwards 
transformed clones were selected by plating 250 µl of the cell suspension on 
YEB agar plates containing the appropriate antibiotic(s) and incubated for 
1-3 days at 30 °C (152). 
 
2.5.3 Preparation of plasmid DNA 
To isolate high amounts of plasmid DNA from E. coli cells (e.g. for cloning 
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purposes) 4 ml of an overnight culture were sedimented (12’100 x g, room 
temperature (RT), 2 min) in a reaction tube. The cell pellet was resuspended in 
300 µl buffer P1 (ribonuclease A (RNase A) was added shortly before use). 
300 µl buffer P2 were added, the reaction tube was inverted several times and 
the suspension was incubated (RT, 2 min). After the addition of 300 µl buffer P3 
cell debris and denatured proteins were separated by centrifugation (12’100 x g, 
RT, 20 min). The resulting supernatant was mixed with 600 µl isopropanol to 
precipitate the plasmid DNA. The plasmid DNA was sedimented by 
centrifugation (12’100 x g, RT, 20 min) and washed with 400 µl 70% (v/v) 
ethanol. Following a final centrifugation step (12’100 x g, RT, 5 min) the 
sedimented plasmid DNA was dried at 37 °C in a thermomixer, dissolved in 
35 µl dH2O and subsequently stored at -20 °C (146). 
Plasmid DNA that was intended for subsequent sequencing was isolated from 
E. coli cells using the QIAprep Spin Miniprep Kit according to the 
manufacturer’s instructions (QIAGEN, Hilden, Germany). 
 
 buffer P1 ethylenediaminetetraacetic  
  acid (EDTA) 10 mM 
  Tris-HCl pH 8.0 50 mM 
  RNase A 100 µg/ml 
 
 RNase A solution  RNase A 10 mg/ml 
  dissolved in 50% (w/v) glycerol 
 
 buffer P2 sodium hydroxide (NaOH) 200 mM 
  SDS 1% (w/v) 
 
 buffer P3 potassium acetate pH 5.5  3 M 
 
2.5.4 Determination of DNA concentration 
 
To determine the concentration and purity of a DNA solution the absorbance at 
260 nm and 280 nm was measured with a spectrophotometer (NanoDrop™ 
ND-1000, PEQLAB Biotechnologie GmbH, Erlangen, Germany). An absorbance 
value of 1 measured at 260 nm represents a concentration of 50 ng/µl of 
double-stranded DNA. Protein impurities in the sample result in high 
absorbance values at 280 nm. That is why the quotient A260/A280 provides 
information about the DNA purity. A DNA sample with a value of 
A260/A280 = 1.8-2.0 is considered to be pure (146). 
 
2.5.5 Amplification of DNA by polymerase chain reaction 
 
To amplify DNA fragments the method polymerase chain reaction (PCR) (153) 
was applied. Therefore, specific oligodeoxynucleotides (2.2.3) were designed 
that bind to a specific region of the template DNA and depending on purpose 
provide recognition sites for endonucleases or homologous regions necessary 
for the In-Fusion® HD cloning method. 
The reaction mixtures contain the template DNA, the respective primers, a 
deoxynucleotide triphosphate (dNTP) mixture, the Phusion® High-Fidelity DNA 
Polymerase and its corresponding GC buffer. Polymerase, buffer and dNTP 
mixture were purchased from New England BioLabs® (Ipswich, MA, USA). 
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Plasmid DNA or a bacterial colony served as a template for the PCR reaction. 
For colony PCR the respective P. aeruginosa colony was suspended in 50 µl 
dH2O and incubated at 95 °C for 10 min. 1 µl of this mixture was used as a 
template for PCR. 
 
 compound amount 
 template DNA 1 µl colony suspension or 1-10 ng plasmid DNA 
 5x GC buffer 4 µl 
 10 mM dNTPs 0.4 µl 
 10 µM forward primer 1 µl 
 10 µM reverse primer 1 µl 
 Phusion® polymerase 0.2 µl 
 dH2O filled up to 20 µl 
 
The PCR reaction is subdivided into several steps. At first single-stranded DNA 
was created by denaturation (98 °C, 30-60 sec). Afterwards 30 cycles 
consisting of denaturation (98 °C, 10 sec), primer annealing (55-75 °C, 
15-30 sec) and elongation (72 °C, 15-30 sec per kilobase of target DNA 
fragment for Phusion® High-Fidelity DNA Polymerase) were performed. The 
PCR reaction was finished by a final elongation step (72 °C, 10 min). PCR 
samples were stored at 4 °C or -20 °C (146). 
 
2.5.6 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to separate DNA fragments in terms of 
their size. Therefore, DNA samples were mixed with the appropriate amount of 
loading dye and filled into the slots of an agarose gel (1% (w/v) in 
1x Tris-acetate-EDTA (TAE) buffer). Additionally the size marker GeneRuler™ 
DNA Ladder Mix (Thermo Fisher Scientific, Waltham, MA, USA) containing 
defined DNA fragments was applied to allow for DNA fragment size 
determination in the sample. For electrophoresis a voltage of 90-110 V was 
applied. Afterwards the agarose gels were incubated in 0.1% (w/v) ethidium 
bromide solution for 15 min or in GelStar® Nucleic Acid Gel Stain (Lonza, Basel, 
Switzerland) for 30 min. DNA visualization was performed using UV or blue light 
sources, respectively (146). 
 
 6x loading dye bromophenol blue 350 µM 
  xylene cyanol FF 450 µM 
  glycerol  50% (w/v) 
 
 1x TAE buffer Tris-acetate pH 8.0 40 mM 
  EDTA 1 mM 
 
2.5.7 Restriction of DNA 
 
Plasmid DNA (vectors) or PCR amplified DNA fragments (inserts) were 
digested by restriction endonucleases according to the manufacturer’s 
instructions (New England BioLabs®, Ipswich, MA, USA). Following restriction 
digest of vector DNA the sample was subjected to agarose gel electrophoresis 
to separate residual restriction enzymes. The agarose gel was stained with 
GelStar® Nucleic Acid Gel Stain (2.5.6) and target DNA was visualized on a 
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blue light detector (Biozym Scientific GmbH, Hessisch Oldendorf, Germany). 
After the excision with a scalpel the target DNA was purified by the QIAquick 
Gel Extraction Kit according to the manufacturer’s instructions (QIAGEN, 
Hilden, Germany). 
 
2.5.8 Dephosphorylation of vector DNA 
 
The 5’ ends of linearized vector DNA were dephosphorylated to prohibit 
self-ligation using Antarctic Phosphatase according to the manufacturer’s 
instructions (New England BioLabs®, Ipswich, MA, USA). 
 
2.5.9 Purification of PCR products  
 
DNA fragments obtained by PCR were purified by the QIAquick PCR 
Purification Kit according to the manufacturer’s instructions (QIAGEN, Hilden, 
Germany). 
 
2.5.10 Ligation of DNA 
 
DNA fragments were ligated using the T4 DNA ligase according to the 
manufacturer’s instructions (New England BioLabs®, Ipswich, MA, USA). In 
general, a molar ratio of 1:4 for vector to insert DNA was used. Reaction 
mixtures were incubated at 17 °C overnight and transformed into competent 
E. coli cells (2.5.2.1). 
 
2.5.11 In-Fusion® HD cloning 
 
In addition to traditional cloning procedures in which insert and vector DNA are 
digested by restriction endonucleases and subsequently ligated to yield the 
desired vector construct the ‘almost’ restriction-free In-Fusion® HD cloning 
method (154) was used in this study. 
Therefore, the vector DNA was linearized by a restriction endonuclease. 
Specific oligodeoxynucleotides (2.2.3) were designed which contain a 15 bp 
homologous overlap to the vector DNA on both sites of the insert. After 
amplification of the desired insert DNA fragment with respective 
oligodeoxynucleotides by PCR (2.5.5) the In-Fusion® HD cloning reaction was 
set up according to the manufacturer’s instructions (Clontech® Laboratories, 
Mountain View, CA, USA). The resulting reaction mixtures were transformed 
into competent E. coli Stellar™ cells according to the manufacturer’s 
instructions (Clontech® Laboratories, Mountain View, CA, USA). 
 
2.5.12 Site-directed mutagenesis 
 
Plasmid DNA vectors can be modified by a method called site-directed 
mutagenesis. Thereby specific primers are designed that allow for the mutation 
of one or several bp at the desired position of the nucleotide sequence. In a 
PCR reaction the specific primers anneal to the target DNA and synthesis of a 
mutated plasmid takes place. In this work the QuikChange Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) was used 
according to the manufacturer’s instructions. Plasmid DNA which wasn’t 
modified during PCR was eliminated by restriction digest with DpnI. 
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The mutated plasmid DNA was transformed into competent E. coli cells 
(2.5.1.2). If no transformed colonies were obtained, the protocol was modified in 
the following way: increase of the primer concentration by 20%, duplication of 
the DNA template amount and addition of 4% (v/v) DMSO to the reaction 
mixture as well as an increase of the annealing temperature to 68 °C. 
 
2.5.13 Construction of vectors 
 
Several vectors were generated in this study by the insertion of DNA fragments 
into existing vector backbones or by modification of present vector constructs. 
The used oligodeoxynucleotides are listed in table 5. Methods for vector 
construction are presented in the sections 2.5.1 to 2.5.12 and resulting plasmids 
are summarized in table 4. 
 
Plasmid for the recombinant production of A-PGHtrunc in E. coli 
 
To recombinantly produce A-PGHtrunc in E. coli BL21(λDE3) cells the gene 
sequence encoding for the amino acids 203-427 of orf PA0919 was amplified by 
PCR from pET22b(+)PA0919-Strep using primers 1 and 2. The PCR fragment 
was inserted into the vector pET22b(+)Strep (2.2.2) by the In-Fusion® HD 
cloning method (2.5.11) resulting in vector pET22b(+)PA0919trunc-Strep (135). 
The correct integration of the DNA fragment into the vector was verified by 
sequencing with primer A. The resulting construct allows for the recombinant 
production of protein A-PGHtrunc fused to an N-terminal E. coli pelB signal 
sequence for periplasmic export and a C-terminal Strep-tag® II (155). Protein 
production in E. coli BL21(λDE3) cells was induced with IPTG via the provided 
T7 promoter (131). 
 
Plasmids for the recombinant production of A-PGHtrunc mutant proteins 
 
For crystallization attempts protein variants of A-PGHtrunc were generated based 
on the Surface Entropy Reduction (SER) approach (156).  
Therefore, the vector pET22b(+)PA0919trunc-Strep (135) was modified by 
site-directed mutagenesis (2.5.12) with primers 3 and 4 resulting in plasmid 
pET22b(+)PA0919trunc-Strep/AAK. The obtained vector was further modified in a 
second mutagenesis reaction with primers 5 and 6 resulting in plasmid 
pET22b(+)PA0919trunc-Strep/AAA. The successful mutagenesis was verified by 
sequencing with primer A. 
 
Plasmids for AcvB and VirJ localization in A. tumefaciens 
 
To analyze the putative export of the proteins AcvB and VirJ into the periplasm 
of A. tumefaciens several localization plasmids based on the IPTG inducible 
pTrc200 vector backbone were constructed. To monitor the export the reporter 
gene alkaline phosphatase (phoA) was used (157). 
For cloning of the insert fragments into the pTrc200 vector the restriction sites 
NcoI and HindIII were chosen. Therefore, the NcoI restriction site within the 
phoA gene on plasmid pFU84 had to be eliminated by QuikChange 
Site-Directed Mutagenesis (2.5.12) using primers 7 and 8. Successful 
mutagenesis was verified by sequencing with primers B and C. The resulting 
plasmid pFU84_QC was used as a template to amplify the phoA gene 
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sequence with or without its own signal sequence by PCR (2.5.5) with the 
primers 9 and 11 or 10 and 11. The DNA fragments were ligated into the 
NcoI/HindIII sites of vector pTrc200 resulting in the plasmids pTrc200 phoA 
(positive control) and pTrc200 ‘phoA (negative control). For the localization 
vectors of AcvB and VirJ synthetic DNA insert fragments (table 7) were 
obtained commercially (Life Technologies GmbH, Carlsbad, CA, USA) which 
were customized for the In-Fusion® HD cloning method (2.5.11). These DNA 
fragments contained a 15 bp homologous sequence (5’ and 3’ end) to the 
pTrc200 vector and the signal sequence of the acvB or virJ gene fused to the 
phoA gene lacking its own signal sequence. The synthetic fragments were 
inserted into the linearized pTrc200 vector via In-Fusion® HD cloning (2.5.11) 
resulting in plasmids pTrc200 leader acvB ‘phoA and pTrc200 leader virJ ‘phoA. 
The four vector constructs (142) were verified by sequencing with primers D 
and E. 
 
Plasmids for the recombinant production of AcvB mutant proteins 
 
To study the function of AcvB protein in T-DNA transfer in A. tumefaciens point 
mutations of conserved amino acids of the potential active site were generated. 
DNA fragments containing the desired point mutation were amplified by PCR 
using primers 12 and 13 from plasmids pET22b(+)Strep_pelB_acvB 
ΔAS1-24-S269A, pET22b(+)Strep_pelB_acvB ΔAS1-24-S336A, 
pET22b(+)Strep_pelB_acvB ΔAS1-24-H433A and pET22b(+)Strep_pelB_acvB 
ΔAS1-24-H433N (137). The PCR fragments were ligated (2.5.10) into the 
NcoI/XmaI sites of vector pTrc200_acvB_Strep (S. Hebecker, unpublished) 
resulting in vectors pTrc200_acvB_Strep-S269A, pTrc200_acvB_Strep-S336A, 
pTrc200_acvB_Strep-H433A and pTrc200_acvB_Strep-H433N. Correct 
integration of the respective DNA fragment into the vector was verified by 
sequencing with primers D and F. 
 
Plasmids for the recombinant production of PA3911 in E. coli 
 
For recombinant production of the PA3911 protein in E. coli BL21(λDE3) cells 
the gene sequence was initially codon-optimized for E. coli and commercially 
obtained as a GeneArt® Strings™ DNA fragment (table 7; Life Technologies 
GmbH, Carlsbad, CA, USA). The DNA fragment was ligated into several vector 
systems to produce PA3911 fusion proteins with different tags. 
 
original plasmid restriction sites resulting plasmid (table 4) 
pET28b(+) NcoI/XhoI pET28b(+)-PA3911 
pET32a(+)/PA3911opt ΔAS 1-19 EcoRI/NotI pET32a(+)-PA3911 
pGEX-6P-1/PA3911opt ΔAS 1-19 EcoRI/NotI pGEX-6P-1-PA3911 
 
The correct insertion of the PA3911 DNA fragment into the respective vector 
was checked by sequencing with primers G and A (pET28b(+)-PA3911), 
primer A (pET32a(+)-PA3911) or primer H (pGEX-6P-1-PA3911). Protein 
production was performed in E. coli BL21(λDE3) cells induced by IPTG addition. 
 
Plasmids for the recombinant production of PA3911 mutant proteins 
 
To study the influence of several amino acid residues on the lipid binding 
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capacity of protein PA3911 a total of ten plasmid variants was generated by 
site-directed mutagenesis (2.5.12) on the basis of plasmid pET32a(+)-PA3911. 
The success of mutagenesis was analyzed by sequencing with primer I (139). 
 
 mutation  primer (table 5) resulting plasmid (table 4) 
 L56R 14, 15 pET32a(+)-PA3911-L56R
 L56W 16, 17 pET32a(+)-PA3911-L56W
 L58R 18, 19 pET32a(+)-PA3911-L58R 
 L58W 20, 21 pET32a(+)-PA3911-L58W
 V69R 22, 23 pET32a(+)-PA3911-V69R 
 V69W 24, 25 pET32a(+)-PA3911-V69W 
 F95R 26, 27 pET32a(+)-PA3911-F95R 
 F95W 28, 29 pET32a(+)-PA3911-F95W 
 L114R 30, 31 pET32a(+)-PA3911-L114R 
 L114W 32, 33 pET32a(+)-PA3911-L114W 
 
Plasmid for PA3911 localization in P. aeruginosa 
 
For localization of PA3911 in P. aeruginosa a vector construct consisting of the 
putative promoter sequence (500 bp upstream of PA3911 gene), orf PA3911 
and a C-terminal Strep-tag® II sequence was cloned. PA3911 gene sequence 
and the putative promoter region were amplified by colony PCR (2.5.5) of 
P. aeruginosa PAO1 (primers 34 and 35). During PCR primer 35 coded for the 
Strep-tag® II sequence at the 3’ end of the fragment. The resulting fragment 
was cloned into the XbaI/BamHI sites of vector pUCP20T resulting in plasmid 
pUCP20T-PPA3911-PA3911. Plasmid transfer into P. aeruginosa PAO1 was 
performed via diparental mating with E. coli ST18 cells. 
 
Plasmid for gene replacement in P. aeruginosa 
 
To delete the complete orf PA3911 from the PAO1 chromosome the gene 
replacement vector pEX18Ap-ΔPA3911 was constructed. This vector contains 
the Gm resistance cassette from vector pPS858 flanked by two genomic 
sequences homologous to the upstream and downstream region of the target 
gene PA3911. Genomic sequences allow for the homologous recombination 
and subsequently the replacement of orf PA3911 by the Gm resistance cassette 
(140). 
 
PCR (2.5.5) was employed to amplify the genomic sequences upstream 
(460 bp) and downstream (649 bp) of orf PA3911 with primers 36 and 37 or 
38 and 39. Vector pPS858 was digested (2.5.7) with BamHI to isolate the 
Gm resistance cassette. The two resulting PCR fragments and the 
Gm resistance cassette fragment were ligated into the KpnI/HindIII sites of 
vector pEX18Ap yielding vector pEX18Ap-ΔPA3911. 
 
2.5.14 Sequencing 
 
Sequence determination of plasmids or PCR products was performed by the 
company GATC Biotech (Konstanz, Germany) based on the Sanger method 
(158) with oligodeoxynucleotides listed in table 6. Analyses of resulting 
sequence files were performed with the Lasergene® software package 
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(DNASTAR, Madison, WI, USA). 
 
2.5.15 Diparental mating with P. aeruginosa 
 
Shuttle vectors can be transferred from E. coli to P. aeruginosa cells by 
conjugation. In this study, the shuttle vector derivatives pEX18Ap-ΔPA3911 and 
pUCP20T-PPA3911-PA3911 (2.2.2) were transferred from E. coli ST18 to 
P. aeruginosa PAO1 via diparental mating.  
The respective plasmid was transformed into CaCl2 competent E. coli ST18 
cells (2.2.1). Overnight pre-cultures of the E. coli ST18 donor strain carrying the 
desired plasmid and the recipient strain P. aeruginosa PAO1 were prepared. 
1 ml of E. coli ST18 pre-culture was mixed with 100 µl P. aeruginosa PAO1 
pre-culture, sedimented (2’400 x g, RT, 2 min) and the resulting pellet was 
gently resuspended in 100 µl LB medium containing 50 µg ALA. The complete 
cell suspension was pipetted onto a LB agar plate and was dried for 30 min in a 
clean bench. After incubation at 37 °C for 6 h the cell material was scraped from 
the LB agar plate with an inoculating loop, resuspended in 1 ml LB medium and 
plated onto LB agar plates containing the respective antibiotic(s) and additives 
to select for transformants (133). 
 
2.5.16 Construction of a markerless P. aeruginosa deletion mutant 
 
For chromosomal deletion of orf PA3911 from P. aeruginosa PAO1 a 
well-established protocol (two step procedure) was used. In the first step the 
chromosomal orf is replaced by a Gm resistance cassette, which will be excised 
in the second step to generate a markerless deletion mutant (140). 
 
The constructed gene replacement vector pEX18Ap-ΔPA3911 (2.5.13) was 
transferred into P. aeruginosa PAO1 via diparental mating (2.5.15). Cells were 
selected for integration of the Gm resistance cassette by homologous 
recombination (double crossover event) by resistance against Gm and their 
ability to grow on D(+)-sucrose. The pEX18Ap-ΔPA3911 vector encodes for the 
enzyme levansucrase (sacB gene) which converts sucrose to the toxic product 
levan and thereby prevents growth in the case of a single crossover event 
(vector still present). The chromosomal Gm resistance cassette is flanked by 
Flp recombinase target (FRT) sites allowing for the excision by the 
Flp recombinase. Therefore, the vector pFLP2 encoding for Flp recombinase 
has to be transferred into the generated P. aeruginosa strain by diparental 
mating resulting in a markerless deletion mutant. 
 
2.6 Protein biochemical methods 
 
2.6.1 Recombinant protein production 
 
2.6.1.1 Production of A-PGH protein variants 
 
A-PGH protein, the truncated version A-PGHtrunc and its mutant variants 
A-PGHtrunc/AAK and A-PGHtrunc/AAA were recombinantly produced in E. coli 
BL21(λDE3) cells containing the respective plasmid pET22b(+)PA0919-Strep, 
pET22b(+)PA0919trunc-Strep, pET22b(+)PA0919trunc-Strep/AAK or 
pET22b(+)PA0919trunc-Strep/AAA (table 4). The resulting proteins were 
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secreted into the periplasm of E. coli via an N-terminal pelB signal sequence 
and fused to a C-terminal Strep-tag® II (2.5.13). 
 
For protein production in baffled flasks 500 ml LB medium was supplemented 
with Ap and inoculated with the respective overnight pre-culture in a ratio of 
1:100 (v/v). Cells were cultivated at 37 °C and 200 rpm to an OD578 of 0.5. Then 
protein production was induced with 25 µM IPTG and cultivation was preceded 
at 17 °C and 180 rpm for 24 h. Cells were sedimented by centrifugation 
(3’000 x g, 4 °C, 20 min) and afterwards resuspended in harvesting buffer A. 
The cell pellets obtained after a second centrifugation step (4’000 x g, 4 °C, 
30 min) were stored at -20 °C (49). 
 
 harvesting buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 150 mM 
  D(+)-sucrose 20% (w/v) 
 
2.6.1.2 Production of L(+)-selenomethionine labeled A-PGH protein 
 
To determine the phase information by anomalous dispersion SeMet can be 
incorporated into the protein during heterologous production. 
Therefore, a pre-culture was generated by inoculation of 50 ml LB-Ap-medium 
(in a baffled flask) with E. coli BL21(λDE3) cells carrying the plasmid 
pET22b(+)PA0919-Strep (table 4). The pre-culture was cultivated at 37 °C and 
130 rpm for ~36 h. 50 ml of this pre-culture was mixed with 50 ml 
LB-Ap-medium and cultivated for 3 h at the same conditions. After the addition 
of 400 ml LB-Ap-medium to the pre-culture cultivation was preceded as 
previously for 2 h. Cells were harvested by centrifugation (6’000 x g, RT, 
10 min), resuspended in 25 ml sterile dH2O and sedimented again (6’000 x g, 
RT, 10 min). This washing step was repeated three times in total. Then cells 
were split up and transferred into 2x 500 ml SeMet minimal medium containing 
SeMet nutrients (2.3.2.5) supplemented with Ap in a 1 l baffled flask and 
cultivated for 30 min at 37 °C and 180 rpm. Following the addition of the amino 
acid mix supplemented with SeMet (2.3.2.4) to the culture cultivation was 
continued at 17 °C and 180 rpm for 15 min. Protein production was induced with 
250 µM IPTG and the cultivation was preceded overnight (~21 h) at 17 °C and 
180 rpm. Cells were harvested as described in chapter 2.6.1.1. 
 
2.6.1.3 Production of AcvB protein and derivatives 
 
The protein AcvB and its variants were produced in E. coli BL21(λDE3) cells 
containing the plasmid pET22b(+)Strep_pelB_acvB ΔAS1-24 or the respective 
derivatives of it (table 4). Similarly to the construct for recombinant production of 
protein A-PGH (2.6.1.1) these plasmids encode for the AcvB protein or mutant 
variants fused to a C-terminal Strep-tag® II. Periplasmic export of the protein is 
facilitated by an N-terminal pelB signal sequence. 
Recombinant protein production was performed exactly as for proteins A-PGH 
and A-PGHtrunc as described in section 2.6.1.1 with a modified inductor 
concentration of 50 µM IPTG (136, 137). 
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2.6.1.4 Production of PA3911 protein and mutant variants 
 
E. coli BL21(λDE3) cells containing the plasmid pET32a(+)-PA3911 or plasmid 
variants (table 4) were used for the recombinant production of PA3911 protein 
or mutant variants fused to an N-terminal thioredoxin-His6-S-tag (2.5.13). The 
sole thioredoxin-His6-S-tag protein was analogously produced in E. coli 
BL21(λDE3) cells containing the plasmid pET32a(+). Further PA3911 fusion 
proteins (2.5.13) were also produced in E. coli BL21(λDE3) cells containing the 
plasmid pET28b(+)-PA3911 (PA3911 fused to an N-terminal His6-tag) or 
plasmid pGEX-6P-1-PA3911 (PA3911 fused to an N-terminal GST-tag). 
 
E. coli BL21(λDE3) cells carrying the desired plasmid were cultivated in 500 ml 
of LB medium containing the respective antibiotic in baffled flasks at 37 °C and 
200 rpm to an OD578 of 0.5-0.6. Protein production was induced by the addition 
of 50 µM IPTG. Further cultivation was performed at 17 °C and 180 rpm 
overnight. The cells were harvested by centrifugation (3’000 x g, 4 °C, 15 min), 
resuspended in harvesting buffer B (His6-tag and thioredoxin-His6-S-tag) or 
harvesting buffer C (GST-tag), sedimented again (3’000 x g, 4 °C, 20 min) and 
stored at -20 °C. 
 
 harvesting buffer B sodium phosphate pH 7.0 50 mM 
  NaCl 300 mM 
 
 harvesting buffer C Tris-HCl pH 8.0 50 mM 
  NaCl 150 mM 
 
2.6.2 Cell disruption 
 
2.6.2.1 Isolation of the periplasmic fraction (A-PGH and AcvB protein) 
 
A-PGH and AcvB protein variants are exported to the periplasm of E. coli via 
their pelB signal sequence. This allows for the specific protein isolation from the 
periplasmic fraction. Therefore, the cells were incubated with polymyxin B 
leading to a permeable cell envelope. The resulting spheroblasts were 
stabilized in the presence of sucrose (159). 
 
The pellet obtained during recombinant protein production (2.6.1.1 or 2.6.1.2) 
was thawed on ice overnight. The cells were gently resuspended in disruption 
buffer A (2 ml buffer for 1 ml pellet volume) and incubated on a roller mixer for 
90 min at 4 °C. To separate the cell debris from the soluble periplasmic fraction 
the cell suspension was centrifuged (12’100 x g, 4 °C, 30 min). 
 
 disruption buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 150 mM 
  D(+)-sucrose 20% (w/v) 
  polymyxin B 2 mg/ml 
 
2.6.2.2 PA3911 protein variants 
 
E. coli BL21(λDE3) cell pellets (2.6.1.4) containing recombinantly produced 
PA3911 protein variants with an N-terminal His6-tag, an N-terminal 
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thioredoxin-His6-S-tag or an N-terminal GST-tag or the sole 
thioredoxin-His6-S-tag were thawed on ice overnight and suspended in 
harvesting buffer B (His6-tag and thioredoxin-His6-S-tag) or harvesting buffer C 
(GST-tag) supplemented with Benzonase® (Merck Millipore, Darmstadt, 
Germany). Cells were disrupted by a single passage through a French Press® 
(Thermo Fisher Scientific, Waltham, MA) at 14’500 psi and were subjected to 
ultracentrifugation (84’000 x g, 4 °C, 1 h) to separate the soluble fraction from 
insoluble cell components. 
 
 harvesting buffer B sodium phosphate pH 7.0 50 mM  
  NaCl 300 mM 
 
 harvesting buffer C Tris-HCl pH 8.0 50 mM 
  NaCl 150 mM 
 
2.6.3 Protein purification by affinity chromatography 
 
2.6.3.1 Purification of A-PGH and AcvB protein variants 
 
A-PGH and AcvB protein variants fused to a Strep-tag® II were purified using 
Strep-Tactin® resin according to the manufacturer’s instructions (iba, Göttingen, 
Germany). Therefore, the isolated periplasmic fraction (2.6.2.1) was initially 
incubated with 0.4 µM avidin (Calbiochem® by Merck, Darmstadt, Germany) for 
15 min at 4 °C on a roller mixer to mask biotinylated proteins. Then the fraction 
was loaded into a Poly-Prep® Chromatography Column (Bio-Rad, Hercules, CA, 
USA) containing 1 ml Strep-Tactin® Superflow® or Strep-Tactin® Superflow® 
high capacity resin which was previously equilibrated with 2x 5 column 
volumes (CV) washing buffer A. The resin was washed twice with 5 CV washing 
buffer A and then the protein of interest was eluted with 4x 1 CV elution 
buffer A. The obtained protein was stored at 4 °C. To regenerate the 
Strep-Tactin® resin it was washed with 3x 5 CV regeneration buffer (iba, 
Göttingen, Germany) according to the manufacturer’s instructions and the 
columns were stored at 4 °C. Before further use the resin was washed 
extensively with washing buffer B until the orange color of the resin disappeared 
completely. To equilibrate the pH value of the resin it was washed with washing 
buffer C. 
 
 washing buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
 washing buffer B Tris-HCl pH 10.5 100 mM 
  NaCl 150 mM 
  EDTA 1 mM 
 
 washing buffer C Tris-HCl pH 8.0 100 mM 
  NaCl 150 mM 
  EDTA 1 mM 
 
 elution buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
  D-desthiobiotin 2.5 mM 
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 regeneration buffer Tris-HCl pH 8.0 100 mM 
  NaCl 150 mM 
  EDTA 1 mM 
  2-(4’-hydroxyl-benzeneazo)- 
  benzoic acid 1 mM 
 
2.6.3.2 Purification of GST-tagged PA3911 protein 
 
The cell free extract containing PA3911 protein with an N-terminal GST-tag 
(2.6.2.2) was loaded onto 2 ml Protino® Glutathione Agarose 4 B 
(Macherey-Nagel, Düren, Germany) which was equilibrated with 10 CV of dH2O 
and 10 CV of harvesting buffer C. The supernatant was incubated with the resin 
for 2 h at RT on a roller mixer. The obtained flow-through was loaded onto the 
resin again, followed by four washing steps with 5 CV of harvesting buffer C, 
respectively. The protein of interest was eluted with 4x 1 CV of elution buffer B. 
Alternatively, protein elution was performed by on-column cleavage with 
PreScission™ Protease (GE Healthcare, Chalfont St Giles, UK). Therefore, 
protein PA3911 bound to glutathione agarose resin was incubated with 200 U 
PreScission™ Protease in 1 CV harvesting buffer C for 20 h at 4 °C on a roller 
mixer. 
 
 harvesting buffer C Tris-HCl pH 8.0 50 mM 
  NaCl 150 mM 
 
 elution buffer B Tris-HCl pH 8.0 50 mM 
  NaCl 150 mM 
  glutathione 10 mM 
 
2.6.3.3 Purification of His6- or thioredoxin-His6-S-tagged PA3911 protein 
 
To purify PA3911 protein variants with an N-terminal His6-tag, an N-terminal 
thioredoxin-His6-S-tag or the sole thioredoxin-His6-S-tag the soluble supernatant 
obtained after ultracentrifugation (2.6.2.2) was loaded onto 1 ml TALON® metal 
affinity resin (Clontech® Laboratories, Mountain View, CA, USA) which was 
equilibrated with 5 CV dH2O and 2x 5 CV of harvesting buffer B. The 
supernatant was incubated with the resin for 20 min at RT on a roller mixer. The 
resin was washed once with 5 CV of harvesting buffer B and then four 
pre-elution steps with 5 CV of harvesting buffer B supplemented with 10, 20, 40 
or 60 mM imidazole were performed. For protein elution 10x 0.5 CV of elution 
buffer C were applied to the column and elution fractions were stored at 4 °C. 
 
 harvesting buffer B sodium phosphate pH 7.0 50 mM 
  NaCl 300 mM 
 
 elution buffer C sodium phosphate pH 7.0 50 mM 
  NaCl 300 mM 
  imidazole  150 mM 
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2.6.4 Dialysis 
 
2.6.4.1 A-PGH protein variants 
 
Elution fractions of protein A-PGH and A-PGHtrunc were pooled and dialyzed in a 
dialysis membrane (dialysis tubing membrane visking, molecular weight cut-off 
(MWCO) of 14 kDa; Roth®, Karlsruhe, Germany) against at least 250 volumes 
of dialysis buffer A, dialysis buffer B or washing buffer A. Dialysis was 
performed in two steps at 4 °C for at least 2 h each with exchange of the 
dialysis buffer in between. The obtained protein solution was stored at 4 °C. 
 
 dialysis buffer A HEPES-NaOH pH 6.8 20 mM 
  
 dialysis buffer B sodium citrate pH 5.4 40 mM 
  NaCl 80 mM 
 
 
 washing buffer A  HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
2.6.4.2 AcvB protein variants 
 
Dialysis of elution fractions of AcvB protein variants was performed in a dialysis 
membrane (dialysis tubing membrane visking, MWCO of 14 kDa; Roth®, 
Karlsruhe, Germany) against at least 250 volumes of washing buffer A. Dialysis 
was performed in two steps at 4 °C for at least 2 h each with exchange of the 
dialysis buffer in between. The dialyzed protein solution was stored at 4 °C. 
 
 washing buffer A  HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
2.6.4.3 PA3911 protein variants 
 
Buffer exchange in PA3911 elution fractions against dialysis buffer C was 
performed with illustra NAP-5 columns according to the manufacturer’s 
instructions (GE Healthcare, Chalfont St Giles, UK). 
 
 dialysis buffer C ammonium acetate 5 mM 
 
2.6.5 Protein concentration 
 
Fractions containing purified protein were concentrated up to the desired protein 
concentration (2-15 mg/ml) in centrifugal concentrators with a MWCO of 10 kDa 
(Amicon® Ultra-0.5 or Vivaspin® Turbo 4) according to the manufacturer’s 
instructions (Merck Millipore, Darmstadt, Germany or Sartorius, Göttingen, 
Germany). 
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2.7  Protein characterization 
 
2.7.1 Determination of protein concentration 
 
Concentrations of purified proteins were determined photometrically using the 
method developed by Bradford (1976) (160). Underlying principle of this method 
is a shift in the absorption maximum of the dye Coomassie Brilliant Blue G-250 
from 470 to 595 nm upon complex formation with proteins. Measurement of the 
absorption at 595 nm allows for the determination of the protein concentration in 
the sample compared to a calibration curve. 
 
Protein concentrations were determined using Bradford reagent 
(Sigma-Aldrich®, St. Louis, MO, USA). Therefore, 30 µl protein solution was 
mixed with 1 ml Bradford reagent and incubated for 10 min. Absorption was 
measured at 595 nm and protein concentration was determined using a 
calibration curve of bovine serum albumin (BSA) dissolved in the respective 
buffer. Samples containing a high protein concentration were diluted with the 
respective buffer before measurement. 
Furthermore, protein concentrations were measured spectrophotometrically 
(NanoDrop™ ND-1000, PEQLAB Biotechnologie GmbH, Erlangen, Germany) 
according to the manufacturer’s instructions considering the molecular weight 
and the extinction coefficient of the respective protein. 
 
2.7.2 Discontinuous sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
 
Protein samples were analyzed under denaturing conditions via discontinuous 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Therefore, the samples are incubated with the anionic detergent SDS to 
denature the proteins and to apply a negative charge to them. Furthermore, the 
addition of 2-mercaptoethanol reduces disulfide linkages in the protein sample. 
This sample preparation allows for the separation of proteins in a 
polyacrylamide gel according to their molecular weights (161). In addition to that 
the use of discontinuous SDS-PAGE sharpens the resulting protein bands and 
increases the separating capacity (162). 
 
Protein samples were mixed with 2x SDS loading dye and incubated at 95 °C 
for 10 min. Afterwards samples were centrifuged (12’100 x g, RT, 5 min) and 
loaded onto a SDS polyacrylamide gel. Two size standards were used: the 
Unstained Protein Molecular Weight Marker and the PageRuler™ Prestained 
Protein Ladder (Thermo Fisher Scientific, Waltham, MA, USA). The latter one 
was employed for polyacrylamide gels subsequently used for blotting. 
Electrophoresis was performed at 45 mA per polyacrylamide gel and 
Coomassie Brilliant Blue R-250 or InstantBlue™ (Expedeon Inc., San Diego, 
CA, USA) were utilized to stain the gels. Protein bands were visualized by 
destaining the background and the polyacrylamide gels were documented on a 
BIO-5000 Plus VIS gel scanner (Serva, Heidelberg, Germany) (146). 
 
 
 
 
 50 
 
 running gel, 12% (w/v) Rotiphorese® Gel 30 2 ml 
  1.5 M Tris-HCl pH 8.8 with 
  0.4% (w/v) SDS 1.25 ml 
  dH2O  1.75 ml 
  10% (w/v) ammonium persulfate 
  (APS)  50 µl 
  N,N,N’,N’-tetramethylethylene 
  diamine (TEMED) 5 µl 
 
 running gel, 15% (w/v) Rotiphorese® Gel 30 2.5 ml 
  1.5 M Tris-HCl pH 8.8 with 
  0.4% (w/v) SDS 1.25 ml 
  dH2O  1.25 ml 
  10% (w/v) APS 50 µl 
  TEMED 5 µl 
 
 stacking gel, 6% (w/v) Rotiphorese® Gel 30 0.5 ml 
  0.5 M Tris-HCl pH 6.8 with 
  0.4% (w/v) SDS 625 µl 
  dH2O  1.375 ml 
  10% (w/v) APS 25 µl 
  TEMED 2.5 µl 
 
 2x SDS loading dye Tris-HCl pH 6.8 50 mM 
  2-mercaptoethanol 2 mM 
  glycerol 10% (v/v) 
  SDS 2% (w/v) 
  bromophenol blue 0.1% (w/v) 
 
 electrophoresis buffer Tris-HCl pH 8.8 50 mM 
  glycine 385 mM 
  SDS 0.1% (w/v) 
 
 staining solution acetic acid 10% (v/v) 
  ethanol 30% (v/v) 
  Coomassie Brilliant 
  Blue R-250 0.25% (w/v) 
 
 destaining solution acetic acid 10% (v/v) 
  ethanol 30% (v/v) 
 
2.7.3 Protein transfer via blotting 
 
Protein samples destined for N-terminal sequence determination (2.7.5) or 
immunochemical detection of specific proteins were separated by discontinuous 
SDS-PAGE (2.7.2). The resulting unstained polyacrylamide gel and two pieces 
of blotting paper (neoLab®, Heidelberg, Germany) were equilibrated in Towbin 
buffer for 10 min. The proteins were transferred onto a methanol-activated and 
in Towbin buffer equilibrated polyvinylidene difluoride (PVDF) membrane 
(Immobilon-P Transfer Membrane with a pore size of 0.45 µm, Merck Millipore, 
Darmstadt, Germany) using the semi-dry Trans-Blot® Turbo™ system (Bio-Rad, 
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Hercules, CA, USA). The transfer was performed at 25 V and the transfer time 
was adjusted based on the molecular weight of the protein of interest. 
 
 sample transfer time (per mini gel) 
 AcvB (localization, chapter 2.12.2) 13 min 
 PA3911 (localization, chapter 2.11)  6 min 
 VirJ (localization, chapter 2.12.2) 7 min 
 
PVDF membranes intended for N-terminal sequence determination (2.7.5) were 
stained with Ponceau S solution to visualize the protein bands and the desired 
bands were excised with a scalpel for further analysis. 
 
 Towbin buffer Tris-HCl pH 9.5 25 mM 
  glycine 192 mM 
  methanol  20% (v/v) 
 
 Ponceau S solution Ponceau S 0.2% (w/v) 
  trichloroacetic acid 3% (w/v) 
  sulfosalicylic acid 3% (w/v) 
 
2.7.4 Immunochemical detection of StrepII-tagged® proteins 
 
For immunochemical detection of StrepII-tagged® proteins the Strep-Tactin® AP 
conjugate was used according to the manufacturer’s instructions (iba, 
Göttingen, Germany) with slight modifications. All incubation steps were 
performed on a roller mixer at RT. 
After protein transfer the PVDF membrane was incubated in 20 ml blocking 
buffer A for 1 h. Following three washing steps with Phosphate Buffered Saline 
(PBS)-Tween® buffer (20 ml buffer, 5 min) biotinylated proteins were masked 
with avidin (Calbiochem® by Merck, Darmstadt, Germany). Therefore, the 
membrane was incubated for 10 min with 10 ml PBS-Tween® buffer containing 
10 µl of a 2 mg/ml avidin stock solution. The antibody Strep-Tactin® AP 
conjugate (iba, Göttingen, Germany) was added to the membrane in a 1:4’000 
dilution in 10 ml PBS-Tween® buffer and incubation took place for 1 h. 
Subsequently, several washing steps were performed: 2x with PBS-Tween® 
buffer (20 ml, 1 min) and 2x with PBS buffer (20 ml, 1 min). For 
immunochemical detection the membrane was initially equilibrated with 15 ml 
reaction buffer for 10 min. This buffer was exchanged against 15 ml reaction 
buffer supplemented with 49.5 µl of nitrotetrazolium blue (NBT) and 49.5 µl of 
5-bromo-4-chloro-3-indolyl phosphate (BCIP) and incubated until optimal 
visualization of protein bands. Dye formation by AP was stopped by several 
washing steps of the membrane with dH2O. 
 
 1x PBS buffer KH2PO4 2 mM 
  KCl 2.7 mM 
  Na2HPO4 10 mM 
  NaCl 137 mM 
 
 PBS-Tween® buffer Tween® 20 0.1% (v/v) 
  in 1x PBS buffer 
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 blocking buffer A BSA 3% (w/v) 
  Tween® 20 0.5% (v/v) 
  in 1x PBS buffer 
 
 reaction buffer Tris-HCl pH 9.5 100 mM 
  NaCl 100 mM 
  MgCl2 5 mM 
 
 BCIP stock solution BCIP 50 mg/ml 
  in 100% (v/v) dimethylformamide 
 
 NBT stock solution NBT 100 mg/ml 
  in 70% (v/v) dimethylformamide 
 
2.7.5 Amino acid sequence determination 
 
Protein identity was verified by determination of the N-terminal amino acid 
sequence. Therefore, a method according to Edman et al. (1950) (163) was 
applied. This work was kindly performed by Beate Jaschok-Kentner (Helmholtz 
Centre for Infection Research, Braunschweig, Germany). 
 
2.7.6 Native molecular mass determination by gel permeation 
chromatography 
 
The native molecular masses of purified proteins were determined by analytical 
GPC using a Superdex™ 200 Increase 5/150 GL or a Superdex™ 200 HR 
10/30 chromatography column (GE Healthcare, Chalfont St Giles, UK). For 
proteins A-PGH, A-PGHtrunc and AcvB the chromatography column was 
equilibrated with washing buffer A. 
Sample volumes from 50-150 µl with a protein concentration of 5-10 mg/ml 
were loaded onto the respective column and elution was performed with a flow 
rate of 0.45 ml/min. During the chromatography run the absorptions at 260 nm 
and 280 nm were detected to monitor DNA and protein elution, respectively. 
Several protein standards from the Gel Filtration Markers Kit for Protein 
Molecular Weights 12’000-200’000 Da (Sigma-Aldrich®, St. Louis, MO, USA) 
were processed analogously to generate a calibration curve which allows for the 
determination of the native molecular mass of the sample. 
 
 washing buffer A  HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
2.7.7 Determination of molecular mass by electrospray ionization mass 
spectrometry 
 
The molecular mass of the purified thioredoxin-His6-S-tagged PA3911 protein 
(2.6.3.2) was determined by electrospray ionization mass spectrometry 
(ESI-MS). For analysis, 250 µl of a freshly purified protein sample was loaded 
onto an illustra NAP-5 column (GE Healthcare, Chalfont St Giles, UK) and 
buffer exchange against dialysis buffer C was performed according to the 
manufacturer’s instructions. The sample was stored at 4 °C until use and 
10% (v/v) formic acid were mixed with the sample immediately before 
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measurement. Sample measurement on an Orbitrap Fusion™ (Thermo 
Scientific, San Jose, CA, USA) with a theoretical mass accuracy of ± 10 ppm 
resulted in an isotope resolved spectrum. Sample measurement and data 
evaluation were kindly performed by Dr. Manfred Nimtz (Helmholtz Centre for 
Infection Research, Braunschweig, Germany). 
 
 dialysis buffer C ammonium acetate 5 mM 
 
2.7.8 Thermal Shift Assay 
 
The Thermal Shift Assay was performed to determine the melting temperature 
(TM) of proteins. This enables the comparison of wild type with mutant proteins 
or the determination of protein stability in different conditions (e.g. buffer 
systems or presence of additives). The underlying principle is the binding of a 
fluorescent dye to the hydrophobic parts of a protein during denaturation and 
unfolding. The maximum of the first derivative of the resulting melting curve 
corresponds to the TM of the protein under the given conditions (164). 
 
Initially 40 µl protein buffer, 5 µl protein solution (0.5, 1 or 2 mg/ml) and 5 µl 
SYPRO® Orange Protein Gel Stain (Thermo Fisher Scientific, Waltham, MA, 
USA) solution (10x, 50x or 100x) were mixed in the wells of a microtiter plate 
(Bio-Rad, Hercules, CA, USA). The plate was sealed (Microseal® ‘B’ seal, 
Bio-Rad, Hercules, CA, USA) air-tight and the measurement was performed in a 
real-time PCR machine (C1000™ Thermal Cycler with CFX96™ real-time 
system, Bio-Rad, Hercules, CA, USA). The samples were heated from 10 °C to 
90 °C in 0.5 °C steps and the fluorescence intensity at 570 nm was determined 
every 15 sec. Based on the melting curves and their derivatives the ideal 
experimental concentrations with respect to protein and fluorescent dye ratio 
were determined. The following measurements were then performed under 
these ideal conditions. Either solutions of wild type protein were compared with 
mutant proteins or the protein of interest was exposed to different buffers or 
additives. To calculate the TM the maximum of the first derivative was 
determined using the software CFX Manager (Bio-Rad, Hercules, CA, USA). 
 
2.7.9 Determination of selenomethionine incorporation by mass 
spectrometry 
 
The SeMet occupancy for protein A-PGH was analyzed via matrix-assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). 
Therefore, elution fractions from affinity purification were separated by 
discontinuous SDS-PAGE (2.7.2) and the polyacrylamide gel was stained with 
Coomassie Brilliant Blue. Following extensive treatment with destaining solution 
and several washing steps with dH2O the relevant protein bands were excised 
from the polyacrylamide gel with a scalpel. The fragments were dried under 
vacuum for 1 h at 30 °C (Speed Vac®, Savant). The sample preparation for 
MALDI-TOF MS analysis (e.g. tryptic digest) as well as the measurement and 
data evaluation was kindly performed by Dr. Manfred Nimtz (Helmholtz Centre 
for Infection Research, Braunschweig, Germany). 
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2.7.10 Small-angle X-ray scattering 
 
Small-angle X-ray scattering (SAXS) is a versatile solution-based method to 
study the structure of biological macromolecules of broad size ranges. In a 
SAXS experiment the sample is exposed to a collimated and focused X-ray 
beam. The scattered intensity is recorded by a detector as a function of the 
scattering angle and the obtained scattering curve allows for the determination 
of a low-resolution model. With this technique the oligomeric state of biological 
macromolecules or complexes can be determined and flexible systems 
undergoing conformational changes can be studied (165, 166). 
 
SAXS experiments were performed by Dr. Jörn Krauße (Helmholtz Centre for 
Infection Research, Braunschweig) at beamline BM29 (167) of the European 
Synchrotron Radiation Facility (ESRF, Grenoble, France) to elucidate the 
A-PGH solution structure. Samples of purified A-PGH protein at concentrations 
ranging from 10-214 µM in dialysis buffer B were loaded to a quartz capillary 
mounted in vacuum by an automated sample changer and exposed to X-ray 
energy of 12.5 keV. Scattering images covering a momentum transfer range of 
0.0025-5 nm-1 were recorded. Ten images per sample with an exposure time of 
one second per frame were recorded. The scattering functions were determined 
using PRIMUS. Data were averaged, normalized and corrected for buffer 
scattering. DAMMIF was used to compute twenty models from SAXS data and 
a representative ab initio model was constructed using DAMAVER and 
SUPCOMP. Utilized programs are part of the ATSAS program package (168). 
 
2.7.11 Protein-lipid overlay assay 
 
To analyze the ability of PA3911 wild type or mutant proteins to bind membrane 
lipids a protein-lipid overlay assay was performed. Therefore, a hydrophobic 
membrane with several lipids spotted onto it was incubated with the purified 
protein of interest. Following several washing steps protein-lipid interaction was 
visualized by immunochemical detection. 
 
The lipid binding capability of PA3911 wild type or mutant proteins was 
investigated using Membrane Lipid Strips™ P-6002 (Echelon Biosciences, Salt 
Lake City, UT, USA) according to the manufacturer’s instructions with slight 
modifications. All steps were performed on a lab rocker at RT unless indicated 
otherwise. 
The lipid strips were blocked overnight at 4 °C in 10 ml blocking buffer B. Then 
0.5 µg/ml purified PA3911 protein or mutant variants (N-terminal 
thioredoxin-His6-S-tag, 2.6.3.3) in 10 ml blocking buffer B were added to the 
lipid strip and incubated for 1 h. Three washing steps with PBS-Tween® buffer 
(2.7.4) were performed (10 ml, 7 min). Afterwards the lipid strip was incubated 
for 1 h with a primary Penta-His mouse monoclonal IgG antibody (QIAGEN, 
Hilden, Germany) diluted 1:2’000 in 10 ml blocking buffer B. The lipid strip was 
washed again as described before and subsequently incubated for 1 h with the 
secondary anti-mouse IgG (Fc-specific)-alkaline phosphatase antibody 
(Sigma-Aldrich®, St. Louis, MO, USA) diluted 1:5’000 in blocking buffer B. 
Unbound antibodies were washed away as described before and 
lipid-interacting proteins were detected by AP-dependent substrate conversion 
of BCIP and NBT. Therefore, the lipid strip was equilibrated in 10 ml reaction 
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buffer (2.7.4) for 10 min. Then 10 ml reaction buffer supplemented with 49.5 µl 
BCIP and 49.5 µl NBT (2.7.4) was added and incubated until optimal 
visualization. The reaction was stopped by extensive washing of the lipid strip in 
dH2O. 
 
 blocking buffer B BSA 3% (w/v) 
  Tween® 20 0.1% (v/v) 
  in 1x PBS (2.7.4) 
 
2.8  Lipid analysis 
 
2.8.1 Lipid extraction 
 
For lipid analysis, P. aeruginosa cells were cultivated for 24 h at 37 °C and 
200 rpm in different media (e.g. LB medium, AB medium pH 5.3 or pH 7.3). The 
bacterial cell suspensions were adjusted to their optical densities (15 ml culture 
with OD578 = 0.6) before harvesting (4’000 x g, 4 °C, 20 min). The cell sediment 
was stored at -20 °C until further processing. E. coli membrane fractions from 
in vitro A-PGS activity assays were harvested by centrifugation (11’000 x g, RT, 
30 min) and the cell sediments were stored at -20 °C. Lipids were extracted by 
a modified method according to Bligh and Dyer (1959) (169). The cell pellet was 
resuspended in a total volume of 100 µl dH2O. 375 µl methanol/chloroform 
(2:1 (v/v)) were added, vigorously mixed with the suspension and incubated for 
3 min at RT. After centrifugation (12’100 x g, RT, 3 min), 200 µl 
chloroform/dH2O (1:1 (v/v)) were intensively mixed with the resulting 
supernatant. Following centrifugation (12’100 x g, RT, 3 min) the lower 
chloroform phase was collected and evaporated at 40 °C in a thermomixer. The 
dried lipids were stored at -20 °C (170). Lipid fractions extracted from in vitro 
A-PGS activity assays were dried at RT and used for scintillation analyses. 
 
2.8.2 Lipid analysis by thin-layer chromatography 
 
To analyze the polar lipid content, lipid extracts from P. aeruginosa cells (2.8.1) 
were dissolved in 20 µl methanol/chloroform (1:1 (v/v)) and loaded onto a 
10x10 cm TLC plate (Alugram® SIL G/UV254, Macherey-Nagel, Düren, 
Germany) in 5 µl steps. Lipid separation was carried out at 25 °C. To analyze 
the major lipid classes of P. aeruginosa the solvent system for the first 
dimension consisted of chloroform/methanol/water (65:25:4 (v/v/v)). The TLC 
plate was dried under a fume hood and was then employed for the second 
dimension with the following solvent system: chloroform/methanol/acetic 
acid/water (80:12:15:4 (v/v/v/v)) (171). Furthermore, solvent systems for the 
specific separation of PA from the major lipid classes were applied with 
chloroform/ethanol/water/triethylamine (30:35:7:35 (v/v/v/v)) (172) or 
chloroform/methanol/water (65:25:4 (v/v/v)) in the first dimension and 
chloroform/methanol/ammonium hydroxide (65:25:4 (v/v/v)) in the second 
dimension (173).  
Reaction mixtures from AcvB/VirJ in vitro activity assays were spotted onto TLC 
plates at defined time points together with L-lysine as a reference. 
One-dimensional TLC separation using n-butanol, acetic acid and water 
(4:1:1 (v/v/v)) as solvent system (174) was carried out at 25 °C.  
Several staining solutions were used to detect specific lipid classes on TLC 
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plates. Spraying with 5% (w/v) molybdatophosphoric acid (in ethanol; Roth®, 
Karlsruhe, Germany) and incubation at 120 °C on a TLC plate heater 
(CAMAG®, Muttenz, Switzerland) allowed for the detection of reducing 
compounds like lipids. Ninhydrin spray solution (0.3% (w/v), Merck, Darmstadt, 
Germany) was used for the identification of compounds containing free amino 
groups, appearing after incubation at 110 °C on a TLC plate heater. 
Molybdenum Blue spray reagent (1.3% (w/v), Sigma-Aldrich®, St. Louis, MO, 
USA) enabled the detection of phospholipids by incubation at RT until spot 
development. 
 
2.8.3 Liquid scintillation counting 
 
4 ml of OptiPhase HighSafe 2 (PerkinElmer, Waltham, MA, USA) was added to 
radioactively labeled phospholipids (2.8.1) and scintillation counting was 
performed in a Tri-Carb® 2900TR liquid scintillation analyzer (PerkinElmer, 
Waltham, MA, USA). 
 
2.8.4 Quantification of phosphatidic acid in P. aeruginosa cells 
 
For quantification of the cellular PA content of P. aeruginosa strains MPAO1 
and PW7609 the commercially available Total Phosphatidic Acid Assay Kit (Cell 
Biolabs, San Diego, CA, USA) was used according to the manufacturer’s 
instructions. 
The sample preparation had to be adjusted due to the use of bacterial cells 
instead of mammalian cells. To ensure comparable conditions for 
PA quantification, P. aeruginosa cells were cultivated aerobically and 
anaerobically to the mid-logarithmic phase defined as the OD578 at the midpoint 
of the linear range of exponential growth. This time point was determined by 
monitoring the growth behavior over a time period of 10 h. 
500 ml AB medium pH 7.3 in baffled flasks (one flask per sample) was 
inoculated to an OD578 of 0.05 using an overnight culture of either strain 
P. aeruginosa MPAO1 or P. aeruginosa PW7609. Cells were cultivated 
aerobically at 37 °C and 200 rpm to the mid-logarithmic phase (~4 h after 
inoculation). Alternatively, 125 ml AB medium pH 7.3 supplemented with 
50 mM potassium nitrate in anaerobic culture flasks (three flasks per sample) 
was inoculated to an OD578 of 0.3 using an overnight culture of P. aeruginosa 
strain MPAO1 or PW7609. Anaerobic cultivation was performed at 37 °C and 
100 rpm to the mid-logarithmic phase (~6.5 h after inoculation). Identical 
amounts of cells (15 ml culture with OD578 = 6) were harvested by centrifugation 
(4’000 x g, 4 °C, 10 min), the cell pellets were washed with cold PBS (2.7.4, 
containing 1 mM CaCl2 and 0.5 mM MgCl2) and were stored at -20 °C. After 
resuspending the cell pellet in 1 ml cold PBS, lipids were extracted according to 
the manufacturer’s instructions. The dried samples were dissolved in 30 µl 
1x Assay Buffer and stored at -80 °C. PA contents in the samples were 
determined as means ± standard deviation (SD) of duplicates from three 
independent experiments. 
 
2.9 Determination of in vitro A-PGS activity 
 
To determine the activity of recombinantly produced and purified A-PGS543-881 
protein variants a well-established in vitro activity assay (47) was performed. 
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The formation of A-PG is catalyzed by the A-PGS which transfers an alanine 
moiety from the corresponding Ala-tRNAAla to the hydroxyl group of PG (43). 
Due to the presence of the alanyl-tRNA synthetase in the assay system the 
uncharged tRNAAla is re-charged and alanylated by consumption of two 
adenosine triphosphate (ATP) molecules. Therefore, the reaction mixture 
contains an ATP regenerating system to provide sufficient ATP molecules. The 
catalytic A-PGS domain (containing amino acid residues 543-881) and mutant 
variants were recombinantly produced in E. coli. Purified proteins used in this 
assay were generously provided by S. Hebecker. 
To recombinantly overproduce the alanyl-tRNA synthetase from P. aeruginosa 
500 ml LB medium (supplemented with 30 µg/ml Kan and Cm) was inoculated 
with an overnight pre-culture of E. coli Rosetta™ (DE3) pLysS 
pET28b(+)PA0903 in a ratio of 1:100 (v/v). Cells were cultivated at 37 °C and 
180 rpm to an OD578 of 0.5. Cultures were shifted to 30 °C and 180 rpm for 
10 min. Then, 200 µM IPTG were added to induce protein production and 
cultivation was continued at 30 °C and 180 rpm for 4 h. Cells were sedimented 
by centrifugation (3’000 x g, 4 °C, 20 min) and washed with 50 mM 
HEPES-NaOH pH 7.8. Following a second centrifugation step (4’000 x g, 4 °C, 
15 min) cells were resuspended in 50 mM HEPES-NaOH pH 7.8 and 
supplemented with DNase I (Invitrogen, Carlsbad, CA, USA). Cells were 
disrupted by a single passage through a French Press® (Thermo Fisher 
Scientific, Waltham, MA, USA) at 19’200 psi. The obtained crude cellular extract 
provides the substrate molecule PG, tRNAAla and the alanyl-tRNA synthetase 
for the in vitro assay. The reaction was performed in a total volume of 700 µl. 
Therefore, 500 µl of this crude cellular extract was supplemented with 2 mM 
ATP, an ATP regenerating system (35 U/ml creatine phosphokinase and 18 mM 
creatine phosphate) and 20 µM [1-14C]-L-alanine (Moravec Biochemicals, Brea, 
CA, USA). The reaction was started by the addition of 10 µM of the respective 
purified A-PGS543-881 protein variant (wild type, K676E, K676S, N683D, N683S, 
R684E, R684S, R687S) and was incubated at 37 °C and 1’000 rpm for 1 h. 
Samples were taken at distinct time points, heat inactivated (60 °C, 5 min) and 
stored at -20 °C for lipid extraction (2.8.1) and scintillation counting (2.8.3). 
 
2.10 In vitro activity assay for AcvB and VirJ 
 
The L-PG hydrolyzing activity of AcvB variants and VirJ was determined in an 
in vitro activity assay. Therefore, 1 mg of 18:1 L-PG (Avanti® Polar Lipids, 
Alabaster, AL, USA) was solubilized in 200 µl dialysis buffer A containing 
3 mg/ml Triton™ X-100 at 37 °C for 15 min under vigorous shaking. 80 µl of this 
L-PG micelle solution was incubated with 80 µl of 20 µM purified AcvB (or 
mutant variant), VirJ or Strep-tag® II protein in dialysis buffer A at 37 °C and 
1’000 rpm for 60 min. At defined time points 5 µl of the respective reaction 
mixture was spotted onto a TLC plate together with 5 µl of a 68 µM L-lysine 
solution (Fluka, Buchs, Switzerland) as a reference. Subsequent to TLC 
separation and ninhydrin staining (2.8.2) spot intensities were determined using 
the software TotalLab Quant (Cleaver Scientific Ltd, Rugby, UK). Comparison 
with a linear calibration curve (spot intensities plotted against the respective 
L-lysine concentration) allowed for the quantification of L-lysine formation during 
in vitro activity assays and for the calculation of specific activities for AcvB 
variants and VirJ. 
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Phenotypic characterization 
 
The P. aeruginosa mutant strain PW7609 was compared with the wild type 
strain MPAO1 concerning the following phenotypic characteristics: twitching, 
swimming and swarming motility, biofilm formation and growth in the presence 
of 1’152 different culture conditions (Phenotype Microarray™). 
 
2.10.1 Confirmation of P. aeruginosa mutant strain PW7609 
 
Prior to the phenotypic characterization of P. aeruginosa mutant strain PW7609, 
the correct insertion of the ISphoA/hah transposon into orf PA3911 was 
confirmed according to a procedure described by the library curators (134). 
Therefore, gene flanking primers 40 and 41 as well as gene flanking primer 41 
and transposon specific primer 42 were utilized in a colony PCR (2.5.5) to verify 
the absence of the gene of interest and the correct insertion of the transposon. 
The obtained transposon specific fragment was purified with the QIAquick PCR 
Purification Kit (QIAGEN, Hilden, Germany) and was sequenced (GATC 
Biotech, Konstanz, Germany) with primer J to verify the transposon insertion 
site. 
 
2.10.2 Standard phenotype assays 
 
2.10.2.1 Twitching motility 
 
To analyze the twitching motility of P. aeruginosa strains the respective 
inoculum was stabbed down to the agar-plastic interface of a thin 1% (w/v) 
LB-Lennox agar plate by a sterile toothpick. The agar plates were incubated in a 
humidified chamber at 37 °C for 24 h. The twitch zones of five independent 
biological experiments using six replicates each were measured (175). For 
comparison of the wild type and mutant strain the twitch zone diameter of the 
wild type strain was set to 100%. 
 
2.10.2.2 Swimming motility 
 
Swimming motility was analyzed on thick M8 agar plates containing 0.3% (w/v) 
agar. A sterile toothpick was dipped into an overnight culture of the respective 
strain and stabbed into the middle of the agar layer. The diameter of the motility 
zone was measured after incubation for 24 h at 37 °C (175). Two independent 
biological experiments with six replicates were performed. 
 
2.10.2.3 Swarming motility 
 
Swarming motility analysis was performed on thick M8 agar plates containing 
0.5% (w/v) agar. The agar plates were inoculated with 2.5 µl of an overnight 
culture of the respective strain and incubated for 21 h at 37 °C before the 
motility zone diameter was determined (175). Two independent biological 
experiments with six replicates were performed. 
 
2.10.2.4 Biofilm assay 
 
The biofilm formation of P. aeruginosa strains was analyzed in a static microtiter 
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plate-based assay in nine independent experiments containing eight replicates. 
Therefore, overnight cultures of the respective strains were grown to stationary 
phase, optical density adjusted (OD600 = 0.05) and diluted in a ratio of 
1:100 (v/v) with fresh LB medium to yield 5x 105 cells/ml. 96-well polypropylene 
round-bottom microtiter plates (Nunc™, Roskilde, Denmark) were inoculated 
with 100 µl cell suspension per well and incubated at 37 °C for 24 h without 
shaking. After the removal of planktonic cells the microtiter plates were 
extensively rinsed with water and surface-attached bacteria were stained with 
0.1% (w/v) crystal violet solution for 10 min. The microtiter plates were again 
extensively rinsed with water and the biofilms were solubilized with 30% (v/v) 
acetic acid for quantification of A595
 (175). 
 
2.10.3 Phenotype Microarray™ analyses 
 
Phenotypic differences for the isogenic mutant strain PW7609 were analyzed 
using a broad range of stress conditions (e.g. salts, pH and antibiotics). For 
analysis the transposon mutant strain PW7609 and the wild type strain MPAO1 
were subjected to an overall of 1’152 growth conditions (MicroPlates™ PM9 to 
PM20) using a commercially available microarray system from Biolog (Hayward, 
CA, USA) according to the manufacturer’s instructions. The plates were 
incubated at 37 °C in an OmniLog® incubator and the color change (reduction of 
a tetrazolium dye as a result of cell respiration) was monitored for 48 h. Growth 
kinetics were analyzed using OmniLog®-PM software (release 
OL_PM_FM/Kin 1.20.02 Aug. 12, 2005). 
Significant growth phenotypes were independently reproduced in 
non-commercial microarray experiments which were performed in triplicate. 
Therefore, the strains were cultivated as described above in the presence of 
minocycline hydrochloride (0.25-9 µg/ml), nafcillin sodium salt 
(100-1’000 µg/ml), oxacillin sodium salt monohydrate (200-2’800 µg/ml), 
chloramphenicol (2-1’200 µg/ml; Roth®, Karlsruhe, Germany), thiamphenicol 
(2.5-1’000 µg/ml) and 1-chloro-2,4-dinitrobenzene (CDNB) (1-200 µg/ml) in 
120 µl IF-10 medium containing tetrazolium dye A (Biolog, Hayward, CA, USA) 
using 96-well plates (REF 82.1581.001, Sarstedt, Nümbrecht, Germany). 
Unless noted otherwise, the chemicals were purchased from Sigma-Aldrich® 
(St. Louis, MO, USA). 
 
2.11 Localization of protein PA3911 in P. aeruginosa 
 
Localization studies were performed with P. aeruginosa PAO1 strain carrying 
plasmid pUCP20T-PPA3911-PA3911. This plasmid encodes for the PA3911 
protein fused to a C-terminal Strep-tag® II sequence. Analysis of subcellular 
fractions was performed via Western blotting with Strep-Tactin® AP conjugate 
(iba, Göttingen, Germany) according to the manufacturer’s instructions. 
 
2.11.1 Cultivation for localization studies 
 
The P. aeruginosa PAO1 strain carrying the plasmid pUCP20T-PPA3911-PA3911 
(2.2.2) was cultivated, harvested and analyzed by subcellular localization 
experiments. 
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1 l LB medium supplemented with Cb (in baffled flasks) was inoculated to an 
OD578 of 0.05 using an overnight culture of strain P. aeruginosa PAO1 
pUCP20T-PPA3911-PA3911 and was incubated at 37 °C and 200 rpm for 4 h 
(end of the exponential growth phase). Cells were harvested by centrifugation 
(3‘000 x g, 4 °C, 15 min), resuspended in 50 ml harvesting buffer A (for analysis 
of the periplasmic and cytoplasmic fraction) or disruption buffer B (for analysis 
of the total membrane fraction) and sedimented again (4’000 x g, 4 °C, 20 min). 
The isolation of the periplasmic and cytoplasmic fraction was performed directly 
after cell harvesting, whereas cell pellets for the isolation of the total membrane 
fraction were stored at -20 °C until further use. 
 
 harvesting buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 150 mM 
  D(+)-sucrose 20% (w/v) 
 
 disruption buffer B Tris-HCl pH 8.0 50 mM 
 
2.11.2 Isolation of the periplasmic and cytoplasmic fraction 
 
To localize the PA3911 protein in P. aeruginosa cells the periplasmic and 
cytoplasmic fraction were isolated. Therefore, cells were treated with 
polymyxin B as already described in chapter 2.6.2.1 and the formed 
spheroblasts were further utilized for the isolation of the cytoplasmic fraction. 
 
The harvested cell pellet (2.11.1) was suspended in the double sediment 
volume of disruption buffer A and was incubated at 4 °C for 90 min on a roller 
mixer. Following a centrifugation step (10’000 x g, 4 °C, 15 min) the supernatant 
contained the periplasmic proteins, whereas the spheroblasts containing 
cytoplasmic and membrane proteins were sedimented. The spheroblast fraction 
was stored at -20 °C until further analysis. 
The thawed spheroblast fraction was resuspended in four volumes of washing 
buffer A for one pellet volume. 750 µl of the obtained cell suspension was mixed 
with 250 mg glass beads and was subjected to cell disruption via FastPrep® 
(3x 45 sec at 5.5 m/s; MP Biomedicals, Santa Ana, CA, USA). After 
centrifugation (20’000 x g, 4 °C, 1 h) the resulting supernatant contained the 
cytoplasmic proteins. 
 
 disruption buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 150 mM 
  D(+)-sucrose 20% (w/v) 
  polymyxin B 2 mg/ml 
 
 washing buffer A  HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
2.11.3 Isolation of the total membrane fraction 
 
To isolate the total membrane fraction the cells were lysed, cell debris was 
separated and the membrane fraction was sedimented from the supernatant by 
high-speed centrifugation (49). 
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Harvested cells (2.11.1) were thawed and suspended in a total volume of 10 ml 
disruption buffer B. Cells were disrupted by a single passage through a 
French Press® (Thermo Fisher Scientific, Waltham, MA, USA) at 19’200 psi and 
cell debris was separated by low-speed centrifugation (20’000 x g, 4 °C, 
20 min). The obtained supernatant was subjected to ultracentrifugation 
(100’000 x g, 4 °C, 1 h) to sediment the total membrane fraction. After three 
washing steps with 500 µl of washing buffer D, respectively, the membrane 
proteins were solubilized. Therefore, the membrane pellet was overlaid with 
5 ml solubilization buffer and was gently stirred for 2 h at 4 °C. In a second 
ultracentrifugation step (100’000 x g, 4 °C, 1 h), lipids were sedimented and the 
resulting supernatant contained the solubilized membrane proteins. 
 
 disruption buffer B Tris-HCl pH 8.0 50 mM 
 
 washing buffer D Tris-HCl pH 8.0 50 mM 
  MgCl2 20 mM 
 
 solubilization buffer Tris-HCl pH 8.0 50 mM 
  MgCl2 20 mM 
  Triton™ X-100 2% (v/v) 
 
2.11.4 Sample preparation and analysis 
 
Samples of the cellular fractions (2.11.2 and 2.11.3) were mixed with 2x SDS 
loading dye in a ratio of 1:1 (v/v), were incubated at 95 °C for 10 min in a 
thermomixer and were separated by SDS-PAGE (2.7.2). The proteins were 
blotted onto a membrane according to the procedure described in chapter 2.7.3. 
Detection of the C-terminal Strep-tag® II sequence of protein PA3911 in the 
cellular fractions was performed as described in section 2.7.4. 
 
2.12 Localization of AcvB and VirJ in A. tumefaciens 
 
For the localization of proteins AcvB and VirJ in A. tumefaciens two different 
methods were employed. Therefore, A. tumefaciens cells carrying the 
respective plasmid were cultivated, fractionated into the soluble periplasmic and 
cytoplasmic part and analyzed either via an AP activity assay or via a Western 
Blot with subsequent immunochemical detection. 
 
2.12.1 Localization of AcvB and VirJ via alkaline phosphatase fusions 
 
2.12.1.1 Cultivation for localization studies 
 
The A. tumefaciens strains carrying plasmids pTrc200 ‘phoA, pTrc200 phoA, 
pTrc200 leader acvB ‘phoA or pTrc200 leader virJ ‘phoA (2.2.2) were cultivated, 
harvested and utilized for fractionation experiments. 
 
40 ml YEB medium supplemented with Spc and Str in baffled flasks was 
inoculated to an OD578 of 0.4 using the respective A. tumefaciens overnight 
culture and incubated at 30 °C and 200 rpm for 30 min. Then 15 µM IPTG was 
added to the bacterial cell culture (OD578 = 0.5) and the incubation was 
 62 
 
preceded for 3.5 to 4 h (end of exponential phase) at 30 °C and 200 rpm. Cells 
were adjusted to their optical densities (35 ml culture with OD578 = 1.6) and 
harvested (10‘000 x g, RT, 5 min). 
 
2.12.1.2 Isolation of the periplasmic and cytoplasmic fraction 
 
Fractionation of A. tumefaciens cells was performed according to the protocol of 
Kang et al. (1994) (62) with modifications. 
The harvested cell pellet (2.12.2) was suspended in 5 ml of disruption buffer C 
or disruption buffer D. The cell suspension was incubated at 4 °C for 30 min on 
a roller mixer. Following a centrifugation step (10’000 x g, 4 °C, 5 min) the 
supernatant contained the periplasmic proteins and the pellet the cytoplasmic 
and membrane proteins. The cell pellet was resuspended in 7 ml of disruption 
buffer B and disrupted by French Press® (Thermo Fisher Scientific, Waltham, 
MA) at 19’200 psi. Undisrupted cells were separated by centrifugation 
(12’000 x g, RT, 5 min). The supernatant was adjusted to a total volume of 8 ml 
with disruption buffer B and subsequently subjected to ultracentrifugation 
(213’000 x g, 4 °C, 60 min). The resulting supernatant contained the 
cytoplasmic proteins and the pellet contained the membrane proteins. 
 
 disruption buffer B Tris-HCl pH 8.0 50 mM 
 
 disruption buffer C Tris-HCl pH 8.0 50 mM 
  D(+)-sucrose 20% (w/v) 
  EDTA 2 mM 
  lysozyme 0.2 mg/ml 
 
 disruption buffer D Tris-HCl pH 8.0 50 mM 
  D(+)-sucrose 20% (w/v) 
  EDTA 2 mM 
  polymyxin B 2 mg/ml 
 
2.12.1.3 Determination of alkaline phosphatase activity 
 
The AP activity was determined in the soluble fractions (periplasm and 
cytoplasm) isolated from A. tumefaciens cells carrying the respective plasmid 
(2.2.2). Activity determination was performed as described by De Maagd and 
Lugtenberg (1986). 
The utilized test solution AP contains p-nitrophenyl phosphate which can be 
converted to p-nitrophenol by AP. The resulting reaction product is yellow and 
can be monitored spectrophotometrically at a wavelength of 405 nm. 
To analyze the soluble fractions (2.12.1.2) concerning their AP activity 50 µl of 
the respective fraction was mixed with 500 µl test solution AP and the 
absorption at 405 nm was monitored with a UV-VIS spectrophotometer (V-650, 
Jasco, Oklahoma City, Oklahoma, USA) for 180 sec. To analyze the 
spontaneous conversion of the substrate to p-nitrophenol during the reaction 
control measurements solely with the test solution AP were performed. For data 
analysis the program Spectra Manager (Jasco, Oklahoma City, Oklahoma, 
USA) was used. 
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 test solution AP Tris-HCl pH 8.5  0.1 M 
  MgCl2 0.4 M 
  p-nitrophenyl phosphate 0.4 mg/ml 
 
2.12.1.4 Plate-based assay for the determination of alkaline phosphatase 
activity in whole cells 
 
As an alternative method to determine AP activity in A. tumefaciens cells a 
plate-based assay with BCIP as substrate was used. BCIP can be hydrolyzed 
by AP to 5-bromo-4-chloroindolyl and phosphate. 5-bromo-4-chloroindolyl can 
then be oxidized with oxygen to the blue dye 5,5’-dibromo-4,4’-dichloroindigo 
(176). If active AP is present in the A. tumefaciens cells carrying the respective 
plasmid (2.2.2), BCIP supplemented to the YEB agar plates will be converted 
into the indigo dye and blue-colored A. tumefaciens colonies will appear. 
For analyses of AP activity YEB agar plates were supplemented with 90 µg/ml 
of BCIP as a substrate. Furthermore, several concentrations of disodium 
hydrogen phosphate pH 7.2 (5-100 mM) were added to the YEB agar plates to 
inhibit the endogenous AP activity (53). Several dilutions of overnight cultures of 
A. tumefaciens cells carrying the respective plasmid (volume 50 µl) were plated 
on YEB agar plates containing BCIP and disodium hydrogen phosphate, 
incubated at 30 °C for four days and analyzed concerning the coloration of the 
colonies (white or blue). 
 
2.12.1.5 Determination of malate dehydrogenase activity 
 
Impurities of the periplasmic fraction with cytoplasmic proteins were detected 
via a malate dehydrogenase (MD) activity assay. MD is a cytoplasmic protein 
and it can convert oxaloacetate to malate (177). During this reaction NADH+H+ 
is oxidized to NAD+ and its decrease can be detected in a UV-VIS 
spectrophotometer (V-650, Jasco, Oklahoma City, Oklahoma, USA) at a 
wavelength of 340 nm. The activity assay was performed according to the 
protocol of De Maagd and Lugtenberg (1986). 
For activity analyses 500 µl test solution MD were mixed with 50 µl of the 
respective periplasmic or cytoplasmic fraction (2.12.1.2). The reaction was 
started by the addition of 25 µl 10 mM oxaloacetate solution and the absorption 
at 340 nm was monitored with a UV-VIS spectrophotometer (V-650, Jasco, 
Oklahoma City, Oklahoma, USA) for 180 sec. For data analyses the program 
Spectra Manager (Jasco, Oklahoma City, Oklahoma, USA) was used. 
 
 test solution MD HEPES-NaOH pH 7.2 50 mM 
  NADH 0.3 mM 
 
2.12.2 Localization of AcvB and VirJ via Western Blot 
 
2.12.2.1 Cultivation for localization studies 
 
A. tumefaciens strains carrying plasmid pTrc200_acvB_Strep or 
pTrc200_virJ_Strep (2.2.2) were cultivated, harvested and cell pellets were 
subjected to fractionation experiments. 
 
A pre-culture of the respective A. tumefaciens strain was used to inoculate 
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500 ml YEB medium supplemented with Spc and Str in a baffled flask to an 
OD578 of 0.1. Cultivation was performed at 30 °C and 200 rpm for 4 h to an 
OD578 ~0.5, 15 µM IPTG were added to the main culture and cultivation was 
preceded for 3 h (OD578 ~1.6). Cells from 1 l cell culture were harvested 
(3’000 x g, 4 °C, 15 min), resuspended in 50 ml harvesting buffer D and 
sedimented again (4’000 x g, 4 °C, 25 min). Cell pellets were stored at -20 °C 
until use. 
 
 harvesting buffer D Tris-HCl pH 8.0 50 mM 
  NaCl 150 mM 
  D(+)-sucrose 20% (w/v) 
 
2.12.2.2 Isolation of the soluble cell fractions 
 
A modified protocol according to Kang et al. (1994) (62) was used to fractionate 
A. tumefaciens cells. 
Suspension of the respective cell pellet (2.12.2.1) in 5 ml of disruption buffer D 
was followed by incubation at 4 °C for 30 min on a roller mixer. The periplasmic 
fraction was separated from the cell pellet containing cytoplasmic and 
membrane proteins by centrifugation (10’000 x g, RT, 5 min). After 
resuspending the remaining cell pellet in 7 ml of disruption buffer B, cells were 
disrupted by French Press® (Thermo Fisher Scientific, Waltham, MA) at 
19’200 psi and unbroken cells were removed by centrifugation (12’000 x g, RT, 
5 min). Adjusting the final suspension volume to 9 ml was followed by 
ultracentrifugation (213’000 x g, 4 °C, 60 min) to separate the soluble 
cytoplasmic proteins from membrane proteins. 
 
 disruption buffer B Tris-HCl pH 8.0 50 mM 
 
 disruption buffer D Tris-HCl pH 8.0 50 mM 
  D(+)-sucrose 20% (w/v) 
  EDTA 2 mM 
  polymyxin B 2 mg/ml 
 
2.12.2.3 Analysis of the fractionation efficiency 
 
To analyze the cross-contamination of the periplasmic fraction with cytoplasmic 
proteins, the MD activity within the isolated soluble fractions (2.12.2.2) was 
determined as described in section 2.12.1.5. 
 
2.12.2.4 Isolation of the total membrane fraction 
 
The sedimented pellet after ultracentrifugation (2.12.2.2) containing the 
membrane proteins was carefully washed with 3x 500 µl of washing buffer D. 
The membrane pellet was covered with 5 ml solubilization buffer and was 
stirred for 2 h at 4 °C. Solubilized membrane proteins were transferred into the 
supernatant by ultracentrifugation (110’000 x g, 4 °C, 60 min). 
 
 washing buffer D Tris-HCl pH 8.0 50 mM 
  MgCl2 20 mM 
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 solubilization buffer Tris-HCl pH 8.0 50 mM 
  MgCl2 20 mM 
  Triton™ X-100 2% (v/v) 
 
2.12.2.5 Sample preparation and analyses 
 
Samples of the cellular fractions (2.12.2.2 and 2.12.2.4) were mixed with 
2x SDS loading dye in a ratio of 1:1 (v/v), were incubated at 95 °C for 10 min in 
a thermomixer and were separated by SDS-PAGE (2.7.2). Protein transfer onto 
a membrane was employed according to the procedure described in 
chapter 2.7.3. The C-terminal Strep-tag® II sequence of the proteins AcvB or 
VirJ within the fractions was detected as described in section 2.7.4. 
 
2.13 A. tumefaciens infection assays 
 
The experiments described in the following chapter were performed during an 
internship in the group of Prof. Franz Narberhaus (Lehrstuhl für Biologie der 
Mikroorganismen, Ruhr-University Bochum). 
 
2.13.1 Potato disc infection assay 
 
The quantitative determination of A. tumefaciens-induced tumorigenesis on 
potato tuber discs was carried out according to Wu et al. (2008) (178). 
Pre-cultures of the respective A. tumefaciens strains were grown overnight at 
30 °C in 5 ml YEB medium supplemented with the appropriate antibiotics. Cell 
suspensions were diluted to an OD600 = 0.1 in 10 ml YEB medium containing 
the respective antibiotics. Cells were cultivated to an OD600 = 0.4, 40 µM IPTG 
were added and cultivation was preceded to an OD600 = 1. Cells were washed 
once with 1x PBS and resuspended in concentrations of 106 or 108 cells/ml in 
1x PBS for inoculation. The surface of peeled potatoes (type Marabel, 
new crop) was disinfected by immersion in 0.625% (w/v) sodium hypochlorite 
for 5 min and subsequently two washing steps in sterile dH2O were performed 
for 1 min each. Cylinders were cut out from potato tubers using a cork borer and 
were cut into discs of ~0.4 cm thickness. For infection, the discs were placed on 
water agar and 10 µl of the respective bacterial cell suspension (106 or 
108 cells/ml) was applied per disc. The petri dishes were sealed and incubated 
in a phytochamber (80 µE light energy, 16 h light/8 h dark period, humidity of 
30-45%) at 23 °C for two days. Discs were transferred to water agar containing 
100 µg/ml Tic to kill the bacteria and incubation was preceded in a 
phytochamber (conditions see above) at 23 °C for three weeks before tumors 
were counted. 
 
2.13.2 Infection of Arabidopsis seedlings with Agrobacterium 
 
To analyze the T-DNA transfer capability of different A. tumefaciens strains into 
plant cells infection assays according to the AGROBEST method (149) were 
performed. 
Arabidopsis thaliana efr-1 seeds were sterilized in 50% (v/v) bleach containing 
0.05% (v/v) Triton™ X-100 for 10 min and subsequently rinsed five times with 
sterile dH2O. Seeds were incubated at 4 °C for three days. Then, ten seeds 
were transferred to each well, filled with 1 ml MS medium (2.3.2.4), of a 6-well 
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plate for germination in a phytochamber (80 µE light energy, 16 h light/8 h dark 
period) at 23 °C for four days. 
Pre-cultures of the respective A. tumefaciens strains were pelleted, 
resuspended to an OD600 = 0.2 in AB-MES pH 5.5 medium (2.3.2.4) 
supplemented by 200 µM AS and 0.4 mM IPTG and cultivation was preceded at 
28 °C and 220 rpm for 12-16 h to induce vir gene expression. Cells were 
sedimented and resuspended to an OD600 = 0.02 in infection medium (2.3.2.4; if 
required, supplemented with 40 mM CaCl2 for strain A. tumefaciens C58 
ΔacvB). The MS medium containing the seedlings was replaced by 1 ml of the 
respective A. tumefaciens suspension (in infection medium) and co-cultivation 
was performed in a phytochamber (conditions see above) at 23 °C for three 
days. 
The seedlings were incubated with 500 µl β-glucuronidase (GUS) staining 
solution containing 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc) per 
well at 37 °C for 6 h to visualize GUS activity. 
 
 GUS staining solution sodium phosphate pH 7.0 1 M 
  K3Fe(CN)6 50 mM 
  K4Fe(CN)6 50 mM 
  Triton™ X-100 10% (v/v) 
  EDTA 0.5 M 
  X-Gluc 100 mM 
 
2.14 Protein crystallization 
 
Protein crystallization via vapor diffusion is one of the standard techniques in 
structural biology. The underlying principle is the equilibration of the vapor 
pressure between the drop of a low concentrated protein-precipitant solution 
with a large reservoir solution containing the precipitant in a higher 
concentration. A prerequisite of this method is the air-tight sealing of the 
crystallization well allowing for the transfer of water from the protein-precipitant 
drop to the reservoir solution due to differences in the vapor pressure. This 
leads to an increase of the protein and precipitant concentration within the drop, 
facilitates nucleation events and thereby the formation of protein crystals (179). 
Two common experimental set-ups for the vapor diffusion method are the 
hanging-drop and the sitting-drop format. In the hanging-drop format the 
protein-precipitant solution is spotted as a drop on the underside of a cover slip 
which covers the reservoir well from the environment, additionally sealed with 
silicone oil at the cover slip-well interface. For the sitting-drop format the 
crystallization wells have to contain a large cavity for the reservoir solution and 
a separated small cavity on a pedestal for the protein-precipitant drop. Sealing 
of the crystallization well (e.g. with an adhesive foil) from the environment is 
also essential for this format (180). 
 
2.14.1 Preparation of crystals from A-PGH protein or variants 
 
Crystallization attempts were performed to determine the three-dimensional 
structure of protein A-PGH. In general, the sitting-drop vapor diffusion method in 
96-well plates (INTELLI-PLATE®, Art Robbins Instruments, Sunnyvale, CA, 
USA) was applied and commercially available NeXtal screens from QIAGEN 
(Cryos Suite, JCSG Core Suite I, JCSG Core Suite II, JCSG+ Suite, PEGs 
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Suite, PEGs II Suite) served as reservoir solutions (60 µl per well). Solutions of 
freshly purified A-PGH, selenomethionine-derivatized A-PGH or A-PGHtrunc 
protein (2.6.3.1), dialyzed against washing buffer A or dialysis buffer B, were 
initially centrifuged (12’100 x g, 4 °C, 10 min) to separate protein aggregates. 
The resulting supernatant containing a protein concentration range of 
5-20 mg/ml was utilized for crystallization attempts. The crystallization plates 
were either prepared at 4 °C or at RT. For each sitting-drop 1 µl of the reservoir 
solution was mixed with either 1 µl of the respective protein solution or 1 µl of 
the respective protein solution containing 5 mM L-alanine or 5 mM 
L-alanine amide during manual plate set-up. For crystallization plates which 
were set-up by the crystallization robot OryxNano (Douglas Instruments, 
Hungerford, UK) only 0.2 µl of reservoir and protein solution were used. The 
plates were sealed (CrystalClear, Manco® Inc., OH, USA) and incubated either 
at 4 °C or 17 °C. 
The hanging-drop vapor diffusion method was applied to optimize crystallization 
conditions which were identified in initial screenings. 24-well plates (Crystalgen 
24 Well SuperClear™ Plate, Jena Bioscience, Jena, Germany) were filled with 
self-made reservoir solutions (500 µl per well) with varying pH values or 
precipitant concentrations compared to the original reservoir solution. For each 
hanging-drop 2 µl of the reservoir solution was mixed with 2 µl of the respective 
protein solution or 2 µl of the respective protein solution containing 5 mM 
L-alanine on the underside of a silanized cover slip. The rim of each well was 
greased with silicone oil before the cover slip with the drop was carefully placed 
onto the well. The plates were incubated at 4 °C or 17 °C. 
Potential crystal formation within the wells was checked manually with a 
microscope (SZX9, Olympus, Tokyo, Japan) on a regular basis and was 
documented by taking pictures with a camera. 
 
 washing buffer A HEPES-NaOH pH 8.0 50 mM 
  NaCl 100 mM 
 
 dialysis buffer B sodium citrate pH 5.4 40 mM 
  NaCl 100 mM 
 
2.14.2 Crystal soaking 
 
Crystals were cryo-protected in the presence of 2.5-10% (v/v) glycerol or 
10% (v/v) (2R,3R)-(-)-2,3-butanediol and flash-cooled in liquid nitrogen. Heavy 
metal derivatives were produced by soaking A-PGH crystals with 66 mM 
Sm(NO3)3 for 20-30 seconds. 
 
2.14.3 Data collection and structure determination 
 
Crystals of adequate size were initially tested in diffraction experiments under a 
nitrogen cryostream at the home source of the Helmholtz Centre for Infection 
Research (Braunschweig), consisting of the microfocus rotating anode X-ray 
generator MicroMax™-007 HF with a Saturn944+ detector (Rigaku, Tokyo, 
Japan). For promising crystals data was collected at European synchrotrons 
(e.g. PETRA III, Hamburg, Germany or Swiss Light Source (SLS), Villigen, 
Switzerland). Data collection, processing and structure determination were 
performed by Dr. Jörn Krauße (Helmholtz Centre for Infection Research, 
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Braunschweig). For structure determination of protein A-PGH X-ray diffraction 
data of a single crystal (crystallization condition JCSG Core Suite II No. 47, 
soaked with 10% (v/v) (2R,3R)-(-)-2,3-butanediol and 66 mM Sm(NO3)3) was 
collected at the home source (anomalous data set) and at beamline P11 (native 
data set), jointly operated by Deutsches Elektronen-Synchrotron (DESY), the 
Max Planck society and the Helmholtz Centre for Infection Research, at 
PETRA III (181) synchrotron (Hamburg, Germany). Data were processed in 
space group I222 with XDS (182, 183). The phase problem was solved by a 
single-wavelength anomalous dispersion (SAD) experiment at λ = 1.541 Å. This 
wavelength is in close proximity to the absorption edges of samarium’s L shell 
(L-I: 1.6025 Å, L-II: 1.6957 Å, L-III: 1.8460 Å) resulting in a data set with Bijvoet 
differences significantly different from zero and so applicable to solve the phase 
problem. Localization of the heavy metal sites, the computation of a first 
electron density map and the building of an initial polyalanine model was 
performed with ShelxC/D/E (184). The native data set contained information of 
higher resolution. The high-resolution structure of A-PGH was determined by 
molecular replacement using the polyalanine model as a search template. 
Subsequent to iterative cycles of manual model building in COOT (185) and 
refinement in PHENIX (186) the final structural model contained amino acids 
34-215 of protein A-PGH. 
 
2.14.4 Bioinformatical analyses 
 
Surface Entropy Reduction approach 
The crystallizability of proteins can considerably depend on their surface 
properties. Especially long and flexible polar side chains (e.g. lysines and 
glutamates) with high conformational entropy can interfere with intermolecular 
contact formation and the assembly of a crystal lattice. Therefore, the selective 
replacement of these residues against small amino acids (e.g. alanine) with little 
or no conformational entropy can significantly improve the protein 
crystallizability and represents the basic principle of the SER approach (156). 
The prediction of promising surface residues for mutation in protein A-PGH was 
performed with the SERp web server (187). The respective vectors (2.5.13) 
were constructed by site-directed mutagenesis of plasmid 
pET22b(+)PA0919trunc-Strep (135). 
 
Protein structure analysis 
The overall quality of the A-PGH34-215 protein structure was verified by 
determination of several quality metrics including the R-factors Rwork and Rfree 
and the root-mean-square deviation (rmsd) from ideal geometry. General 
validation was performed with the MolProbity analysis tool (188). To calculate 
the Matthews coefficient and the corresponding solvent content the Matthews 
Probability Calculator (189) was employed. Average B-factors were determined 
using the program baverage from the CCP4 suite (190, 191). Electrostatic 
surface potentials were computed employing the program APBS v1.4 (192). 
 
Protein structure comparison 
For comparison of the 3D protein structure of A-PGH34-215 against protein 
structures submitted in the Protein Data Bank (PDB) the Dali web server 
DaliLite v. 3 (193) was used. The underlying principle for the structural 
alignment is the distance alignment matrix method (194). 
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2.15 Bioinformatic tools 
 
Sequence comparison 
Protein sequences homologous to the respective protein of interest were 
identified using the basic local alignment search tool (BLAST) (195) with the 
default settings and were aligned by Clustal Omega (196). 
 
Operon prediction 
The Database of prOkaryotic OpeRons2 (DOOR2) (197) was utilized for operon 
prediction of the respective protein of interest according to the provider’s 
instructions. 
 
Prediction of signal sequences and transmembrane helices 
Potential N-terminal signal sequences or transmembrane helices within the 
respective protein sequences were analyzed by the following online tools: 
LipoP 1.0 (198), LocTree 3 (199), Phobius (200), PrediSi (201), Psortb v3.0 
(202), SignalP 4.1 (203) and TMHMM v. 2.0 (106). 
 
Protein structure homology modeling 
A three-dimensional structural model of protein PA3911 based on the human 
SCP-2 like domain (PDB code 1IKT) as a template was generated employing 
the SWISS-MODEL server (204). 
 
Molecular visualization software 
PyMOL (205) was used for the molecular visualization of three-dimensional 
protein structures and their structural superposition for the purpose of 
comparison. 
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3. Results and Discussion 
 
3.1 Identification of A-PGS amino acids involved in tRNA interaction 
The aminoacylation of PG by aaPGS enzymes represents a bacterial 
adaptation strategy to various stress conditions (42). For P. aeruginosa it was 
demonstrated that the transmembrane protein A-PGS catalyzes the transfer of 
alanine from the corresponding Ala-tRNAAla to a hydroxyl group of PG (1.2.1). 
Synthesis of the aminoacylated glycerophospholipid A-PG results in increased 
resistance of P. aeruginosa against e.g. antimicrobials and CAMPs (43, 48). 
Accordingly, the design of a specific A-PGS inhibitor was proposed as a 
promising strategy to disbalance lipid homeostasis and consequently to render 
P. aeruginosa more susceptible to antimicrobial compounds. To develop 
specific enzyme inhibitors, it is important to understand the molecular reaction 
mechanism in detail. 
In the framework of a paper revision the question has been raised which 
surface-located A-PGS amino acids are involved in the interaction with the 
tRNA-cosubstrate. The subsequent part of this chapter solely refers to this 
isolated question to support the A-PGS investigation of Dr. S. Hebecker during 
her parental leave.  
Based on an in silico model (figure 4) of the C-terminal catalytic domain of the 
A-PGS (including amino acids 543-881) and a tRNA molecule (PDB code 
1TN1) amino acids Lys676, Asn683, Arg684 and Arg687 were proposed as key 
residues for the A-PGS/tRNA interaction. These amino acids are all located on 
α-helix 5 in van der Waals distance (except Asn683) from the already identified 
recognition elements of the tRNAAla acceptor stem (47). 
In a site-directed mutagenesis approach these mainly positively charged amino 
acids were either exchanged against the small polar amino acid serine or a 
negatively charged amino acid (e.g. aspartic acid or glutamic acid). A-PGS543-881 
wild type and mutant proteins K676E, K676S, N683D, N683S, R684E, R684S 
and R687S were recombinantly produced in E. coli, purified via affinity 
chromatography and analyzed in a well-established in vitro A-PGS activity 
assay (47). 
Therefore, the respective A-PGS protein variant was mixed with ATP, an ATP 
regenerating system, [1-14C]-L-alanine and the crude cellular extract from E. coli 
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cells overproducing the alanyl-tRNA synthetase (2.9). This synthetase transfers 
14C-labeled alanine to the corresponding tRNAAla which is provided by the 
E. coli extract. The [1-14C]-L-alanine moiety is subsequently transferred from the 
[1-14C]-L-Ala-tRNAAla to a hydroxyl group of PG catalyzed by the purified 
A-PGS543-881 protein variant. At distinct time points samples were taken from the 
reaction mixture, heat inactivated and subjected to lipid extraction (2.8.1). The 
incorporation of [1-14C]-L-alanine into the lipid fraction by the formation of 
radioactively labeled A-PG was analyzed by scintillation counting (2.8.3). The 
in vitro activity of the wild type enzyme was set to 100% and all other activities 
were related to that. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Model for the interaction of the catalytic domain of the A-PGS and a 
tRNA molecule (according to Hebecker et al. (2015) (57)) 
Based on the A-PGS/tRNA model potential amino acids involved in tRNA interaction 
were proposed. Amino acid substitution on positions Lys676, Arg684 and Arg687, 
which are located on helix 5 in van der Waals distance from the already identified 
recognition elements of the tRNAAla acceptor stem (47), resulted in impaired or 
abolished in vitro A-PGS activity. 
 
The mutant proteins K676S, N683D, R684S and R687S resulted in impaired 
in vitro activities of 29 ± 8%, 11 ± 1%, 21 ± 1% and 13 ± 1%, respectively. A 
rather slight reduction of the in vitro activity to 71 ± 2% was determined for the 
N683S variant. By contrast, for K676E and R684E in vitro A-PGS activity was 
no longer detectable. These results indicate a potential tRNA interaction with 
amino acids Lys676, Arg684 and Arg687 of protein A-PGS543-881. The outcome 
of the overall investigation is summarized in Hebecker et al. (2015) (57). 
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3.2 Towards the structure of protein A-PGH from P. aeruginosa 
In a previous study protein PA0919 was identified as an A-PGH involved in the 
regulatory circuit of A-PG dependent lipid homeostasis in the membrane of 
P. aeruginosa (49). It was shown that the fine-tuning of the A-PG content plays 
an important role in the bacterial susceptibility to specific antimicrobial 
compounds. To gain insight into the underlying molecular principles of A-PG 
hydrolysis it was intended to elucidate the three-dimensional A-PGH structure 
by X-ray crystallography. 
 
3.2.1 Production and purification of native A-PGH protein 
For crystallization purposes protein A-PGH was recombinantly produced in 
E. coli BL21(λDE3) cells carrying plasmid pET22b(+)PA0919-Strep (2.6.1.1) 
and purified according to a well-established protocol (2.6.3.1) from Arendt et al. 
(2013) (49). Figure 5 presents the SDS-PAGE analysis of a typical A-PGH 
protein purification.  
 
 
 
 
 
 
 
 
 
Figure 5: SDS-PAGE analysis of an A-PGH protein purification 
Protein A-PGH was recombinantly produced in E. coli BL21(λDE3) cells and purified 
via Strep-tag® II affinity chromatography as described previously (49). Sample fractions 
were denatured with 2x SDS loading dye (95 °C, 10 min), subjected to SDS-PAGE 
analysis (12% (w/v) running gel) and proteins were visualized by Coomassie Brilliant 
Blue staining (2.7.2). An arrow indicates protein A-PGH with a calculated molecular 
weight of 44.6 kDa.   
Lane M: Unstained Protein Molecular Weight Marker, relative molecular masses 
(*1’000) are indicated; Lane 1: 10 µl periplasmic fraction; Lane 2: 10 µl column 
flow-through; Lane 3: 10 µl washing step 1; Lane 4: 10 µl washing step 2; Lane 5: 2 µl 
elution fraction 1; Lane 6: 2 µl elution fraction 2. 
 
The periplasmic fraction (lane 1) from E. coli cells overproducing protein A-PGH 
was isolated by polymyxin B treatment (2.6.2.1) and loaded onto Strep-Tactin® 
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resin for affinity chromatography (2.6.3.1). Unbound proteins ran through the 
column and remained in the flow-through fraction (lane 2). A reduction of the 
band intensity for the protein of interest in lane 2 compared to lane 1 indicates 
that a significant amount of the StrepII-tagged® protein was immobilized on the 
resin. Contaminating proteins were removed from the resin by extensive 
washing (lanes 3 and 4). Homogeneous A-PGH protein fractions (lanes 5 
and 6) were eluted from the column by the addition of D-desthiobiotin. A typical 
purification yielded ~3 mg A-PGH protein from 1 l E. coli culture. Elution 
fractions were dialyzed for buffer exchange (2.6.4.1) and concentrated to 
10 mg/ml (2.6.5) for subsequent crystallization experiments. 
 
3.2.2 Production and purification of a selenomethionine derivative 
Since no protein structure with sufficient homology to protein A-PGH was 
available, de novo phase determination methods had to be considered. 
One possible approach is the derivatization of the protein with SeMet. 
Therefore, SeMet was incorporated into the protein instead of L(+)-methionine 
during heterologous protein production. This method is well-established to solve 
the phase problem and is made possible by selenium functioning as an 
anomalous scatterer. One major advantage of this technique is to obtain all the 
data required from one crystal without facing the problem of obtaining 
non-isomorphic crystals as commonly occurring during subsequent heavy atom 
incorporation (206). For a successful structure determination based on a 
multi-wavelength anomalous dispersion experiment approximately one 
selenomethionine residue is necessary per ~75-100 amino acids (207). The 
A-PGH protein (without signal sequence) is composed of 395 aa containing 
eight methionines which represents a promising starting point for the intended 
SeMet approach. 
For the production of protein SeMet-A-PGH a protocol according to 
Heidler (2015) (150) with minor modifications (2.6.1.2) was used. Therefore, 
E. coli BL21(λDE3) cells carrying plasmid pET22b(+)PA0919-Strep were initially 
grown in LB medium. Media components of the rich medium were removed by 
extensive washing and cells were resuspended in minimal medium containing 
SeMet. Protein production was induced with IPTG and the cultivation was 
continued overnight. The typical result of a SeMet-A-PGH protein purification, 
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analyzed by SDS-PAGE, is depicted in figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Analysis of the SeMet-A-PGH purification by SDS-PAGE 
E. coli BL21(λDE3) cells were employed for the recombinant production of 
SeMet-A-PGH. The protein of interest was purified via its Strep-tag® II by affinity 
chromatography analogously to the native A-PGH protein. Sample fractions were 
denatured with 2x SDS loading dye (95 °C, 10 min), subjected to SDS-PAGE analysis 
(12% (w/v) running gel) and proteins were visualized by staining with InstantBlue™ 
(2.7.2).  
Lane M: Unstained Protein Molecular Weight Marker, relative molecular masses 
(*1’000) are indicated; Lane 1: 10 µl periplasmic fraction; Lane 2: 10 µl column 
flow-through; Lane 3: 10 µl washing step 1; Lane 4: 10 µl washing step 2; Lane 5: 10 µl 
elution fraction 1; Lane 6: 10 µl elution fraction 2. 
 
Harvested cells were disrupted by polymyxin B treatment (2.6.2.1) to release 
the periplasmic fraction (lane 1). StrepII-tagged® SeMet-A-PGH was purified 
from this cellular fraction by affinity chromatography using Strep-Tactin® resin 
(2.6.3.1) analogously to the native A-PGH protein. The flow-through fraction 
(lane 2) contained proteins that were not able to bind to the column material. 
The washing steps (lanes 3 and 4) allowed for the efficient removal of unbound 
proteins from the resin so that the resulting elution fractions (lanes 5 and 6) 
contained almost homogeneous SeMet-A-PGH protein. Approximately 1 mg 
protein was obtained from 1 l E. coli culture, corresponding to one-third of the 
yield obtained for the native A-PGH protein. For crystallization experiments the 
elution fractions were dialyzed (2.6.4.1) and concentrated to 10 mg/ml (2.6.5). 
To determine the SeMet incorporation rate MALDI-TOF MS analysis (2.7.9) was 
performed by Dr. Manfred Nimtz (Helmholtz Centre for Infection Research, 
Braunschweig). An incorporation rate of ~80% was observed verifying efficient 
SeMet derivatization and also the successful export of SeMet-A-PGH protein 
into the periplasm of E. coli. 
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3.3 Thermal Shift Assays 
For crystallization experiments protein stability is of great importance. A simple 
method for the determination of protein stability in different buffer systems and 
in the presence of additives represents the Thermal Shift Assay also referred to 
as Thermofluor Assay. In principle, the temperature increases during the 
measurement, the respective protein denatures and exposes its hydrophobic 
core to the environment. Thereupon the dye SYPRO® Orange induces an 
increase in fluorescence due to the binding to these hydrophobic regions. 
However, protein aggregation finally leads to the quenching of the fluorescence 
signal. Protein stability is determined in terms of the respective TM, 
corresponding to the minimum of the negative first derivative of the melting 
curve (164). 
Starting point for stability determination was the purified native A-PGH protein in 
dialysis buffer A (20 mM HEPES-NaOH pH 6.8) as utilized for in vitro activity 
assays in previous work (49). At first, different concentrations of protein 
(0.5, 1 or 2 mg/ml) and fluorescent dye (10x, 50x or 100x) were tested to 
identify optimal protein to dye ratios. The established conditions (2 mg/ml 
A-PGH protein and 100x SYPRO® Orange dye, data not shown) were employed 
for subsequent experiments. Protein stability was determined in several buffer 
systems containing 40 mM of the respective buffering compound and 
0-400 mM NaCl covering a pH range from 4.0 to 9.4. The pH influence of 
selected buffer systems (40 mM buffering compound and 80 mM NaCl) on the 
TM of protein A-PGH is shown exemplarily in figure 7. 
The negative first derivatives of the melting curves for A-PGH in diverse buffer 
systems are plotted against the temperature. To compare protein stability the 
corresponding TM values were determined represented by the minimum of each 
curve. The TM in the original buffer condition (20 mM HEPES-NaOH pH 6.8) 
was 31 °C. A prominent decrease in the TM
 of A-PGH was detected under acidic 
(e.g. acetate pH 4.4 / TM = 26.5 °C) and in (slightly) alkaline (Tris 
pH 8.4 / TM = 19 °C; CHES pH 9.4 / TM = 15.5 °C) buffer systems. HEPES 
buffer pH 7.4 resulted in an almost similar TM of 29.5 °C when compared to 
31 °C in the original buffer. By contrast, MES buffer pH 6.4 and citrate buffer 
pH 5.4 significantly increased the TM to 35 °C and 36 °C, respectively. 
According to these findings purified A-PGH protein was extensively dialyzed 
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(2.6.4.1) against dialysis buffer B (40 mM sodium citrate pH 5.4, 80 mM NaCl) 
prior to further crystallization experiments. 
 
 
 
 
 
 
 
 
Figure 7: Graph for TM determination of protein A-PGH in different buffer systems 
A-PGH melting curves and the resulting TM were determined via Thermal Shift Assay 
(2.7.8) with 2 mg/ml purified A-PGH protein in dialysis buffer A and 100x SYPRO® 
Orange in a temperature range of 10-90 °C. The depicted buffer systems contained 
20 mM HEPES-NaOH pH 6.8 (original buffer) or 40 mM of the respective buffering 
compound and 80 mM NaCl covering a pH range from pH 4.4-9.4. TM values were 
calculated using the CFX Manager program and the diagram was generated with the 
graphing software OriginPro. 
 
3.4  Structure determination of protein A-PGH 
 
3.4.1 Crystallization of native A-PGH  
Freshly purified, dialyzed and concentrated A-PGH protein was utilized for initial 
screenings using commercially available NeXtal screens employing the 
sitting-drop vapor diffusion method in 96-well plates (2.14.1). For screening 
purposes different protein concentrations (5-20 mg/ml) as well as A-PGH 
protein mixtures in the presence of L-alanine or L-alanine amide were used and 
the experiments were incubated at 4 °C or 17 °C. 
An overview of conditions in which protein crystals of native A-PGH were 
obtained is given in table 9. In general, protein crystals were obtained under 
conditions containing polyethylene glycol (PEG) with a molecular weight ranging 
from 3’350-20’000 g/mol. Crystal formation was documented and promising 
A-PGH crystallization conditions are depicted in figure 8. 
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Table 9: Crystallization conditions that produced native A-PGH protein crystals 
Specifically highlighted (*) crystallization conditions derived from (135). 2,3-BD, (2R,3R)-(-)-2,3-butanediol; HEPES, 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; MES, 2-(N-morpholino)ethanesulfonic acid; MPD, 2-methyl-2,4-pentanediol; N.D., not 
determined; PEG, polyethylene glycol; Sm(NO3)3, samarium nitrate. 
 
NeXtal screen and number, 
crystallization condition 
protein buffer 
incubation 
temperature 
[°C] 
time period 
for crystal 
formation, 
appearance 
cryopro-
tectant 
diffraction 
limit using 
Cu Kα 
radiation 
diffraction 
limit using 
synchrotron 
radiation 
optimization in 
24-well plates, 
hanging-drop  
vapor diffusion  
JCSG Core Suite I No. 17, 
0.1 M HEPES pH 7.5 
20% (w/v) PEG 4’000 
10% (v/v) isopropanol 
dialysis buffer B 
or  
washing buffer A  
4 (fig. 8 A 
and B), 
17 (fig. 8 C) 
2-8 weeks, 
cluster of 
rod-shaped 
crystals 
- 
~2.6 Å, 
complete 
data set 
collected 
N.D. 
HEPES pH 6.5-8.0, 
4.5-12% isopropanol 
or 0-10% MPD, 4 °C,  
no suitable crystals 
JCSG Core Suite II No. 51, 
1.0 M Lithium chloride 
0.1 M MES pH 6.0 
20% (w/v) PEG 6’000 
dialysis buffer B 4 
4 months, 
lens-shaped 
soaked with 
10% (v/v) 
glycerol 
~10 Å N.D. 
MES pH 5.5-7.0, 
5-25% (w/v) PEG, 
4 °C, no crystal 
improvement 
JCSG Core Suite II No. 19, 
0.2 M Lithium acetate 
20% (w/v) PEG 3’350 
dialysis buffer B 17 
4 weeks,  
plate cluster 
- N.D. N.D. - 
JCSG Core Suite II No. 40, 
0.2 M Potassium sulfate 
20% (w/v) PEG 3’350 
dialysis buffer B 17 
4 weeks,  
needle cluster 
- N.D. N.D. - 
* JCSG Core Suite II No. 47, 
0.1 M MES pH 6.5, 
12% (w/v) PEG 20'000 
washing buffer A 17 
5 weeks, 
rhombohedral 
or rod-shaped 
soaked with 
10% (v/v) 
2,3-BD and 
Sm(NO3)3 
~2.0 Å, 
complete 
anomalous 
data set 
collected 
1.64 Å,  
(DESY, 
Hamburg) 
- 
* JCSG Core Suite II No. 34, 
0.1 M HEPES pH 6.5, 
10% (w/v) PEG 6’000, final pH 7.0 
washing buffer A 17 
2 months, 
rhombohedral 
soaked with 
10% (v/v) 
2,3-BD and 
Sm(NO3)3 
~2.0 Å N.D. - 
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Figure 8: A-PGH crystals obtained under different crystallization conditions  
A: Crystal screen JCSG Core Suite I (0.1 M HEPES pH 7.5, 20% (w/v) PEG 4’000, 
10% (v/v) isopropanol), 10 mg/ml A-PGH protein in dialysis buffer B, crystals were 
obtained within 14 days. B: Crystal screen JCSG Core Suite I (0.1 M HEPES pH 7.5, 
20% (w/v) PEG 4’000, 10% (v/v) isopropanol), 10 mg/ml A-PGH protein in dialysis 
buffer B containing 5 mM L-alanine, crystals were obtained within 14 days. C: Crystal 
screen JCSG Core Suite I (0.1 M HEPES pH 7.5, 20% (w/v) PEG 4’000, 10% (v/v) 
isopropanol), 10 mg/ml A-PGH protein in washing buffer A, crystals were obtained 
within eight weeks (135). D: Crystal screen JCSG Core Suite II (1.0 M Lithium chloride, 
0.1 MES pH 6.0, 20% (w/v) PEG 6’000), 10 mg/ml A-PGH protein in dialysis buffer B, 
crystals (indicated by an arrow) were obtained within four months. E: Crystal screen 
JCSG Core Suite II (0.2 M Lithium acetate, 20% (w/v) PEG 3’350), 20 mg/ml A-PGH 
protein in dialysis buffer B, crystals were obtained within four weeks. F: Crystal screen 
JCSG Core Suite II (0.2 M Potassium sulfate, 20% (w/v) PEG 3’350), 20 mg/ml A-PGH 
protein in dialysis buffer B, crystals were obtained within four weeks. G: Crystal screen 
JCSG Core Suite II (0.1 M MES pH 6.5, 12% (w/v) PEG 20‘000), 10 mg/ml A-PGH 
protein in washing buffer A containing 5 mM L-alanine amide, crystals were obtained 
within five weeks (135). H: Crystal screen JCSG Core Suite II (0.1 M HEPES pH 6.5, 
10% (w/v) PEG 6‘000, final pH 7.0), 10 mg/ml A-PGH protein in washing buffer A, 
crystal was obtained within two months (135). 
 
3.4.2 Crystallization of SeMet-A-PGH 
Screenings for crystallization conditions were performed with freshly purified, 
dialyzed and concentrated SeMet-A-PGH protein as described for the native 
protein (3.4.1). 
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Table 10: Crystallization conditions resulting in SeMet-A-PGH crystals 
MES, 2-(N-morpholino)ethanesulfonic acid; MPD, 2-methyl-2,4-pentanediol; N.D., not determined; PEG, polyethylene glycol; SLS, Swiss Light 
Source. 
 
NeXtal screen and number, 
crystallization condition 
protein buffer 
incubation 
temperature 
[°C] 
time period for 
crystal formation, 
appearance 
cryoprotectant 
diffraction 
limit using 
Cu Kα 
radiation 
diffraction limit 
using synchrotron 
radiation 
optimization of 
JCSG Core Suite II, No. 51, 
1.0 M Lithium chloride 
0.1 M MES pH 6.5 
20% (w/v) PEG 6’000 
dialysis buffer B 4 
2 weeks, needle 
cluster or lens-shaped 
soaked with  
5% (v/v) glycerol 
~10 Å N.D. 
JCSG Core Suite I, No. 43, 
0.2 M di-Ammonium tartrate 
20% (w/v) PEG 3’350 
dialysis buffer B 17 
3 months, 
cluster of rod-shaped 
crystals 
soaked with  
10% (v/v) glycerol 
~3.3 Å 
~3.0 Å (SLS, 
Villigen, Switzerland) 
Cryos Suite, No. 90, 
0.17 M Sodium acetate 
0.085 M Tris-HCl pH 8.5 
25.5% (w/v) PEG 4’000 
15% (v/v) glycerol 
dialysis buffer B 4 
4 days,  
plates 
- N.D. 
~2.8 Å (SLS, 
Villigen, Switzerland) 
 
Similar to the native A-PGH protein, crystals were obtained under conditions (table 10) containing different PEG variants 
(3’350-6’000 g/mol). Conditions were regularly monitored for crystal formation and potential SeMet-A-PGH crystals, shown in figure 9, 
were documented. For SeMet-A-PGH crystals from conditions JCSG Core Suite I No. 43 and Cryos Suite No. 90 complete data sets 
were collected at the synchrotron SLS (Villigen, Switzerland) by Dr. Jörn Krauße (Helmholtz Centre for Infection Research, 
Braunschweig). However, the data quality was not sufficient to solve the phase problem. 
 
 
 81 
 
 
Figure 9: SeMet-A-PGH crystals grown under different crystallization conditions 
A: Optimization of No. 51 from crystal screen JCSG Core Suite II (1.0 M Lithium 
chloride, 0.1 M MES pH 6.5, 20% (w/v) PEG 6’000), 10 mg/ml SeMet-A-PGH protein in 
dialysis buffer B containing 5 mM L-alanine, crystals were obtained within two weeks. 
B: Crystal screen JCSG Core Suite I (0.2 M di-Ammonium tartrate, 20% (w/v) 
PEG 3’350), 10 mg/ml SeMet-A-PGH protein in dialysis buffer B containing 5 mM 
L-alanine amide, crystals were obtained within three months. C: Crystal screen 
Cryos Suite (0.17 M Sodium acetate, 0.085 M Tris-HCl pH 8.5, 25.5% (w/v) PEG 4’000, 
15% (v/v) glycerol), 10 mg/ml SeMet-A-PGH protein in dialysis buffer B, crystals were 
obtained within four days. 
 
3.4.3 Soaking of native A-PGH crystals with heavy metals 
Given that structure solution based on SeMet-A-PGH crystals was not 
successful another de novo phase determination method was carried out. For 
this purpose, native A-PGH crystals were soaked with heavy metals. The 
binding of heavy metal atoms to specific positions within the protein crystal 
results in intensity changes in the diffraction pattern which allow for phase 
determination, for example by using the SAD method. 
To generate heavy metal derivatives the rhombohedral A-PGH crystals from 
conditions No. 34 and 47 from JCSG Core Suite II (3.4.1) were soaked in the 
respective reservoir solution containing 10% (v/v) (2R,3R)-(-)-2,3-butanediol as 
a cryoprotectant and 66 mM Sm(NO3)3 as a heavy metal (2.14.2). The crystals 
diffracted up to 2.0 Å at the home source and a complete anomalous data set 
was recorded for one crystal from condition No. 47 (figure 8 G). For the same 
crystal a complete native data set with a maximal resolution limit of 1.64 Å was 
recorded by Dr. Jörn Krauße (Helmholtz Centre for Infection Research, 
Braunschweig) at beamline P11 at the PETRA III synchrotron (Hamburg, 
Germany). These data sets (native and anomalous) allowed for the 
three-dimensional structure elucidation using the SAD approach. 
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3.4.4 Structure determination, refinement and validation 
Processing of collected data and structure determination were performed by 
Dr. Jörn Krauße (Helmholtz Centre for Infection Research, Braunschweig). The 
observed reflections (native and anomalous data set) of a crystal from condition 
No. 47 of the JCSG Core Suite II (3.4.3) were indexed and scaled using the 
XDS package (182, 183). The crystal belonged to the body centered 
orthorhombic space group I222 (No. 23) with unit cell dimensions a = 67.85 Å, 
b = 72.76 Å and c = 76.42 Å and according angles α = β = γ = 90° (table 11). 
The number of molecules per asymmetric unit was estimated by the 
determination of the Matthews coefficient (208), ranging from 1.68-3.53 Å³/Da 
for proteins, using the Matthews Probability Calculator (189). Assuming one 
A-PGH protein per asymmetric unit an unusual Matthews’s coefficient of 
1.06 Å³/Da was obtained. Accordingly, it was hypothesized that the full-length 
A-PGH protein cannot be crystallized within these unit cell dimensions. 
The three-dimensional structure of protein A-PGH was determined by SAD 
phasing. For this purpose, a data set was collected at the home source at 
λ = 1.541 Å. This wavelength is in close proximity to the absorption edges of 
samarium’s L shell (L-I: 1.6025 Å, L-II: 1.6957 Å, L-III: 1.8460 Å) resulting in a 
data set with Bijvoet differences significantly different from zero and so 
applicable to solve the phase problem. The resolution limit of the recorded data 
set is dmin = 2.03 Å. This initial data set was sufficient for the localization of the 
heavy metal sites, the computation of a first electron density map and the 
building of an initial polyalanine model with ShelxC/D/E (184). A native data set 
recorded at beamline P11 (DESY, Hamburg) contained information of higher 
resolution (dmin = 1.64 Å). The high-resolution structure of A-PGH was 
determined by molecular replacement using the polyalanine model as a search 
template. Subsequent to iterative cycles of manual model building in COOT 
(185) and refinement in PHENIX (186) the final structural model contained 
amino acids 34-215 of protein A-PGH. The data collection statistics are 
summarized in table 11. 
Thorough investigation of the calculated electron density map revealed that the 
C-terminal part of protein A-PGH is not traceable in the obtained electron 
density and thus it was concluded that the protein A-PGH was proteolytically 
degraded prior to the crystallization process. SDS-PAGE analyses confirmed 
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that crystallization plates were set up with a solution containing the native 
A-PGH protein, whereas samples of crystal-containing drops from different 
conditions only revealed the presence of a ~20 kDa protein corresponding to 
the N-terminal part of protein A-PGH (135). Recalculation of the Matthews 
coefficient with the N-terminal part of protein A-PGH (amino acids 34-215) 
resulted in a reasonable Matthews value of 2.38 Å³/Da in the presence of one 
molecule per asymmetric unit with a solvent content of 48.44%, which is within 
the expected range of 27-65% for protein crystals (208). 
 
Table 11: Data collection and processing parameters of A-PGH34-215 
‡Rmerge = 
        
                  
        
       
; n, number of independent measurements;       , intensity 
of a reflection;       , average of symmetry-related observations of a unique reflection. 
*Rmeas = 
     
 
   
    
                  
        
       
. †Fraction of correlation between intensities from 
random half-datasets (209). Values in parentheses are for the highest-resolution shell. 
No., number. 
 
Data set A-PGH34-215 anomalous native 
Data collection 
Beamline 
MicroMax™-007 HF, 
HZI (Braunschweig) 
PETRA III P11 
DESY (Hamburg)  
Temperature [K] 100 100 
Wavelength [Å] 1.541 Å 1.008 Å 
Data processing 
Resolution range, dmax-dmin [Å] 
30.260-2.034  
(2.106-2.034) 
19.940-1.640  
(1.699-1.640) 
Space group I222 
Unit cell dimensions [Å] a = 67.85, b = 72.76, c = 76.42 
Angles [°] α = β = γ = 90° 
No. of observed reflections 254’908 (16’716) 287’711 (28’829) 
No. of unique reflections 12’368 (1’133) 22’888 (2’313) 
Multiplicity 20.6 (14.7) 12.6 (12.5) 
Completeness  0.95 (0.93) 0.97 (0.99) 
Mean I/σ(I) 35.74 (5.98) 24.96 (2.14) 
Wilson B-factor [Å²] 23.38 22.60 
Rmerge
‡ 0.0888 (0.5343) 0.0624 (1.2900) 
Rmeas*  0.0910 (0.5536) 0.0651 (1.3440) 
CC(1/2)
† 0.999 (0.946) 1.000 (0.843) 
 
To validate refined three-dimensional protein structures the crystallographic 
R-factors Rwork and Rfree (210) are determined. Rwork represents a measure of 
consistency between the X-ray diffraction data and the constructed 
crystallographic model. Rfree is calculated analogously to Rwork only utilizing a 
defined amount (usually 5%) of the reflections from the data set for calculation. 
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This so-called ‘test set’ is excluded from the refinement process and 
determination of Rfree allows for the estimation of over-interpretation of the data. 
For the refined structure of A-PGH34-215 (see table 12 for statistics) Rwork and 
Rfree were determined to be 21.04% and 23.36%, respectively. The rmsd of 
bond lengths and bond angles of the refined model differ by 0.01 Å and 1.07° 
from ideal geometry. 
The temperature factor, also referred to as Debye-Waller factor or B-factor, is a 
measure to quantify the uncertainty of atom positions within a protein crystal 
(211, 212). Particularly rigid parts in the protein (e.g. α-helices) exhibit low 
B-factors compared to flexible regions (e.g. loops) with considerably higher 
B-factors. For the refined structure of A-PGH34-215 an average B-factor of 
33.05 Å² was determined. 
 
Table 12: Refinement statistics 
*Rwork = 
                
         
; │Fo│, structure factor magnitudes observed; │Fc│, structure 
factors calculated. §Rfree is computed as Rwork but using 5% randomly assigned 
reflections excluded from refinement. Values in parentheses are for the 
highest-resolution shell. No., number; Rmsd, Root-mean-square deviation. 
 
Data set A-PGH34-215 native 
No. of reflections 
In refinement 22’846 (2’313) 
For Rfree 1’145 (116) 
Refinement 
Rwork* [%] 21.04 (27.52) 
Rfree
§ [%] 23.36 (30.37) 
No. of non-hydrogen atoms per asymmetric unit 
Total 1’479 
Protein 1’391 
Ligands 3 
No. of molecules per asymmetric unit 
Protein 1 
Water 68 
Additional molecules (Sm3+) 3 
Atomic displacement factor B 
Average B [Å²] 33.05 
Rmsd from ideal geometry 
Bond lengths [Å] 0.01 
Bond angles [°] 1.07 
Ramachandran statistics 
Favored [%] 98.4 
Allowed [%] 1.6 
Disallowed [%] 0.0 
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Further validation of the final structure model was performed by calculating the 
Ramachandran plot (213) with the MolProbity analysis tool (188). In these plots 
the backbone torsion angles Psi (ψ, Cα-C bond) and Phi (φ, N-Cα bond) are 
plotted against each other thereby displaying the statistical distribution of 
combinations from these dihedral angles. The plot visualizes the occurrence of 
secondary structures which cluster around average φ and ψ torsion angles: -60° 
and -45° for common right-handed α-helices, +60° and +45° for rare left-handed 
α-helices and -135° and +135° for β-sheets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Ramachandran plot of the refined A-PGH34-215 structure 
In the Ramachandran plot computed by the MolProbity analysis tool (2.14.4) the torsion 
angle ψ is plotted against the torsion angle φ. Outer contours in light blue define 
favored regions, whereas dark blue lines border allowed regions. Residual areas 
belong to the disallowed regions. The Ramachandran plot of all residues, except 
proline and glycine, shows that most of the residues (98.4%) are in the favored region 
and only a minor part (1.6%) is in the allowed region. No outliers were identified. 
 
Glycine residues are an exception from clustering around the α-helix and 
β-sheet regions. Because of their missing side chain they are highly flexible in 
the polypeptide chain and can adopt normally forbidden rotation angles. 
The Ramachandran plot can be consulted for quality control of the determined 
structure. In figure 10 the respective Ramachandran plot for the general case 
(except proline and glycine residues) of the refined A-PGH34-215 structure is 
presented. 98.4% of the ψ/φ torsion angle combinations are in the favored and 
1.6% in the allowed regions. No outliers were identified in the refined structure. 
Ramachandran statistics taken together with determined R-factors verified the 
appropriate fitting of the structure into the electron density. 
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3.4.5 Structure description 
The three-dimensional structure of A-PGH34-215 consists of a central eight 
stranded β-sheet in strand order 12435678 with the second β-strand being 
antiparallel to the others. The topology is depicted in figure 11 and the amino 
acids of each secondary structural element are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Topology diagram of A-PGH34-215 
Helices are depicted as cylinders (light blue) and β-strands as arrows (dark blue). The 
amino acids of each secondary structural element are indicated. 
 
The three-dimensional structure (figure 12) shows a highly twisted β-sheet so 
that the first and last strands are orthogonal to one another. Furthermore, it is 
surrounded by five α-helices which connect strands β3, β4, β5 and β6 as well as 
β7 and β8. Helices α1 and α5 are located on one side, whereas helices α2, α3 and 
α4 are located on the opposite side of the β-sheet. A disulfide bridge is formed 
by amino acids Cys97 and Cys156, thereby connecting helix α2
 and the loop 
between strands β6 and β7. Three samarium ions of the heavy atom derivative 
are located in van der Waals distance to the negatively charged amino acids 
Asp136, Asp148 and Asp197, respectively. 
B-factor analysis (figure 13 A) revealed that the majority of protein atoms exhibit 
low B-factors indicating a well-ordered structure. Elevated B-factors were 
determined at the terminal ends (Met33 and Gln215) due to high flexibility. 
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Figure 12: Cartoon model of the N-terminal part of protein A-PGH from 
P. aeruginosa 
The N-terminal part of protein A-PGH consisting of amino acids 34-215 (based on the 
native A-PGH protein sequence) is composed of a central eight stranded β-sheet which 
is surrounded by five α-helices. Disulfide bridge formation occurs between amino acids 
Cys97 and Cys156. Samarium ions of the heavy atom derivative are presented as 
violet spheres.  
 
 
Figure 13: Presentation of the B-factor distribution (A) and the electrostatic 
surface potential (B) of A-PGH34-215 
A: The B-factors are visualized by color, displaying low (blue), medium (green) and 
high (red) B-factor values. Large structure parts exhibit low B-factors, especially the 
α-helices and β-strands, whereas the terminal ends and some loop regions display 
medium to high B-factors. The protein structure orientation is equivalent to figure 12. 
B: The electrostatic surface potential was computed by APBS v1.4 (192). Negatively 
charged regions of A-PGH34-215 are colored in red, whereas positively charged regions 
are presented in blue (± 6 kBT). Neutrally charged regions are shown in white. The 
protein structure is oriented according to figure 12. 
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Besides this, high B-factors were determined for amino acids Glu93, Asn94 and 
Gly95 in the loop region between the secondary structure elements β4 and α2. 
The electrostatic surface potential was calculated by APBS v1.4 (192) and the 
corresponding depiction of the surface is presented in figure 13 B. In general, 
several charged amino acids are distributed within the protein and generate 
locally positive or negative surface potentials. Remarkably, the protein exhibits 
one region with a highly negative electrostatic surface potential (colored in red) 
primarily caused by the amino acids aspartic acid and glutamic acid (mainly 
Glu93, Asp148, Glu153, Asp175 and Asp178). Although the three-dimensional 
structure of the C-terminal part of protein A-PGH and its spatial arrangement 
related to the N-terminal part is not known this region of highly negative 
electrostatic surface potential might be involved in protein-substrate or 
protein-protein interaction. 
 
3.5 Dali search 
In previous work, the key catalytic residues Ser307 and His401 located on the 
C-terminal part of protein A-PGH were characterized (49). However, for the 
N-terminal part no biochemical function is assigned and so a structure-based 
search for homologs by the Dali web server (193) was conducted. The 
structural alignment performed with protein structures already deposited in the 
PDB is based on the distance alignment matrix method (194). 
The obtained results allow for the identification of homologous structures based 
on structural similarity specified via Z-scores. A Z-score above two corresponds 
to ‘significant similarities’ and usually similar folds. ‘Strong matches’ are defined 
as exhibiting sequence identities above 20% or a Z-score exceeding a specific 
cut-off based on the protein size (193). Furthermore, key residues or functional 
sites of a new structure might be identified due to conserved residues that might 
point towards a potential molecular function (214). 
In general, the Dali search resulted in 967 PDB entries exceeding a Z-score of 
2.0 and thus implicating a similar fold. The obtained results display low 
sequence identities (< 20%) to the query structure and the maximum Z-score 
reached a value of 16.8. Numerous matches are hydrolases or esterases 
catalyzing reactions with varying substrates. Detailed sequence comparison did 
not reveal any conservation of key residues in the structure of A-PGH34-215. The 
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top six results for protein A-PGH are ranked according to Z-scores in table 13. 
 
Table 13: List of Dali search results for the query structure A-PGH34-215 
Obtained results are ordered by decreasing Z-scores which correlate with the structural 
similarity between the query and the respective PDB structure. No., number; PDB ID, 
Protein Data Bank identification code. 
 
No. 
PDB ID-
Chain 
Z-score 
total  
No. of 
aligned 
residues 
sequence 
identity [%] 
description 
1 3QIT-A 16.8 172 14 thioesterase 
2 5CML-A 16.6 172 12 
OsmC domain carboxyl 
esterase 
3 3F67-A 15.8 173 13 
putative dienelactone 
hydrolase 
4 3KXP-I 15.7 167 8 
2-(acetamidomethylene) 
succinate hydrolase 
5 3QM1-A 15.7 171 11 cinnamoyl esterase 
6 4AO7-A 15.1 173 10 cold-adapted esterase 
 
These structures, deposited under PDB IDs 3QIT (215), 5CML (216), 3F67 
(unpublished), 3KXP (217), 3QM1 (218) and 4AO7 (219), all exhibit an 
α/β hydrolase fold that typically consists of eight β-strands connected by six 
α-helices (220). 
Referring to the conserved structural core presented in Carr and Ollis (2009) 
(221), α-helix D (between strands β6 and β7) is replaced by an extended loop 
region in protein A-PGH34-215. Furthermore, the catalytically active Ser-His-Asp 
residues of structures 3QIT, 5CML, 3KXP, 3QM1 and 4AO7 or Cys-His-Asp 
residues of structure 3F67 are not conserved in the structure of the A-PGH 
fragment. These proteins all contain a subdomain, putatively modulating the 
accessibility of the active site, which is not present in the structure of 
A-PGH34-215. However, structural alignments show that these subdomains are 
located in the region of the highly negatively charged patch of A-PGH34-215 
which also includes several flexible residues showing high B-factors (3.4.5). 
 
3.6 Strategies to solve the structure of the C-terminal part of A-PGH 
As described in section 3.4 the three-dimensional structure of A-PGH34-215 
(N-terminal part) was successfully resolved but the obtained crystals from native 
or SeMet-A-PGH protein did not allow for the structure determination of the 
full-length protein. Accordingly, alternative strategies had to be pursued. On the 
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one hand crystallization experiments with a truncated A-PGH variant containing 
only the C-terminal part were performed; on the other hand the SER approach 
(156) was applied to improve the crystallizability of the native A-PGH protein. 
 
3.6.1 Production and purification of the C-terminal part of protein A-PGH 
or mutant variants 
To crystallize the sole C-terminal part of protein A-PGH a truncated variant 
(A-PGHtrunc) containing amino acids 203-427 was recombinantly produced in 
E. coli BL21(λDE3) cells (2.6.1.1) carrying plasmid pET22b(+)PA0919trunc-Strep 
(135). 
Protein sequence analysis using the SERp web server (156) indicated that 
replacing amino acid residues Glu378, Glu379 and Lys380 (numbered 
according to the native A-PGH sequence) by alanine could significantly improve 
the crystallizability of protein A-PGH. Based on this theoretical analysis the 
proposed cluster was mutated for A-PGHtrunc either into Glu176Ala and 
Glu177Ala or into Glu176Ala, Glu177Ala and Lys178Ala (numbered according 
to the A-PGHtrunc sequence). 
The two variants were produced analogously to protein A-PGHtrunc in 
E. coli BL21(λDE3) cells carrying the plasmid pET22b(+)PA0919trunc-Strep/AAK 
or pET22b(+)PA0919trunc-Strep/AAA (2.6.1.1), respectively. The purification 
procedure (2.6.3.1) was adopted from Arendt et al. (2013) (49). A 
representative SDS-PAGE analysis of an A-PGHtrunc protein purification is 
shown in figure 14. 
The A-PGHtrunc protein or mutant variants were isolated from the periplasmic 
fraction (lane 1) of the respective E. coli strain which was obtained by 
polymyxin B treatment (2.6.2.1). This fraction was utilized for affinity 
chromatography using Strep-Tactin® resin (2.6.3.1). Significant amounts of 
A-PGHtrunc protein were immobilized as indicated by an obvious intensity 
reduction of the respective protein band in the column flow-through (lane 2). 
Extensive washing steps (lanes 3 and 4) efficiently removed unbound proteins 
so that almost homogeneous A-PGHtrunc protein fractions (lanes 5 and 6) were 
eluted using D-desthiobiotin. Approximately 3 mg A-PGHtrunc protein or 2 mg 
A-PGHtrunc-AAK or A-PGHtrunc-AAA protein were obtained from 1 l E. coli 
culture. Elution fractions were dialyzed (2.6.4.1), concentrated to 10 mg/ml 
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(2.6.5) and applied for crystallization experiments. For protein purifications of 
A-PGHtrunc-AAK and A-PGHtrunc-AAA similar SDS-PAGE results were obtained, 
however the protein yields were slightly decreased when compared to protein 
A-PGHtrunc. 
 
 
 
 
 
 
 
 
 
Figure 14: SDS-PAGE analysis of an A-PGHtrunc protein purification 
Protein A-PGHtrunc was recombinantly produced in E. coli BL21(λDE3) cells and purified 
via Strep-tag® II affinity chromatography analogously to the native A-PGH protein. 
Sample fractions were denatured with 2x SDS loading dye (95 °C, 10 min), subjected 
to SDS-PAGE analysis (12% (w/v) running gel) and proteins were visualized by 
staining with InstantBlue™ (2.7.2) (135). An arrow indicates protein A-PGHtrunc with a 
calculated molecular weight of 26.4 kDa. 
Lane M: Unstained Protein Molecular Weight Marker, relative molecular masses 
(*1’000) are indicated; Lane 1: 10 µl periplasmic fraction; Lane 2: 10 µl column 
flow-through; Lane 3: 10 µl washing step 1; Lane 4: 10 µl washing step 2; Lane 5: 10 µl 
elution fraction 1; Lane 6: 10 µl elution fraction 2. 
 
The truncated A-PGH protein version was initially characterized by the 
determination of the relative molecular mass and the oligomeric state by 
analytical GPC (2.7.6) using a Superdex™ 200 Increase 5/150 GL 
chromatography column (135). Considering the elution volumes of A-PGHtrunc 
and standard proteins employed for calibration a relative molecular mass of 
28’000 was determined (see appendix figure 31). Comparison of the 
experimental result with the calculated molecular mass of 26.4 kDa indicated 
that A-PGHtrunc exhibits a monomeric architecture under the employed 
conditions. Additionally, the elution profile indicated an almost homogeneous 
protein fraction which is a good prerequisite for subsequent crystallization 
attempts. 
 
 
 92 
 
3.6.2 Crystallization experiments for protein A-PGHtrunc or mutant variants  
Initial screenings for crystal formation employing the sitting-drop vapor diffusion 
method in 96-well plates (2.14.1) were performed with freshly purified, dialyzed 
(against washing buffer A) and concentrated A-PGHtrunc, A-PGHtrunc-AAK or 
A-PGHtrunc-AAA protein. Therefore, the commercially available NeXtal screens 
were utilized and protein concentrations ranging from 5-10 mg/ml were 
employed for A-PGHtrunc, A-PGHtrunc-AAK and A-PGHtrunc-AAA. Crystal plates 
were set up manually and incubated at 17 °C. 
For protein A-PGHtrunc either pyramid- or rod-shaped crystals were obtained 
after 4 days in the Cryos Suite in condition No. 23 (0.085 M Tris pH 8.5, 
21.25% (v/v) tert-butanol, 15% (v/v) glycerol) and No. 35 (0.85 M imidazole 
pH 7.0, 15% (v/v) glycerol) using a protein concentration of 10 mg/ml. However, 
initial X-ray diffraction analyses at the home source clearly indicated the 
presence of salt crystals (135). By contrast, protein solutions of A-PGHtrunc-AAK 
and A-PGHtrunc-AAA tended to precipitate at concentrations above 7.5 mg/ml 
and yielded no crystals in the employed NeXtal screens PEGs Suite and 
JCSG+ Suite. Within the framework of this study no crystallization condition(s) 
for protein A-PGHtrunc or mutant variants were identified. 
 
3.7 Determination of the A-PGH solution structure by small-angle X-ray 
scattering 
Since the three-dimensional structure of the full-length A-PGH protein could not 
be obtained by X-ray crystallography in the present study a low-resolution 
model for protein A-PGH was determined by SAXS. This method can provide 
complementary information to high-resolution techniques concerning the shape, 
conformation and interaction of biological macromolecules in solution (222). 
For SAXS experiments protein A-PGH was purified (2.6.3.1), dialyzed (2.6.4.1) 
and dilute solutions in a defined concentration range were prepared (2.7.10). 
Sample measurement at the ESRF in Grenoble, data analysis and building of 
the low-resolution model were performed by Dr. Jörn Krauße (Helmholtz Centre 
for Infection Research, Braunschweig). 
The obtained low-resolution envelope possesses an elongated shape with a 
protrusion which is visible in the right half of figure 15. Furthermore, a potential 
arrangement of the N- and C-terminal part of protein A-PGH is indicated. If the 
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three-dimensional structure of the C-terminal part of A-PGH is obtained by 
X-ray crystallography, this A-PGH solution structure will provide information 
about how the N- and C-terminal part are spatially arranged within the protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Solution structure of protein A-PGH 
Experimental SAXS data obtained from a soluble A-PGH sample was used to generate 
a representative ab initio model using the ATSAS program package (168). A potential 
arrangement of the N- and C-terminal part of protein A-PGH is indicated. 
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3.8 Role of AcvB and VirJ in the lipid homeostasis of A. tumefaciens 
 
3.8.1 AcvB and VirJ are A-PGH homologs 
Only recently, the fine-tuning of cellular A-PG concentrations in P. aeruginosa 
by an A-PGS (PA0920)/A-PGH (PA0919) system (43, 47, 57, 49) was 
investigated in our laboratory. Sequence comparison, operon prediction and 
cluster analysis identified homologous PA0920 and PA0919 orfs for several 
Gram-negative bacteria, e.g. A. tumefaciens, B. phymatum, R. pickettii and 
R. tropici (49). 
In A. tumefaciens orfs Atu2521 (lpiA) and Atu2522 (acvB) were identified as 
PA0920 and PA0919 homologs, respectively. Strains containing an 
octopine-type Ti-plasmid possess with virJ a non-chromosomal, paralogous 
version of acvB. VirJ equates the C-terminal part of AcvB and shows a 
sequence identity of 52% (61). In the literature a potential function of VirJ and 
AcvB as periplasmic chaperones involved in the translocation of T-DNA and 
effector proteins into the plant cell (64, 65) was proposed. Furthermore, it was 
demonstrated that AcvB is essential for A. tumefaciens virulence (60). However, 
a direct function of AcvB and VirJ has not been elucidated to date.  
Comparison of the AcvB and VirJ protein sequences with protein A-PGH (see 
appendix figure 33) clearly indicates that the catalytically relevant active site 
residues Ser307 and His401 of protein A-PGH (49) are conserved, pointing 
towards a potential role of AcvB and VirJ in L-PG hydrolysis and thus in lipid 
homeostasis of A. tumefaciens. 
 
3.8.2 Production and purification of AcvB variants and VirJ 
To investigate the biochemical function of AcvB and VirJ from A. tumefaciens 
protein production and purification procedures for the wild type and mutant 
proteins were established (136, 137, 223). All proteins were isolated from the 
periplasmic fraction of E. coli cells carrying the respective plasmid and purified 
by affinity chromatography using Strep-Tactin® resin (2.6.3.1) as described in 
detail in sections 3.2.1, 3.2.2 and 3.6.1. Almost homogeneous elution fractions 
were obtained, dialyzed and concentrated for subsequent use in in vitro activity 
assays. Typically 3 mg of purified AcvB protein (or mutant variants) and 
0.05 mg of purified VirJ protein were obtained from 1 l E. coli culture. 
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3.8.3 In vitro activity assays with AcvB variants and VirJ 
Based on the biochemically characterized A-PGS/A-PGH system from 
P. aeruginosa a hydrolase function of AcvB and VirJ was assumed. Instead of 
A-PG present in P. aeruginosa membranes, A. tumefaciens contains L-PG 
(224) which is synthesized in a tRNA-dependent reaction by the 
lysyl-phosphatidylglycerol synthase (L-PGS) enzyme termed LpiA (25). 
Accordingly, L-PG was tested as a potential substrate for AcvB and VirJ. 
To analyze a potential L-PG hydrolyzing activity of AcvB and VirJ an in vitro 
activity assay was established (2.10). For this purpose commercially available 
L-PG was solubilized in buffer containing Triton™ X-100 under vigorous 
shaking. The resulting L-PG containing micelles were incubated with purified 
AcvB25-456 protein (or mutant variants) or the employed Strep-tag
® II protein 
(negative control). During incubation samples were taken at defined time points 
and spotted onto a TLC plate together with L-lysine as a reference. The reaction 
mixture was separated by TLC and compounds containing free amino groups 
were identified by subsequent ninhydrin staining (2.8.2). Representative 
experimental results using proteins AcvB25-456 and Strep-tag
® II are shown in 
figure 16 (137). 
 
Figure 16: Lipid analyses of reaction products from in vitro activity assays 
Purified AcvB25-456 protein and the employed Strep-tag
® II protein (negative control) 
were used for in vitro activity assays (2.10). 80 µl of a 5.13 mM L-PG micelle solution 
was incubated with 80 µl of 20 µM purified AcvB25-456 protein or the Strep-tag
® II at 
37 °C and 1’000 rpm for 60 min. At defined time points (0-60 min), 5 µl of the 
respective reaction mixture was spotted onto a thin-layer chromatography (TLC) plate 
together with 5 µl of a 68 µM L-lysine solution as a reference and were separated using 
n-butanol, acetic acid and water (4:1:1 (v/v/v)) as solvent system (174). TLC plates 
were sprayed with ninhydrin solution and incubated at 110 °C until spot development 
(2.8.2). 
 
The employed solvent system allows for a distinct separation of the substrate 
L-PG and the potential reaction products PG and lysine. Under the employed 
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reaction conditions constant amounts of the substrate L-PG were detected over 
time for in vitro assays that contained either buffer (not shown) or the 
Strep-tag® II protein (figure 16) indicating that no spontaneous L-PG hydrolysis 
occurs. By contrast, a significant reduction of the L-PG amount goes along with 
an increase of the lysine amount over time for in vitro assays containing protein 
AcvB25-456. These results clearly indicate that protein AcvB25-456 is able to 
hydrolyze its potential natural substrate L-PG in vitro. 
To calculate the specific activity of protein AcvB25-456 a L-lysine calibration curve 
was prepared. Therefore, L-lysine solutions of different concentrations were 
spotted onto a TLC plate and subsequently separated and stained as carried 
out for the in vitro activity assay. Spot intensities were determined using the 
software TotalLab Quant (Cleaver Scientific Ltd, Rugby, UK). By plotting the 
spot intensities (background intensity subtracted) against the respective L-lysine 
concentration a linear calibration curve was obtained which enabled the 
quantification of L-lysine formation during the in vitro activity assay. According 
to this procedure a specific activity of 0.44 µmol·mgenzyme
-1·min-1 was calculated 
for protein AcvB25-456 (137). For comparison a specific activity of 
11 ± 3 nmol·mgenzyme
-1·min-1 was determined for the hydrolysis of the artificial 
substrate L-alanine 4-nitrophenyl ester by the homologous A-PGH protein (49). 
However, a direct comparison of the specific activities is not feasible due to the 
significantly different employed reaction conditions (e.g. natural vs. artificial 
substrate or temperature). 
Based on a sequence alignment of the homologous proteins A-PGH and AcvB 
conserved serine and histidine residues (Ser269, Ser336 and His433) of AcvB 
were identified (see appendix figure 33). These potential active site residues 
were exchanged by site-directed mutagenesis and mutant proteins were 
produced and purified according to the AcvB wild type protein (2.6.1.3, 2.6.2.1, 
2.6.3.1). Stability of the purified mutant proteins was analyzed by Thermal Shift 
Assays (2.7.8). TM values between 54.5 and 55 °C were determined for the wild 
type protein and the mutant variants AcvB S269A, AcvB S336A, AcvB H433A 
and AcvB H433N indicating the integrity of the mutant proteins (145). 
Purified AcvB mutant proteins were subsequently analyzed in the in vitro activity 
assay. For protein AcvB S269A significantly reduced L-PG hydrolyzing activity 
was detected as further substantiated by a specific activity of 
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0.07 µmol·mgenzyme
-1·min-1, whereas AcvB variants S336A, H433A and H433N 
completely lost their ability to hydrolyze L-PG in vitro (137). These results 
highlight the key function of amino acids Ser336 and His433 of AcvB in the 
enzymatic reaction and are in full agreement with the findings obtained for 
mutagenesis of residues Ser307 and His401 of protein A-PGH from 
P. aeruginosa (49). 
Existence of VirJ, a truncated AcvB version devoid of the ~200 N-terminal 
amino acids, raised the question if the hydrolyzing activity is inherent to the 
C-terminal region. Purified VirJ22-255 protein and the N-terminally truncated 
variant AcvB232-456 were used for in vitro activity assays (223). Both proteins 
showed comparable L-PG hydrolyzing activity to the wild type AcvB protein. 
These results reveal that VirJ functions as an L-PG hydrolase in vitro and that 
the C-terminal region of AcvB contains all key catalytic residues, inter alia 
Ser336 and His433, for L-PG hydrolysis. 
 
3.8.4 Membrane alterations in A. tumefaciens ΔlpiA and ΔacvB strains 
A typical A. tumefaciens membrane contains the main phospholipid 
components PE, PG, PC, DPG and MMPE as well as minor amounts of DMPE 
(28). MMPE and DMPE are precursors for the biosynthesis of PC from PE 
(225). In addition, A. tumefaciens possesses the lpiA gene. The related gene 
product allows for the formation of L-PG in a tRNA-dependent reaction (25). 
In cooperation with the group of Prof. Franz Narberhaus from the 
Ruhr-University Bochum lpiA and acvB deletion mutants in the nopaline-type 
A. tumefaciens strain C58 were generated. Subsequently, the membrane 
composition and growth behavior of these strains was analyzed. 
In the wild type strain the common phospholipids were identified by 
two-dimensional TLC and subsequent cupric sulfate staining. Furthermore, 
small amounts of L-PG were present under neutral and acidic growth 
conditions. Similar observations were recently described for 
Bacillus licheniformis and Bacillus thuringiensis and it was postulated that L-PG 
formation in the bacterial membrane is not only a specific adaptation 
mechanism to acidic conditions but rather a general adaptation mechanism to 
diverse environmental surroundings (58). 
The ΔlpiA mutant strain did not reveal the presence of L-PG within its 
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membrane which verifies the proposed function of LpiA as a L-PGS in 
A. tumefaciens. By contrast, the ΔacvB mutant strain contained increased L-PG 
amounts when compared to the wild type under neutral and acidic growth 
conditions pointing towards the in vivo function of AcvB as a L-PG hydrolase. 
Normal L-PG levels were observed for ΔlpiA and ΔacvB strains complemented 
by a plasmid-encoded lpiA or acvB gene, respectively. 
In accordance with the P. aeruginosa ΔPA0919 strain (49) and an atvA 
transposon mutant of R. tropici (52), a growth phenotype of the ΔacvB strain 
was observed under acidic conditions (pH 5.5), but not under neutral conditions 
(pH 7.5). This growth defect under acidic conditions was restored by providing a 
plasmid-encoded acvB gene. Alternatively, supplementation of the cultivation 
medium with 40 mM calcium chloride which functions as a membrane stabilizing 
agent (226) resulted in wild type-like growth. The obtained results imply that 
AcvB is important for A. tumefaciens growth under acidic conditions. 
A similar growth defect was observed for a R. tropici point mutant where the 
serine residue of the characteristic LIPASE_SER motif was chromosomally 
exchanged against alanine, resulting in a strain that synthesizes nonfunctional 
AtvA protein (52). Taking these observations into consideration, one might 
speculate that the function of aa-PG hydrolyzing enzymes (e.g. AtvA, AcvB, 
A-PGH) is of key importance under acidic conditions and that the respective 
protein is not relevant as a structural component. Dysbalancing the membrane 
composition by elevated L-PG or A-PG levels appears to have a negative 
impact on bacterial growth under acidic, but not under neutral conditions. 
 
3.9 Localization of AcvB and VirJ in A. tumefaciens 
 
3.9.1 Prediction of signal sequences and transmembrane helices 
An important aspect in understanding protein function is the subcellular 
localization of the protein of interest. Initial evidence can be obtained using 
bioinformatic tools predicting e.g. signal sequences and/or transmembrane 
helices. Several prediction tools (2.15) were used to analyze the localization of 
AcvB and VirJ in A. tumefaciens. 
For protein AcvB a signal sequence with a cleavage site after amino acid 24 
was predicted by LipoP 1.0, Phobius, PrediSi and SignalP 4.1. Localization of 
AcvB in the periplasmic space was also predicted by LocTree 3 and 
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TMHMM v. 2.0 detected no transmembrane helix. 
Presence of a signal sequence with a cleavage site after amino acid 19 
(Phobius and PrediSi) or 22 (LipoP 1.0 and SignalP 4.1) was also predicted for 
VirJ. Furthermore, TMHMM v. 2.0 postulated one helical segment from amino 
acid positions 5-22 and LocTree 3 predicted VirJ to be localized in the inner 
membrane. 
These theoretical results point towards a periplasmic localization of AcvB and 
VirJ due to the identification of N-terminal signal sequences. However, VirJ 
might be also anchored in the inner membrane of A. tumefaciens by a helical 
segment. 
 
3.9.2 Localization studies using cellular fractions of A. tumefaciens 
AcvB and VirJ localization experiments were performed using the wild type 
strain A. tumefaciens C58 carrying either plasmid pTrc200_acvB_Strep or 
pTrc200_virJ_Strep. Therefore, cells were cultivated to the early log-phase, 
induced with IPTG and cultivation was continued to the mid-log phase. After 
harvesting, cells were treated with polymyxin B to release periplasmic proteins 
which were subsequently separated from cytoplasmic and membrane proteins 
by centrifugation. The remaining spheroblasts were lysed and unbroken cells 
were sedimented by low-speed centrifugation. The soluble fraction was 
subjected to ultracentrifugation to separate cytoplasmic from membrane 
proteins (2.12.2.2). The obtained pellet was washed, the membrane proteins 
were solubilized by Triton™ X-100 treatment and the soluble fraction was 
obtained by ultracentrifugation (2.12.2.4). Protein fractions were separated by 
SDS-PAGE (2.7.2) and transferred onto a PVDF membrane (2.7.3) for 
subsequent immunochemical detection of the C-terminal Strep-tag® II of AcvB 
or VirJ (2.7.4). The corresponding PVDF membrane for AcvB localization is 
presented in figure 17. 
AcvB was clearly detectable in the fractions containing disrupted cells (lane 2) 
or soluble cytoplasmic proteins (lane 3). In contrast, neither the soluble 
periplasmic fraction (lane 1) nor the fraction containing solubilized membrane 
proteins (lane 4) reveal the presence of AcvB in this type of analysis. In 
previous work the same experimental approach was employed and revealed 
that the homologous protein A-PGH is localized in the cytoplasmic membrane of 
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P. aeruginosa where it is anchored by one transmembrane helix (227). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Localization of AcvB in A. tumefaciens C58 
A. tumefaciens strain C58 carrying plasmid pTrc200_acvB_Strep was cultivated to the 
early log-phase, IPTG was added and cultivation was continued until the mid-log phase 
was reached. Cells were harvested and fractionated into the periplasmic, cytoplasmic 
and membrane fraction as described in chapters 2.12.2.2 and 2.12.2.4. Samples were 
separated by SDS-PAGE, transferred onto a PVDF membrane and AcvB was 
immunochemically detected via its C-terminal Strep-tag® II (2.12.2.5). An arrow 
indicates protein AcvB with a calculated molecular weight of 50.3 kDa. 
Lane M: PageRuler™ Prestained Protein Ladder, relative molecular masses (*1’000) 
are indicated; Lane 1: soluble periplasmic fraction; Lane 2: cells disrupted by French 
Press®; Lane 3: soluble cytoplasmic fraction; Lane 4: membrane proteins solubilized by 
Triton™ X-100. 
 
Based on theoretical analyses a periplasmic localization of AcvB was proposed 
(3.9.1). However, the obtained results of this fractionation experiment do not 
confirm this. One possible reason might be that the utilized immunochemical 
detection method is not sensitive enough to detect low protein amounts of AcvB 
in the periplasmic fraction. Besides this, the employed Strep-Tactin® AP 
conjugate recognizes an innate A. tumefaciens protein with a relative molecular 
mass of ~25’000 (see lane 2). Therefore, this antibody is not applicable to 
unambiguously detect the VirJ protein with a relative molecular mass of ~27’000 
in cellular fractions. Based on these results an alternative experimental 
approach was employed to analyze the localization of AcvB and VirJ in 
A. tumefaciens. 
 
3.9.3 Protein localization analyses via alkaline phosphatase fusions 
A second experimental approach was pursued to localize AcvB and VirJ in 
soluble cellular fractions of A. tumefaciens (142). For this purpose the 
periplasmic protein AP was used as a reporter protein that can easily be 
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detected in the respective cellular fractions by activity measurements (157). 
Two localization vectors containing the putative signal sequences of acvB or 
virJ fused to the AP gene phoA without its own signal sequence were 
generated. As a control, two localization vectors for PhoA were constructed; 
one containing the full-length phoA gene (positive control) and one carrying the 
truncated phoA gene lacking its own signal sequence (negative control). 
 
A. tumefaciens C58 cells carrying either plasmid pTrc200 ‘phoA, pTrc200 phoA,   
pTrc200 leader acvB ‘phoA or pTrc200 leader virJ ‘phoA were cultivated to the 
early log-phase, induced with IPTG and cultivation was continued to the end of 
the exponential phase (2.12.1.1). Identical amounts of cells were harvested and 
the periplasmic proteins were released by polymyxin B treatment. Following 
separation of the periplasmic proteins from cytoplasmic and membrane proteins 
by centrifugation the obtained spheroblasts were disrupted by French Press®. 
Cell debris was separated by low-speed centrifugation and the supernatant was 
subjected to ultracentrifugation to sediment the total membrane fraction 
(2.12.1.2). The isolated soluble periplasmic and cytoplasmic fractions were 
utilized for the determination of AP activity (2.12.1.3) as well as MD activity 
(2.12.1.5) according to De Maagd and Lugtenberg (1986) (177). 
To investigate the quality of the cell fractionation procedure the MD activity 
assay was performed. The cytoplasmic protein MD can convert oxaloacetate to 
malate while NADH+H+ is oxidized to NAD+. The decrease of NADH+H+ in the 
reaction mixture can be monitored spectrophotometrically at a wavelength of 
340 nm. 
The measurements clearly revealed MD activity in the isolated cytoplasmic 
fractions of all four localization strains, whereas it was nearly absent in the 
periplasmic fractions (see appendix figure 32). The determined MD activity in 
the periplasmic fraction was related to the one of the cytoplasmic fraction (set to 
100%). The following activity ratios for the localization strains were calculated: 
pTrc200 ‘phoA (negative control): 0.29%, pTrc200 phoA (positive control): 
0.08%, pTrc200 leader acvB ‘phoA: 0.16% and pTrc200 leader virJ ‘phoA: 
0.20%. These findings demonstrate that the periplasmic fractions contained 
only minor cytoplasmic contaminants. 
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Furthermore, the soluble fractions were subjected to an activity assay using the 
substrate p-nitrophenyl phosphate which is converted to the yellow reaction 
product p-nitrophenol by the periplasmic enzyme AP. The formation of 
p-nitrophenol was monitored spectrophotometrically at a wavelength of 405 nm. 
One AP activity determination, as a representative of four independent 
experiments, is presented in figure 18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Determination of AP activity in the soluble periplasmic fractions 
isolated from four different localization strains. 
The spectrophotometrically monitored absorption at 405 nm, representing the formation 
of p-nitrophenol due to AP activity, is plotted against time. The graphs depicted 
correspond to the blank (black), the negative control (red), the positive control (green), 
the strain pTrc200 leader acvB ‘phoA containing the acvB signal sequence (pink) and 
the strain pTrc200 leader virJ ‘phoA containing the virJ signal sequence (blue). 
 
The determined AP activity resulted in graphs of different steepness based on 
the formation of p-nitrophenol over a time period of 180 sec (figure 18). The 
graph for the blank (sole test solution) only slightly increases over time which 
represents the spontaneous conversion of the substrate to p-nitrophenol in the 
test solution. The graph for the negative control (PhoA without its own signal 
sequence) exhibits a similar curve. This indicates that the PhoA protein without 
its signal sequence remained in the cytoplasmic fraction and thus no AP activity 
was detected in the periplasmic fraction. The slight increase in the absorption 
value over time can be ascribed to the spontaneous substrate hydrolysis as 
already mentioned above. 
By contrast, the graph for the positive control (PhoA with its own signal 
sequence) shows a constant increase of the absorption over time representing 
the formation of p-nitrophenol by AP activity. This result confirms the successful 
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export of PhoA into the periplasm of A. tumefaciens. 
PhoA enzyme activity in the periplasmic fraction was calculated as units (one 
unit corresponds to an absorption change of 0.001 per minute (62)) considering 
the time interval ranging from 100 to 160 sec. On the basis of four independent 
experiments the following activities for the blank and the localization strains 
were calculated: blank: 0.3-0.8 U, pTrc200 ‘phoA: 0.2-0.7 U, pTrc200 phoA: 
5.1-29.4 U, pTrc200 leader acvB ‘phoA: 1.9-7.2 U and pTrc200 leader virJ 
‘phoA: 5.3-45.6 U. For all strains significantly increased PhoA enzyme activities 
were detected in comparison to strain pTrc200 ‘phoA representing the negative 
control. These results clearly indicate the export of the reporter protein PhoA 
into the periplasm of A. tumefaciens facilitated by the native signal sequences 
of the genes acvB and virJ. 
 
3.9.4 Determination of alkaline phosphatase activity in whole cells 
The folding of PhoA is dependent upon disulfide bond formation in the bacterial 
periplasm (228). Accordingly, the export of the PhoA enzyme into the periplasm 
is essential for its activity. Active PhoA can hydrolyze BCIP which leads to the 
formation of an indigo dye (176) and thus a blue appearance of the bacterial 
colonies. In white-colored colonies the substrate BCIP is not hydrolyzed which 
indicates that the enzyme remained in the cytoplasm and thus is not active. This 
system was used to study PhoA localization in whole A. tumefaciens cells 
depending on the respective signal sequence (142). 
Initial experiments revealed a high endogenous PhoA activity in the 
A. tumefaciens wild type strain C58. For further experiments BCIP agar plates 
were thus supplemented with 25 mM disodium hydrogen phosphate which 
efficiently suppresses this undesirable activity. 
The obtained results for the four localization strains are presented in figure 19. 
After four days of cultivation the color of the A. tumefaciens colonies was 
evaluated. For the negative control (figure 19 A) white-colored colonies 
appeared, whereas for the positive control (figure 19 B) blue-colored colonies 
were observed indicating that PhoA remained in the cytoplasm or was exported 
into the periplasm, respectively. For the localization strains containing the acvB 
or virJ signal sequence colonies with a light blue (figure 19 C) or a dark blue 
color (figure 19 D) were observed. So in both cases PhoA was exported into the 
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periplasm, folded into its active form and hydrolyzed the substrate BCIP. 
In summary, the export of the reporter protein PhoA into the periplasm of 
A. tumefaciens is facilitated by the acvB and virJ signal sequences as 
demonstrated in cellular fractions (3.9.3) and whole cells (3.9.4). These results 
clearly indicate a periplasmic localization of proteins AcvB and VirJ in the 
A. tumefaciens C58 strain. 
 
 
 
 
 
 
 
 
 
Figure 19: Determination of AP activity in whole cells of the respective 
localization strains 
The generated A. tumefaciens localization strains were cultivated for four days at 30 °C 
on YEB agar plates supplemented with 90 µg/ml BCIP and 25 mM disodium hydrogen 
phosphate pH 7.2 as described in chapter 2.12.1.4. The AP activity was evaluated 
based on the colony color from white (no AP activity) to blue (high AP activity). The 
results of the following localization strains are depicted: (A) pTrc200 ‘phoA (negative 
control), (B) pTrc200 phoA (positive control), (C) pTrc200 leader acvB ‘phoA (signal 
sequence of acvB), (D) pTrc200 leader virJ ‘phoA (signal sequence of virJ). 
 
3.10 A. tumefaciens infection assays 
 
3.10.1 Tumorigenesis studies on potato discs 
The phytopathogenic bacterium A. tumefaciens is able to induce crown gall 
tumor formation at wound sites of several dicotylic and some monocotylic plant 
species (70, 68). Therefore, the attached Agrobacterium cell translocates its 
T-DNA and effector proteins via the T4SS into the plant cell where the T-DNA is 
integrated into the genome (229). Infected plant cells thereupon synthesize 
opines as well as the phytohormones auxin (230) and cytokinin (231) which 
induce unlimited cell proliferation and thus crown gall formation. 
To analyze the potential role of proteins LpiA and AcvB in A. tumefaciens 
tumorigenesis the deletion mutant strains A. tumefaciens C58 ΔlpiA and ΔacvB 
were employed for potato tuber disc assays (2.13.1) which were performed 
during an internship in the group of Prof. Franz Narberhaus (Ruhr-University 
Bochum). The analyses revealed that deleting lpiA does not influence tumor 
formation on potato discs compared to the wild type, whereas no tumors formed 
 106 
 
after the infection with the ΔacvB mutant. In addition, plasmid-based 
complementation experiments were performed. Therefore, the A. tumefaciens 
strain ΔacvB carrying plasmid pTrc200_acvB_Strep was used for the potato 
tuber disc assay. The complemented strain formed the same amount of tumors 
on potato discs when compared to the wild type strain carrying the empty 
pTrc200 vector. This indicates that the plasmid-based acvB gene restored 
tumor formation and virulence. The obtained results for the ΔacvB mutant and 
the complemented strain are in agreement with the observations made by 
Wirawan et al. (1993) (60). These findings point out that the lpiA gene product is 
not relevant for A. tumefaciens tumorigenesis, whereas the acvB gene product 
is essential. Interpreted in terms of membrane lipid composition these results 
might imply that the absence of L-PG in the ΔlpiA mutant strain is not crucial for 
tumor formation. By contrast, an artificially elevated L-PG amount in the ΔacvB 
mutant strain might interfere with the infection process. 
 
3.10.2 T-DNA transfer from A. tumefaciens into plant cells 
Upon external stimuli (e.g. phenolic compounds, monosaccharides or an acidic 
extracellular pH (73)) the transcription of the Ti plasmid-encoded virulence 
operons (vir genes) is induced and the respective Vir proteins form the T4SS 
(232). This system is responsible for the transfer of the T-strand in complex with 
several Vir proteins (T-complex) into the plant cell (75). Therefore, the T-DNA is 
recognized for processing and transfer by its flanking regions (left and right 
T-DNA border) composed of 25 bp direct repeats (233). The T-complex is 
targeted into the nucleus of the plant cell and subsequently the T-strand is 
integrated into the genome (76). 
 
3.10.2.1 T-DNA transfer assay using β-glucuronidase as a reporter 
Due to the loss of tumor formation ability of the ΔacvB mutant strain on potato 
discs (3.10), it was of interest whether the T-DNA transfer into the plant cell is 
affected for this mutant strain. The corresponding experiments were performed 
during an internship in the group of Prof. Franz Narberhaus (Ruhr-University 
Bochum). 
For analyses the T-DNA binary vector pBISN1 (234), containing inter alia the 
β-glucuronidase gene (gusA) delimited by the left and right T-DNA border, was 
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employed. Transformation of this plasmid into the respective A. tumefaciens 
strains, subsequent infection of A. thaliana efr-1 seedlings according to the 
AGROBEST method (149) and the determination of GUS activity in the 
seedlings (2.13.2) allowed to analyze the T-DNA transfer capability of the 
different strains. GUS staining of the seedlings was performed three days 
post-infection with the respective A. tumefaciens strain. For staining, the 
seedlings were incubated with X-Gluc which is an artificial substrate of the GUS 
enzyme (235). Dark blue-colored cotyledons imply a strong GUS activity and so 
a successful transfer of the T-DNA into plant cells, whereas no GUS activity is 
detected in unstained cotyledons indicating that the T-DNA is not transferred. 
For stained seedlings infected with the A. tumefaciens C58 wild type, the wild 
type containing the empty pTrc200 vector or the ΔlpiA mutant blue-colored 
cotyledons were observed as shown in figure 20 A. These results suggest that 
the T-DNA transfer is not affected in the wild type and the ΔlpiA mutant which is 
in compliance with their ability to form tumors on potato discs (3.10.1). 
By contrast, infection with the ΔacvB strain and subsequent GUS staining 
resulted in unstained cotyledons (figure 20 A). The seedling infection takes 
place in an acidic cultivation medium. Under these conditions the ΔacvB strain 
exhibits a growth defect that can be restored by the supplementation of 40 mM 
calcium chloride to the cultivation medium (3.8.4). To rule out an impaired 
T-DNA transfer of the ΔacvB mutant due to a growth defect, infection assays 
supplemented with 40 mM calcium chloride were performed. However, GUS 
staining of the respective seedlings revealed again unstained cotyledons (figure 
20 A) indicating that the A. tumefaciens growth phenotype is not related to the 
impaired T-DNA transfer. Infection of the seedlings with the A. tumefaciens 
ΔacvB pTrc200_acvB_Strep strain resulted in blue-colored cotyledons (figure 
20 A) after GUS staining. This implies that the T-DNA transfer ability was 
restored by the plasmid-encoded acvB gene. 
These results point towards an essential role of protein AcvB and/or its L-PG 
hydrolyzing activity for the T-DNA transfer process. The impaired T-DNA 
transfer ability of the ΔacvB strain might also account for the absence of tumors 
on infected potato discs (3.10.1). 
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Figure 20: A. thaliana efr-1 seedlings infected by different A. tumefaciens strains 
and subsequently stained to determine GUS activity 
The different A. tumefaciens strains containing the pBISN1 plasmid were cultivated in 
AB-MES pH 5.5 medium containing 200 µM AS to induce vir gene expression. 
Four-day-old A. thaliana efr-1 seedlings were infected with the respective strain and 
co-cultivated in infection medium (MS medium and AB-MES pH 5.5 medium in a ratio 
of 1:1 (v/v) containing 200 µM AS). Three days post-infection the seedlings were 
stained to determine GUS activity (2.13.2). Two independent experiments are depicted 
in figure parts A and B. The following A. tumefaciens strains were employed: wild type 
(WT), wild type carrying plasmid pTrc200 (WT pTrc200), ΔlpiA mutant (ΔlpiA), ΔacvB 
mutant with or without 40 mM calcium chloride supplementation to the cultivation 
medium (ΔacvB + CaCl2 or ΔacvB - CaCl2), ΔacvB mutant carrying plasmid 
pTrc200_acvB_Strep (ΔacvB + acvB), ΔacvB mutant carrying plasmid pTrc200 (ΔacvB 
pTrc200), ΔacvB mutant carrying either plasmid pTrc200_acvB_Strep-S269A, 
pTrc200_acvB_Strep-S336A, pTrc200_acvB_Strep-H433A or 
pTrc200_acvB_Strep-H433N (ΔacvB + acvB S269A, ΔacvB + acvB S336A, 
ΔacvB + acvB H433A, ΔacvB + acvB H433N) and the wild type carrying plasmid 
pTrc200_lpiA (WT + lpiA). 
 
To get further insight into the role of AcvB in T-DNA transfer, several plasmids 
based on the pTrc200 vector encoding for AcvB variants S269A, S336A, H433A 
and H433N were constructed (2.5.13). These AcvB proteins were previously 
analyzed in in vitro activity assays revealing residual L-PG hydrolyzing activity 
for protein AcvB S269A, whereas the AcvB mutant proteins S336A, H433A and 
H433N completely lost their ability to hydrolyze L-PG (3.8.3). 
For T-DNA transfer assays the ΔacvB strains carrying the respective plasmids 
containing acvB mutant genes were used. These plasmids restore the deleted 
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acvB gene by the respective gene variant. The infected A. thaliana seedlings 
were stained to determine GUS activity and the obtained results are shown in 
figure 20 B. Cotyledons of seedlings infected by the wild type or the 
complemented ΔacvB strain containing plasmid pTrc200_acvB_Strep were 
blue-colored after GUS staining which demonstrates a successful T-DNA 
transfer, whereas infection with the ΔacvB mutant strain containing the empty 
pTrc200 vector resulted in unstained cotyledons as described above. 
Following seedling infection with the ΔacvB strain containing plasmid 
pTrc200_acvB_Strep-S269A and GUS staining the cotyledons obtained a blue 
color indicating an effective T-DNA transfer. By contrast, plasmid-based 
complementation of the ΔacvB strain with the AcvB point mutant S336A 
resulted in unstained cotyledons after seedling infection and staining which 
means that the T-DNA was not transferred into the plant cells. Cotyledons 
infected with ΔacvB strains complemented by AcvB point mutants H433A or 
H433N showed isolated blue dots which imply an impaired T-DNA transfer 
compared to the wild type strain. Furthermore, the wild type strain 
overexpressing the lpiA gene was analyzed and showed a defective T-DNA 
transfer comparable to the ΔacvB mutant and the complemented variant 
ΔacvB + acvB S336A. 
L-PG amounts in the different A. tumefaciens strains were analyzed by 
two-dimensional TLC and subsequent cupric sulfate staining to estimate the 
in vivo activity of the AcvB protein variants or LpiA. The following L-PG contents 
were estimated: WT pTrc200: ~1%, ΔacvB pTrc200: ~12%, ΔacvB + acvB: 
~2%, ΔacvB + acvB S269A: ~2%, ΔacvB + acvB S336A: ~9%, 
ΔacvB + acvB H433A: ~5%, ΔacvB + acvB H433N: ~4%, WT + lpiA: ~7%. The 
in vivo activities are in good agreement with the in vitro activities (3.8.3) except 
for the ΔacvB strains complemented by AcvB point mutants H433A and H433N. 
These mutant proteins were not able to hydrolyze L-PG in vitro, but show 
residual in vivo activity. Overproduction of LpiA in the wild type strain resulted in 
comparable L-PG amounts to the ΔacvB strain complemented by AcvB point 
mutant S336A. 
The results might indicate that elevated L-PG amounts in the A. tumefaciens 
membrane impair or completely prevent the T-DNA transfer. This implies that a 
fine-tuned cellular L-PG amount on the basis of a functional AcvB protein is 
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essential for A. tumefaciens T-DNA transfer by the T4SS. 
In the present study it was shown that complete lack of L-PG in the ΔlpiA 
mutant strain did not influence tumor formation when compared to the wild type 
strain (3.10.1). Similar findings were recently described for the DPG-deficient 
A. tumefaciens double mutant Δcls1/Δcls2 (170). In contrast, it was 
demonstrated that reduced PC amounts in a ΔpmtA mutant or complete lack of 
PC in a ΔpmtA/Δpcs double mutant resulted in delayed or even abolished tumor 
formation on Kalanchoё leaves, respectively (38). These effects were ascribed 
to a reduced or complete lack of vir gene expression in the particular 
A. tumefaciens strains resulting in an impaired or defective T4SS. 
A. tumefaciens also synthesizes phosphorus-free ornithine lipids. Mutant strains 
of the respective biosynthetic genes olsB and olsE were either deficient of 
ornithine lipids or they only synthesized unmodified ornithine lipids. For these 
strains accelerated tumor formation on potato tuber discs was observed when 
compared to the wild type strain (236). It was proposed that ornithine lipids are 
detected by the plant which then induces defense mechanisms that might be 
hampered or absent during infection with the ΔolsB and ΔolsE mutant strains. 
These related studies clearly illustrate that membrane lipids can play a critical 
role at diverse stages of A. tumefaciens tumorigenesis. 
In the present study the relevance of a functional AcvB protein in the context of 
T-DNA transfer and tumorigenesis was demonstrated (3.10.1, 3.10.2). For 
crown gall tumor formation in plant cells a coordinated infection process takes 
place which includes, inter alia, the attachment of A. tumefaciens to the host 
cell, T-DNA processing and transfer into the host cell by the T4SS, T-DNA 
transport to the nucleus as well as nuclear import and genomic integration 
(237). 
In different studies the initial infection processes of an acvB mutant strain and 
the wild type strain were analyzed. No differences were observed concerning 
the signal molecule sensing and subsequent activation of the two-component 
regulatory system VirA/VirG (63), vir gene expression (62, 61, 63), the 
attachment to plant cells (60, 63) and T-strand formation (62). By contrast, 
related investigations described a significantly impaired T-DNA transfer ability of 
the acvB mutant strain to maize or tobacco plant cells (63, 238, 239) and it was 
proposed that AcvB and VirJ might be involved in T-DNA transfer. However, 
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within all these investigations the observed phenotypes were not related to an 
L-PG hydrolyzing activity of AcvB. The present investigation for the first time 
links the cellular L-PG level to the related infection phenotypes of the 
investigated acvB mutant strains. Accordingly, lipid homeostasis might play a 
critical role during the individual stages of the infection process. 
To get further insight into the detailed role of L-PG in A. tumefaciens T-DNA 
transfer further analyses concerning the T4SS maturation are required. 
Furthermore, an altered membrane composition might influence the recognition 
of A. tumefaciens by plant cells. This might also result in the activation of plant 
defense mechanisms which could prevent T-DNA transfer. 
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3.11 Protein PA3911 is upregulated under anaerobic biofilm conditions 
In a recent proteomics study performed by Magnowska and co-workers (113, 
175) the iTRAQ labeling technique in combination with liquid chromatography 
and mass spectrometry (2D-LC-MS/MS) was employed to assess the 
adaptation of P. aeruginosa to anaerobic biofilm conditions of the CF lung 
(1.4.1). Therefore, P. aeruginosa biofilms were grown on artificial sputum 
medium agar plates under aerobic and anaerobic conditions to mimic the 
metabolic changes during infection progression. The obtained iTRAQ-MS data 
from three independent experiments revealed that protein PA3911 was the 
second-most significantly upregulated protein under anaerobic biofilm 
conditions. This result was statistically evaluated (116) and indicated a 5- to 
10-fold induction as judged from 12 unique peptides with a sequence coverage 
of 43%. 
So far, this 19 kDa protein is solely described in the literature as a conserved 
hypothetical protein that is encoded at the 3’ end of a proposed operon 
including orfs PA3913, PA3912 and PA3911 (117). Several experimental 
approaches revealed a significant upregulation of these orfs under low oxygen 
and anaerobic conditions (121, 119, 117, 118, 120) as described in chapter 
1.4.1 which is in agreement with the findings described by Magnowska (2010) 
(113). 
 
3.12 Orthologous PA3911 sequences and operon prediction 
Protein homologs of PA3911 from P. aeruginosa were identified using the 
blastp tool (195). Orthologous proteins are present in α-, β- and 
γ-proteobacteria, whereas related proteins are not conserved in Gram-positives, 
archaea, fungi, plants and mammals. 
Among eukarya, moderate sequence homology of PA3911 to one part of the 
58 kDa SCP-X was determined. This protein is composed of an N-terminal 
3-ketoacyl CoA thiolase and a C-terminal 13 kDa SCP-2 domain that can be 
cleaved off post-translationally (128). SCP-2 domain-containing proteins have 
been described in the literature as non-specific LBP which are associated with 
many proposed functions in cholesterol transport and lipid metabolism in 
vertebrates and insects (127, 240, 241). 
The PA3913, PA3912 and PA3911 operon of P. aeruginosa was also predicted 
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by the DOOR² database (197). The hypothetical proteins PA3913 and PA3912 
were predicted to be members of the peptidase family U32 and PA3911 to 
belong to the SCP-2 sterol transfer family by the Pfam database (242). 
Theoretical analyses using the DOOR2 database revealed similar operon 
structures for several α-, β- and γ-proteobacteria. In β- and γ-proteobacteria an 
operon encoding for PA3913, PA3912 and PA3911 orthologous genes is 
conserved, whereas in α-proteobacteria the genes are rearranged to PA3911, 
PA3913 and PA3912. Moreover, in several species belonging to the class of α- 
or β-proteobacteria (e.g. A. tumefaciens, Paracoccus denitrificans or Laribacter 
hongkongensis) this operon structure is expanded by a fourth gene at the 5’ or 
3’ end, encoding for a hypothetical protein, an oxidoreductase or a regulatory 
protein. 
 
3.13 Phenotypic characterization  
To analyze the physiological role of PA3911 in P. aeruginosa a mutant strain 
was analyzed concerning its growth behavior under various conditions and its 
motility in comparison to the wild type strain. 
 
3.13.1 P. aeruginosa PA3911 mutant strain 
For phenotypical analyses the deletion of orf PA3911 from the wild type strain 
P. aeruginosa PAO1 was intended. For mutant generation the method 
described by Hoang et al. (1998) (140) was employed (2.5.16). However, the 
genomic integration of the gentamicin resistance cassette only occurred as a 
single crossover instead of a double crossover event. Accordingly, no 
markerless PA3911 deletion strain was obtained for further experiments. 
Therefore, P. aeruginosa strain PW7609 (kindly provided by Prof. Susanne 
Häußler from the Helmholtz Centre for Infection Research, Braunschweig) 
carrying a transposon insertion in orf PA3911 was employed for subsequent 
phenotypical characterizations. The integrity of the PA3911 mutant strain was 
confirmed by PCR analyses and subsequent sequence determination (2.10.1) 
as recommended by the transposon mutant library curators (134). The 
sequenced PCR fragment (431 bp) clearly revealed the integration of the 
transposon ISphoA/hah at base position 5 of gene PA3911 which is fully 
consistent with the information provided by the library curators. 
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3.13.2 Growth behavior in complex and minimal medium 
The growth behavior of the P. aeruginosa strains MPAO1 (parental strain) and 
PW7609 (PA3911 mutant) was analyzed in LB complex and AB pH 7.3 minimal 
medium under aerobic and anaerobic conditions as described in chapter 2.4.5. 
Under all conditions identical growth curves for both strains were obtained. 
 
3.13.3 Phenotype Microarray™ analyses 
A commercially available Phenotype Microarray™ system from Biolog 
(Hayward, CA, USA) was applied for comparative analyses of the wild type 
strain MPAO1 and the mutant strain PW7609 (2.10.3). An overall of 
1’152 growth conditions covering a broad range of stressors (e.g. salts, pH and 
antibiotics) were tested. The cell respiration in the different growth conditions 
was visualized by a tetrazolium dye functioning as a redox indicator. 
Similar growth of both strains was observed in the utilized IF-10 minimal 
medium which is a good prerequisite to perform comparative studies (figure 
21 C). The commercial experiment revealed an increased susceptibility of strain 
PW7609 compared to the wild type in nine different conditions. 
Due to the fact that the manufacturer Biolog does not provide the respective 
compound concentrations, significant growth phenotypes were independently 
reproduced in non-commercial microarray experiments. Therefore, 96-well 
plates were filled with defined concentrations of the respective compounds in 
IF-10 minimal medium containing the tetrazolium dye, inoculated with the 
particular P. aeruginosa strain and cultivated as described for the commercial 
experiment (2.10.3). 
The observed trends were independently reproduced in three experiments of 
which one is exemplarily depicted in figure 21. An increased susceptibility of 
strain PW7609 against the compounds initially identified in the commercial 
experiment was successfully confirmed in the non-commercial experiments. 
The respective MICs were determined for selected antimicrobials by serial 
experiments in the presence of linearly increasing compound concentrations. 
Figure 21 A shows the observed susceptibility differences for the wild type and 
the PA3911 mutant strain PW7609 using sub-inhibitory or inhibitory compound 
concentrations (for details see the caption of figure 21). Strain PW7609 was 
more susceptible to the semisynthetic tetracycline derivative minocycline, the 
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β-lactames nafcillin and oxacillin as well as chloramphenicol and its derivative 
thiamphenicol. The following MIC values for the mutant versus the wild type 
strain were determined: 3 or 8 µg/ml for minocycline, 275 or 750 µg/ml for 
nafcillin, 800 or 2’600 µg/ml for oxacillin, 25 or 1’000 µg/ml for chloramphenicol 
and 50 or 700 µg/ml for thiamphenicol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Characterization of strain PW7609 using Phenotype Microarrays™ 
The cell respiration value (arbitrary OmniLog units 0-500) of the P. aeruginosa wild 
type strain (green line) and the PA3911 mutant strain PW7609 (red line) was plotted 
against the time (48 h). A: Strains were cultivated at 37 °C in 120 µl IF-10 medium 
supplemented with tetrazolium dye A and inhibitory concentrations of the following 
substances: 0.25, 3 or 8 µg/ml minocycline; 100, 275 or 750 µg/ml nafcillin; 200, 800 or 
2’600 µg/ml oxacillin; 2, 25 or 1’000 µg/ml chloramphenicol; 2.5, 50 or 700 µg/ml 
thiamphenicol; 1, 10 or 100 µg/ml 1-chloro-2,4-dinitrobenzene (CDNB). Serial 
experiments in the presence of linearly increasing compound concentrations allowed 
for the accurate determination of the respective MIC values. B: Identical growth 
experiment as described in part A using IF-10 medium pH 4.5. C: Control experiment in 
the presence of IF-10 minimal medium. 
 
A 1- to 5-fold reduction of MICs in the presence of diverse antimicrobials has 
recently been described for P. aeruginosa mutant strains impaired in lipid 
homeostasis, e.g. the A-PGS mutant strain ΔPA0920, when compared to the 
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wild type (48, 49). MIC values were similarly reduced for strain PW7609 in the 
presence of minocycline (2.6-fold), nafcillin (2.7-fold) and oxacillin (3.3-fold). For 
comparison, a 1.2-fold reduced MIC value for oxacillin was observed for strain 
P. aeruginosa ΔPA0920 when related to the wild type (48). However, 
pronounced MIC reductions of 14-fold and 40-fold were observed for strain 
PW7609 in the presence of thiamphenicol and chloramphenicol, respectively. 
These findings indicate that the PA3911 gene product contributes to the high 
intrinsic antibiotic resistance of P. aeruginosa and understanding the underlying 
molecular principles is of central importance for the future development of new 
antimicrobial strategies. 
For the compound CDNB, an artificial substrate of the glutathione S-transferase 
(243), an increased susceptibility of the mutant strain compared to the wild type 
was observed which is reflected in MIC values of 10 versus 100 µg/ml (figure 
21 A). With respect to the PA3911 mutant, CDNB might influence the 
glutathione homeostasis and thus the related redox state of the cell. 
Furthermore, the commercial Phenotype Microarray™ experiment revealed a 
growth phenotype of strain PW7609 under an overall of three acidic conditions, 
as exemplified in figure 21 B. These results might indicate that PA3911 is also 
involved in the adaptation of P. aeruginosa to acidic environmental conditions. 
Under these conditions similar effects were observed for P. aeruginosa strains 
with an unbalanced cellular lipid composition (43, 49). 
 
3.13.4 Motility and biofilm formation assays 
Several properties influence the virulence of P. aeruginosa, inter alia, different 
types of motility like swimming, swarming and twitching as well as the ability to 
form biofilms. 
 
3.13.4.1 Motility assays 
P. aeruginosa is highly motile which enables the colonization of several 
environmental habitats and it was demonstrated that motility is to some extent 
required for P. aeruginosa virulence (86, 244, 245). Accordingly, strain PW7609 
was tested for swarming, swimming and twitching motility in comparison to the 
wild type strain (2.10.2). 
Concerning swarming and swimming motility no phenotypical differences were 
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observed between the two strains (data not shown). To analyze twitching 
motility the well-established stab-inoculation method was employed in five 
independent experiments. Twitching zones were stained with crystal violet and 
measured for comparison (2.10.2.1). The average twitch zone of the wild type 
strain was set as 100% and the value of strain PW7609 was related to that. 
 
 
 
 
 
 
 
 
 
 
Figure 22: Twitching motility assay 
1% LB-Lennox agar plates were stab-inoculated with a toothpick to the plate bottom 
and incubated in a humidified chamber at 37 °C for 24 h (2.10.2.1). A: For visualization 
purposes the twitching motility zones were stained with 1% (w/v) crystal violet solution 
for 10 min. Scale bars = 1 cm. B: The average twitch zone of the wild type strain was 
set as 100% and the value of the PA3911 mutant strain was related to that. The data 
from five independent experiments performed in at least sextuplicate is shown (**, 
significance with p < 0.01). 
 
As depicted in figure 22, strain PW7609 showed clearly enhanced twitching 
motility with an average twitch zone of 146% (significance with p < 0.01). This 
type of motility is mediated via type IV pili and is necessary for the active 
expansion of P. aeruginosa colonies on semisolid or solid surfaces (246). 
Furthermore, it is required for the spatial organization of mushroom-shaped 
structures within a biofilm (247–249). Accordingly, biofilm formation of strain 
PW7609 was subsequently investigated. 
 
3.13.4.2 Biofilm formation 
Based on the finding that strain PW7609 shows significantly enhanced twitching 
motility compared to the wild type (3.13.4.1), both strains were subjected to a 
well-established static biofilm formation assay in 96-well microtiter plates 
(2.10.2.4). After 24 h incubation, the surface-attached bacteria were stained 
with crystal violet, solubilized and the absorbance at 595 nm was determined. 
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The data from nine independent experiments revealed that the biofilm formation 
in the PA3911 mutant strain is significantly impaired when compared to the wild 
type strain (65% versus 100%, significance with p < 0.001). These findings 
might indicate that orf PA3911 is relevant for P. aeruginosa biofilm formation 
under the employed conditions. 
 
3.14 Localization of the PA3911 protein in P. aeruginosa 
 
3.14.1 Prediction of signal sequences and transmembrane helices 
To gain further insight into the physiological function of protein PA3911 its 
subcellular localization is of central importance. The employed prediction tools 
(2.15) LipoP 1.0, LocTree3 and SignalP 4.1 detected no signal peptide and thus 
proposed a cytoplasmic localization. This finding is supported by the absence of 
transmembrane helices in PA3911 as predicted by TMHMM v. 2.0. Solely the 
online tool Phobius detected a signal sequence with a cleavage site after amino 
acid position 20. However, a genome-wide study to identify P. aeruginosa 
exported proteins using the PhoA fusion method revealed an unclear picture 
with regard to the cellular localization of PA3911 (53). 
 
3.14.2 Localization of protein PA3911 in cellular fractions 
The P. aeruginosa strain PAO1 pUCP20T-PPA3911-PA3911 was employed for 
localization studies. This strain was cultivated to the end of the exponential 
growth phase. Subsequently, the cells were harvested and subjected to 
different fractionation techniques. Protein PA3911 was detected within the 
cellular fractions by its C-terminal Strep-tag® II using the Strep-Tactin® AP 
conjugate. 
The soluble periplasmic fraction was isolated from harvested cells of the 
respective strain by polymyxin B treatment and subsequent centrifugation to 
sediment the spheroblasts. The obtained spheroblasts were homogenized, cell 
debris was separated by centrifugation and the soluble cytoplasmic fraction was 
received (2.11.2). 
To isolate the total membrane fraction, harvested cells were disrupted by a 
French Press® and cell debris was sedimented by low-speed centrifugation. The 
obtained supernatant was subjected to high-speed centrifugation to sediment 
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the total membrane fraction. Membrane proteins were solubilized out of it using 
Triton™ X-100 (2.11.3). 
Samples of the isolated fractions were separated by SDS-PAGE (2.7.2) and 
transferred onto a PVDF membrane (2.7.3) for subsequent immunochemical 
detection of the employed Strep-tag® II (2.7.4). The obtained PVDF membrane 
for PA3911 localization is presented in figure 23. 
 
 
 
 
 
 
 
 
Figure 23: Localization of protein PA3911 in P. aeruginosa 
Subcellular fractions of the P. aeruginosa strain PAO1 carrying plasmid 
pUCP20T-PPA3911-PA3911 were separated by SDS-PAGE, transferred onto a PVDF 
membrane by Western blotting and the PA3911 protein was detected by its 
Strep-tag® II (relative molar mass of ~21’000) using the Strep-Tactin® AP conjugate 
(2.11). Lane M: PageRuler™ Prestained Protein Ladder, relative molecular masses 
(*1’000) are indicated; Lane 1: whole cells; Lane 2: supernatant after cell disruption by 
a French Press® and low-speed centrifugation; Lane 3: total membrane fraction; 
Lane 4: supernatant after high-speed centrifugation; Lane 5: whole cells; 
Lane 6: soluble periplasmic fraction; Lane 7: soluble cytoplasmic fraction. 
 
Protein PA3911 was detected in intact cells of the respective P. aeruginosa 
strain (lane 1). After cell disruption and the removal of unbroken cells by 
low-speed centrifugation PA3911 was present in the membrane containing 
supernatant (lane 2). However, in the isolated total membrane fraction (lane 3) 
protein PA3911 was no longer detectable. By contrast, the supernatant from the 
high-speed centrifugation step, containing soluble cytoplasmic and periplasmic 
proteins, revealed a dominant PA3911 band (lane 4). 
In an independent experiment intact P. aeruginosa cells (lane 5) were incubated 
with polymyxin B to release the soluble periplasmic fraction (lane 6) which did 
not indicate the presence of protein PA3911. In the fraction containing soluble 
cytoplasmic proteins (lane 7) protein PA3911 was clearly detected. The 
obtained results imply that PA3911 is a soluble protein located in the cytoplasm 
of P. aeruginosa PAO1. 
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3.15 Production and purification of protein PA3911 
For functional in vitro studies purified PA3911 protein was required. Initially, the 
Codon Adaptation Index (CAI) as a measure of codon usage bias was 
determined. The codon usage of the heterologous expression system (e.g. 
E. coli) is compared with the codons present in the gene of interest (e.g. 
PA3911) and a frequency score, the CAI, is calculated (250). This score ranges 
from zero to one and a high value indicates a high proportion of the most 
abundant codons in the gene of interest. For the PA3911 gene from 
P. aeruginosa a CAI of 0.273 was calculated for the heterologous expression in 
E. coli cells. Thereupon a synthetic fragment containing the codon-optimized 
PA3911 gene sequence (table 7) was used for vector construction. 
Several vector constructs for PA3911 with different N-terminal tags (GST-tag, 
His6-tag, thioredoxin-His6-S-tag) were generated (2.5.13) and recombinant 
protein production was performed in E. coli BL21(λDE3) cells (2.6.1.4). 
Harvested cells were disrupted by French Press® passage and insoluble 
components were separated by high-speed centrifugation. His6-tagged PA3911 
protein was purified using TALON® metal affinity resin (2.6.3.3), whereas for the 
GST-tagged variant Protino® Glutathione Agarose 4 B resin (2.6.3.2) was 
employed. The purifications of the His6- and GST-tagged variant yielded only 
negligible protein amounts (data not shown). 
Purification of protein PA3911 with an N-terminal thioredoxin-His6-S-tag using 
TALON® metal affinity resin (2.6.3.3) resulted in protein amounts sufficient for 
subsequent in vitro studies. In an identical procedure, the pET32a(+) vector was 
used for the heterologous overproduction and purification of the sole 
thioredoxin-His6-S-tag protein. This protein was used as an appropriate control 
for in vitro studies. 
The corresponding SDS-PAGE analysis is depicted in figure 24. Lanes 1 and 2 
show the total protein content of E. coli BL21(λDE3) cells containing plasmid 
pET32a(+)-PA3911 before and after IPTG induction, indicating high cellular 
PA3911 concentrations after induction. A representative elution fraction of 
purified PA3911 protein is depicted in lane 3. Comparison of lanes 2 and 3 
clearly illustrates that large amounts of the produced protein appear in the 
insoluble fraction. Nevertheless, 1 mg almost homogeneous PA3911 protein per 
liter E. coli culture was obtained. 
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The major contaminant in the elution fraction with a relative molar mass of 
~57’300 was identified as the E. coli chaperone GroEL by N-terminal amino 
acid sequence determination (2.7.5; kindly performed by Beate 
Jaschok-Kentner, Helmholtz Centre for Infection Research, Braunschweig). 
Several techniques (e.g. ATP washing steps and anion or cation exchange 
chromatography) were tested to remove GroEL during protein purification. 
However, none of the employed methods resulted in the successful separation 
of GroEL and PA3911. 
 
 
 
 
 
 
 
 
Figure 24: SDS-PAGE analysis of a PA3911 and thioredoxin-His6-S-tag protein 
purification 
Protein PA3911 was recombinantly produced in E. coli BL21(λDE3) cells and purified 
via its N-terminal thioredoxin-His6-S-tag using TALON
® metal affinity resin (2.6.3.3). 
Sample fractions were denatured with 2x SDS loading dye (95 °C, 10 min), subjected 
to SDS-PAGE analysis (12% (w/v) running gel) and proteins were visualized by 
InstantBlue™ staining (2.7.2).   
Lane M: Unstained Protein Molecular Weight Marker, relative molecular masses 
(*1’000) are indicated; total protein of E. coli cells carrying plasmid pET32a(+)-PA3911 
before (lane 1) and after (lane 2) IPTG induction; Lane 3: purified PA3911 protein with 
a relative molar mass of ~37’000; total protein of E. coli cells carrying plasmid 
pET32a(+) before (lane 4) and after (lane 5) IPTG induction; Lane 6: purified 
thioredoxin-His6-S-tag protein with a relative molar mass of ~20’000. 
 
The integrity of the target protein with a relative molar mass of 37’000 (as 
judged from SDS-PAGE) was confirmed to be 37’048.3 Da by ESI-MS 
measurements (2.7.7) which were kindly performed by Dr. Manfred Nimtz 
(Helmholtz Centre for Infection Research, Braunschweig). 
For control experiments the sole thioredoxin-His6-S-tag protein was produced 
and purified analogously from E. coli BL21(λDE3) cells containing plasmid 
pET32a(+). After IPTG induction high amounts of the tag protein are visible in 
the total protein fraction (compare lanes 4 and 5) and after purification almost 
homogenous protein (lane 6) with a relative molar mass of ~20’000 was 
obtained. 
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3.16 Protein-lipid overlay assays 
Sequence analyses revealed that protein PA3911 shares homology with LBP 
(3.12). Accordingly, the lipid binding capability of protein PA3911 was explored 
in in vitro studies. Therefore, the thioredoxin-His6-S-tagged PA3911 protein as 
well as the thioredoxin-His6-S-tag as a control protein were recombinantly 
produced in E. coli cells (2.6.1.4) and purified using TALON® metal affinity resin 
(2.6.3.3). 
Protein-lipid overlay experiments were performed with commercially available 
Membrane Lipid Strips™ (Echelon® Biosciences, Salt Lake City, UT, USA), 
hydrophobic membranes whereon 15 different lipids are spotted. After 
incubating the membranes with equimolar amounts of either protein PA3911 or 
the tag protein, several washing steps followed and the respective lipid bound 
protein was detected immunochemically by its His6-tag (2.7.11). The obtained 
Membrane Lipid Strips™ are presented in figure 25. 
 
 
 
 
 
 
 
 
 
 
Figure 25: Protein-lipid overlay assays using Membrane Lipid Strips™ 
The PA3911 protein and the sole thioredoxin-His6-S-tag protein (control) were purified 
from the cytoplasm of E. coli by His6-tag chromatography using TALON
® metal affinity 
resin. Subsequently, the lipid binding capability was analyzed with Membrane Lipid 
Strips™ (Echelon® Biosciences) according to the manufacturer’s instructions. The 
detected spot intensities were classified in the following way: strong PA binding (++), 
no PA binding (-). TG, triglyceride; DAG, diacylglycerol; PA, phosphatidic acid; PS, 
phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PG, 
phosphatidylglycerol; CL, cardiolipin; PI, phosphatidylinositol; PI(4)P, 
phosphatidylinositol (4)-phosphate; PI(4,5)P2, phosphatidylinositol (4,5)-bisphosphate; 
PI(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; CS, cholesterol; SM, 
sphingomyelin; 3-SGC, 3-sulfogalactosylceramide. 
 
Referring to the set of lipids spotted onto the Membrane Lipid Strips™, protein 
PA3911 specifically binds to PA under the employed conditions. PA is a simple 
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diacyl-glycerophospholipid which acts as an essential precursor for 
glycerophospholipid biosynthesis as described in chapter 1.1.1. By contrast, the 
sole thioredoxin-His6-S-tag protein did not bind to the spotted lipids at all 
indicating that lipid binding of protein PA3911 is not mediated by the employed 
protein tag. 
In contrast to PA, the following structurally related phospholipids did not reveal 
the binding of protein PA3911: (I) the PA derivative DAG which lacks the 
phosphate ‘headgroup’ that appears to be a relevant determinant for the binding 
of PA3911; (II) PS, PE, PC, PG, PI, PI (4)-phosphate, PI (4,5)-bisphosphate, 
PI (3,4,5)-trisphosphate and sphingomyelin containing, inter alia, an ‘increased 
polar headgroup’ which might indicate that a more bulky phosphodiester group 
is not accepted by protein PA3911; (III) CL/DPG contains a modified polar head 
group and two additional fatty acids when compared to PA which might hamper 
the binding of PA3911; (IV) the molecules triglyceride, cholesterol and 
3-sulfogalactosylceramide are devoid of a phosphate group which might prevent 
the binding of PA3911. According to these results protein PA3911 is proposed 
to be a specific PA binding protein under the employed conditions. 
 
3.17 Characterization of the potential lipid binding pocket of PA3911 
Due to the homology of protein PA3911 to members of the SCP-2 sterol 
transfer family (3.12), the existence of a lipid binding pocket was proposed. For 
SCP-2 protein variants from different origins it was described that they contain 
tunnel-like cavities or binding pockets, mainly lined by hydrophobic residues 
(240). 
To initially characterize this potential lipid binding pocket of PA3911 a structural 
modeling approach was used. Therefore, the SWISS-MODEL server (204) was 
employed to identify suitable templates for modeling. The search revealed 33 
potential templates with low to moderate sequence identities ranging from 
10-27%. Considering the sequence identity and sequence coverage the 
structure of the human SCP-2-like domain in complex with Triton™ X-100 (PDB 
code 1IKT, 19.8% sequence identity) was employed as a template for the 
modeling of PA3911. A structure-based sequence alignment is presented in 
figure 26. 
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Figure 26: Structure-based sequence alignment of PA3911, 1IKT and 4UEI 
Alignment of protein sequences PA3911 from P. aeruginosa PAO1, SCP-2-like domain 
of human multifunctional enzyme type 2 (PDB code 1IKT) and SCP-2 domain of 
Helicoverpa armigera (PDB code 4UEI) was generated using the SWISS-MODEL 
server. Residues proposed to be involved in PA binding by PA3911 and spatially 
related residues in 1IKT or 4UEI are depicted in bold letters. Amino acids mutagenized 
by site-directed mutagenesis are highlighted. 
 
Based on the obtained three-dimensional model of protein PA3911 (figure 27) 
several amino acids, located in the potential hydrophobic lipid binding pocket, 
were proposed to be involved in PA binding: Leu56 (Phe34), Leu58 (Trp36), 
Val69 (Ile50), Phe95 (Phe79) and Leu114 (Leu98); spatially related residues in 
the hydrophobic binding pocket of the human SCP-2 like domain structure (PDB 
code 1IKT) are specified in brackets.  
 
 
 
 
 
 
 
 
 
Figure 27: Three-dimensional model of protein PA3911 
The three-dimensional model of PA3911 was generated by the SWISS-MODEL server 
using the human SCP-2-like domain in complex with Triton™ X-100 (PDB code 1IKT) 
as a template. The proposed amino acids for PA binding are located in the putative 
lipid binding pocket and are shown as sticks. The depicted ligand was adopted from the 
structure of 1IKT to illustrate the location of the putative lipid binding pocket.   
 
For amino acids Leu56, Leu58, Val69 and Phe95 a potential interaction with the 
hydrophobic part of PA was assumed, whereas Leu114 is positioned at the 
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potential binding pocket entry site and might modulate its accessibility. These 
amino acids were mutagenized by either a hydrophobic, bulky tryptophan 
residue or by a positively charged arginine residue. The resulting ten 
site-directed PA3911 mutant proteins were produced and purified analogously 
to the wild type protein (2.6.1.4, 2.6.3.3) and the integrity was tested by Thermal 
Shift Assays as described in chapter 2.7.8 (139). TM values between 67.5 and 
69 °C were determined for the wild type protein and the mutant variants and 
confirm their integrity. 
To study the lipid binding capability of all PA3911 mutant proteins in comparison 
to the wild type protein, they were simultaneously employed in protein-lipid 
overlay experiments using Membrane Lipid Strips™. In general, none of the 
analyzed mutant proteins showed a broadened lipid binding capacity under the 
tested conditions (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Excerpts of protein-lipid overlay assays depicting the PA binding of 
PA3911 mutant proteins 
Ten PA3911 mutant proteins were produced, purified and analyzed concerning their 
lipid binding capability analogously as the wild type protein (139). The classified spot 
intensities for PA binding (strong PA binding (++), reduced PA binding (+), no PA 
binding (-)) are indicated in the panels A and B for the tryptophan and arginine mutants, 
respectively. The brightness of all images was adjusted to obtain an identical 
background level as for the PA3911 wild type experiment (figure 25) using the 
Inkscape software. 
 
The analyses, depicted in figure 28, revealed the following differences for 
PA3911 mutant proteins with respect to the binding of PA: binding was not 
influenced for mutant proteins L56W, F95W and F95R when compared to the 
wild type protein. This might indicate that amino acid residue Phe95 is not 
involved in PA binding. For mutant proteins L58W, V69W and L114W reduced 
PA binding related to spot intensities was observed (figure 28 A). To some 
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extent, tryptophan might act as a substitute for the respective leucine or valine 
residues in the proposed binding pocket of PA3911. 
Substitution of the respective amino acids with arginine resulted in more 
pronounced effects. Significantly reduced PA binding for mutant proteins L56R 
and V69R was detected, whereas it was completely prevented for mutant 
proteins L58R and L114R (figure 28 B). From these findings it was concluded 
that amino acids Leu56, Leu58, Val69 and Leu114 are constituents of the 
proposed lipid binding pocket, whereof Leu58 and Leu114 are of prime 
importance for the binding of PA by protein PA3911. 
A similar modeling approach as employed in this study was performed to model 
the three-dimensional structure of the SCP-2 protein from the Oriental leafworm 
moth Spodoptera litura (251). Docking simulations were carried out using the 
structure model to identify putative amino acids involved in ligand binding. 
Subsequently, site-directed mutant proteins were tested for their binding activity 
to CS and palmitic acid. A complete loss of binding to CS and palmitic acid was 
observed for mutant protein F53W, whereas variant F53A was still able to bind 
to palmitic acid with a reduced activity. Besides this, mutant I115M showed 
enhanced CS binding activity, but could no longer bind to palmitic acid. These 
two amino acids of the SCP-2 protein from S. litura were, among others, 
identified as important for CS and/or palmitic acid binding and sequence 
comparison revealed that they are related to amino acids Leu58 and Leu114 of 
PA3911 which were identified as key residues for PA binding in this study. 
Only recently the three-dimensional structure of the SCP-2 protein from cotton 
bollworm was elucidated (252). The CS binding activity of this protein was 
analyzed using docking simulations and subsequent mutagenesis experiments. 
Amino acids Tyr51 and Phe53 were identified, inter alia, as key residues for the 
binding of CS. Sequence comparison (figure 26) and superposition of the 
PA3911 model clearly relates these SCP-2 residues to the lipid binding residues 
Leu56 and Leu58 of PA3911 which were identified in this study. 
To some extent, the differing specificity of PA3911 and SCP-2 proteins might be 
mediated via spatially conserved Cα positions (e.g. Leu56/Tyr51, Leu58/Phe53 
and Leu114/Ile115) in combination with varying hydrophobic side chains. 
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3.18 Comparative lipid analyses 
It was demonstrated that protein PA3911 is able to bind the lipid PA on 
Membrane Lipid Strips™ (3.16). Therefore, PA3911 function might be related to 
the phospholipid metabolism of P. aeruginosa with PA serving as a central hub 
metabolite. Accordingly, the cellular lipid composition of strain PW7609 was 
analyzed using well-established two-dimensional TLC according to Tindall 
(1990) (171) in combination with molybdatophosphoric acid, molybdenum blue 
and ninhydrin staining (2.8.2). The analyses were performed with cells 
cultivated under neutral conditions (pH 7.3) or under acidic conditions (pH 5.3) 
which allow for A-PG formation in P. aeruginosa. However, no differences in the 
cellular concentration of PE, PG, DPG and A-PG between the parental and the 
mutant strain were observed. 
Furthermore, alternative solvent systems for the specific PA separation from the 
major lipid classes using TLC techniques in combination with molybdenum blue 
staining were employed (2.8.2). In the one-dimensional TLC approach 
according to Vaden et al. (2005) (172) lipid separation was not sufficient to 
clearly identify PA in the respective P. aeruginosa sample. The two-dimensional 
TLC method described by Abramson and Blecher (1964) (173) allowed for 
significantly enhanced lipid separation. After molybdenum blue staining a PA 
spot was assigned by comparison to the migration characteristics of a reference 
sample. However, detected PA amounts were extremely low so that the reliable 
comparison of the wild type and the mutant strain was not possible. 
 
3.19 Phosphatidic acid quantification assay 
For the cellular PA content a relative ratio of 0.2-2% compared to the overall 
lipid content has been described in the literature (253, 254). Therefore, a more 
sophisticated methodology than lipid analyses by TLC and subsequent staining 
(3.18) was required to quantify the PA content in the parental and the mutant 
strain. A commercially available coupled enzymatic quantification assay (Cell 
Biolabs, San Diego, CA, USA) was used which allowed for the fluorometric 
determination of micromolar PA amounts. 
For analyses, cells of the P. aeruginosa strains MPAO1 and PW7609 were 
cultivated aerobically and anaerobically in AB minimal medium pH 7.3 
(supplemented with KNO3 for anaerobic growth) to the mid-logarithmic phase. 
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Identical amounts of the respective cells were harvested, washed and stored at 
-20 °C. The lipids were extracted and the PA quantification assay was 
performed according to the manufacturer’s instructions (2.8.3). PA that is 
present in the particular sample is initially hydrolyzed by a lipase yielding G3P 
and the respective fatty acids. Afterwards G3P is oxidized by a G3P oxidase 
resulting in the stoichiometric formation of dihydroxyacetone phosphate and 
hydrogen peroxide. The subsequent reaction of a fluorometric probe with 
hydrogen peroxide in the presence of a peroxidase results in a detectable 
fluorescence signal. To calculate the PA content of a particular sample the 
measured fluorescence value is compared to a PA calibration curve as depicted 
in figure 29. 
 
 
 
 
 
 
 
 
Figure 29: PA calibration curve 
To quantify the PA amount in the respective samples a PA calibration curve was 
prepared. Therefore, the PA standard (provided by the manufacturer) was diluted to 
defined concentrations in the range of 0-250 µM. These PA standard solutions were 
subsequently employed for the Total Phosphatidic Acid Assay according to the 
manufacturer’s instructions. A new calibration curve was prepared each time the assay 
was performed. For the coefficient of determination values of R² > 0.995 were obtained 
for all prepared calibration curves. 
 
For aerobically grown P. aeruginosa MPAO1 cells a PA content of 
4.2 ± 0.3 pmol per OD578 was determined. Compared to that, a decreased value 
of 2.6 ± 1.0 pmol per OD578 was obtained for the PA3911 mutant strain 
PW7609. Based on the findings of Magnowska (2010) (113) that PA3911 is the 
second-most significantly upregulated protein under anaerobic culture 
conditions, the cellular PA concentrations of anaerobically grown MPAO1 or 
PW7609 cultures with NO3
- as an alternative electron acceptor were quantified. 
For both strains a significantly decreased PA content compared to the 
aerobically grown cells was determined: 1.3 ± 0.4 or 1.5 ± 0.3 pmol per OD578 
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for the parental or mutant strain, respectively. 
These results show that there is no direct correlation between the PA3911 
content and the overall cellular PA amounts. Complex regulatory circuits for the 
lipid homeostasis of P. aeruginosa might be related to varying PA3911 protein 
concentrations, resulting in variations of the cellular PA status. With respect to 
this, PA3911 might be responsible for the short-term storage and/or the 
subsequent channeling of the lipophilic PA molecule within the framework of 
glycerophospholipid homeostasis. 
 
In the present study it was demonstrated that PA3911 is a specific PA binding 
protein (key residues Leu58 and Leu114) (3.16, 3.17), which can influence the 
overall PA content of the cell (3.19). In comparison to other polar 
glycerophospholipids the low-abundant PA is carrying a characteristically small, 
highly negatively charged head group (255). The cellular PA concentration 
might thus alter the charge characteristics, the fluidity and/or the permeability of 
the bacterial membrane (255–257). Biophysical studies could show that PA 
molecules favor a negative membrane curvature and tend to form 
microdomains (255). The local arrangement of specific glycerophospholipids 
was described to be essential for many membrane-associated processes, e.g. 
the localization of membrane proteins, the regulation of protein channels and/or 
the direct microdomain-antimicrobial interaction (258, 31). 
Such indirect effects might be also related to the increased twitching motility 
and impaired biofilm formation of the PA3911 mutant strain (3.13.4). In the 
literature analogous phenotypical effects were also described for P. aeruginosa 
in response to compounds from hosts, e.g. lactoferrin (259, 260), serum (261) 
or mucin (262), or due to the treatment with antimicrobial compounds like small 
cationic peptides (263, 264). However, the underlying molecular mechanisms 
are complex and not yet fully understood. 
PA serves as a key intermediate for the synthesis of neutral lipids (di- and 
triacylglycerols) and glycerophospholipids including inter alia PG, PE, PC, DPG 
and A-PG (265, 266). Sustaining the cellular PA concentration at low levels of 
~0.2-2% (253, 254) might be essential for the coordinated synthesis of 
phospholipids. At that point, the soluble PA binding protein PA3911 might 
contribute to PA homeostasis by its potential function as a short-term storage 
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and/or carrier of PA molecules. Figure 30 summarizes the main metabolic 
phospholipid pathways in P. aeruginosa and highlights the diverse physiological 
processes for which PA3911 function was demonstrated to be relevant. This 
includes for instance the antimicrobial susceptibility, resistance to acidic pH 
conditions, twitching motility and biofilm formation. Further work is required for 
the molecular understanding of PA3911-dependent physiological processes. 
 
 
Figure 30: Model of PA3911-dependent lipid homeostasis and the related 
physiological processes in P. aeruginosa 
Schematic representation of the biosynthetic pathway for glycerophospholipids starting 
from water soluble glycerol-3-phosphate (G3P) (6). The sn1-position of G3P is acylated 
by the glycerol-3-phosphate acyltransferase (PlsX/PlsY). The resulting phospholipid 
lysophosphatidic acid (LPA) is further acylated at the sn2-position by a LPA 
acyltransferase (PlsC) to produce phosphatidic acid (PA), a central hub metabolite of 
glycerophospholipid biosynthesis. PA is activated with cytidine triphosphate (CTP) to 
form cytidine diphosphate-diacylglycerol (CDP-DAG) by the enzyme CdsA. Multiple 
glycerophospholipids are produced from CDP-DAG: inter alia 
phosphatidylethanolamine (PE, by phosphatidylserine synthase/phosphatidylserine 
decarboxylase (PssA/Psd)), phosphatidylcholine (PC, by PC synthase (Pcs)) and 
phosphatidylglycerol (PG, by phosphatidylglycerol-phosphate synthase/ 
phosphatidylglycerol-phosphate phosphatase (PgsA/PgpA)). Condensation of two PG 
molecules allows for the formation of diphosphatidylglycerol (DPG) by the enzyme 
cardiolipin synthase (Cls). PG can be modified by aminoacylation. 
Alanyl-phosphatidylglycerol synthase (A-PGS) catalyzes the synthesis of A-PG (43). 
Cellular A-PG levels are tightly controlled by the alanyl-phosphatidylglycerol hydrolase 
(A-PGH) (49). PA can be recovered by virtue of phospholipase D (PLD). PA acts as a 
key precursor which specifically binds to the water soluble PA3911 protein (key 
residues Leu58 and Leu114 are highlighted). Sustaining a low cellular PA level might 
be essential for cellular lipid homeostasis. PA3911 function is relevant for 
P. aeruginosa antimicrobial susceptibility, resistance to acidic pH conditions, twitching 
motility and biofilm formation. CDNB, 1-chloro-2,4-dinitrobenzene. 
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4. Summary 
 
Adaptation of the bacterial membrane composition to changing environmental 
conditions represents an essential survival strategy. One mechanism is the 
modification of existing glycerophospholipids. Aminoacylation of 
phosphatidylglycerol (PG) with e.g. alanine or lysine is catalyzed in a 
transfer RNA (tRNA)-dependent reaction by aminoacyl-phosphatidylglycerol 
synthases (aaPGS) and results in increased resistance against several 
antimicrobial compounds. Accordingly, aaPGS inhibition was proposed as a 
promising strategy to restore bacterial susceptibility. In this context the 
interaction of the alanyl-phosphatidylglycerol synthase (A-PGS) from 
P. aeruginosa with the tRNA acceptor stem was analyzed and the key residues 
Lys676, Arg684 and Arg687 were identified. 
The protein alanyl-phosphatidylglycerol hydrolase (A-PGH) represents the 
A-PGS counterpart which contributes to the fine-tuning of the cellular 
alanyl-phosphatidylglycerol (A-PG) content in P. aeruginosa. To understand the 
molecular principles of A-PG hydrolysis, A-PGH protein crystals were analyzed 
by X-ray crystallography. The three-dimensional A-PGH structure of the 
N-terminal part (containing amino acids 34-215) was solved at a resolution of 
1.64 Å via single-wavelength anomalous dispersion phasing. Structure-based 
alignments related the N-terminal part of unknown function to hydrolases and 
esterases possessing an α/β fold. Alternatively, the sole C-terminal part of the 
A-PGH enzyme or mutants generated based on the Surface Entropy Reduction 
approach were employed for initial crystallization experiments. The A-PGH 
low-resolution structure was obtained by small-angle X-ray scattering. 
The operon encoding for A-PGS and A-PGH homologs is conserved in several 
Gram-negatives. For A. tumefaciens the respective related proteins LpiA or 
AcvB and VirJ were identified. An altered membrane lipid composition was 
detected in A. tumefaciens strains ΔlpiA or ΔacvB which is characterized by 
either the complete lack of lysyl-phosphatidylglycerol (L-PG) or elevated L-PG 
amounts. Accordingly, the L-PG hydrolyzing activity of the recombinantly 
produced and purified proteins AcvB and VirJ was demonstrated in vitro. Based 
on site-directed AcvB mutant proteins the catalytically relevant active site 
residues Ser336 and His433 were identified. Furthermore, a periplasmic 
localization of AcvB and VirJ in A. tumefaciens was shown. It was demonstrated 
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that functional AcvB protein is crucial for the translocation of transfer-DNA 
(T-DNA) during tumorigenesis and it is proposed that a fine-tuned cellular L-PG 
amount in the A. tumefaciens membrane might be important for T-DNA transfer 
via the type IV secretion system. 
Adaptation of P. aeruginosa to anaerobic biofilm conditions of the cystic fibrosis 
lung was analyzed in a recent proteomics study which identified the conserved 
uncharacterized protein PA3911 as the second-most significantly upregulated 
one. A P. aeruginosa PA3911 transposon mutant exhibited a growth phenotype 
under acidic conditions, an increased susceptibility to specific antimicrobial 
compounds, enhanced twitching motility and impaired biofilm formation when 
related to the wild type. A localization study identified PA3911 in the cytoplasm 
of P. aeruginosa. The PA3911 protein and mutant variants were recombinantly 
produced in E. coli, purified and subjected to in vitro studies. Under the 
employed conditions PA3911 was demonstrated to be a specific phosphatidic 
acid (PA) binding protein and key residues Leu58 and Leu114 for PA binding 
were identified. It is proposed that protein PA3911 might contribute to 
PA homeostasis in P. aeruginosa. 
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5. Outlook 
 
The following investigations are suggested for future experiments: 
 
 Elucidation of the three-dimensional structure of full-length A-PGH or 
alternatively the sole C-terminal part in the presence of a substrate 
molecule 
 
 Investigation of the detailed role of L-PG in T-DNA transfer of 
A. tumefaciens 
 Elucidation of the three-dimensional structure of AcvB and VirJ in the 
presence of a substrate molecule 
 Characterization of AcvB and VirJ substrate specificity 
 Identification of the catalytically relevant active site residues of VirJ 
 
 In vitro lipid binding assays for protein PA3911 in the presence of 
liposomes 
 Comparative MS-based lipidome analyses for the P. aeruginosa PA3911 
transposon mutant and the wild type strain 
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7. Appendix 
 
7.1  GPC analysis of protein A-PGHtrunc 
The relative molecular mass and oligomeric state of protein A-PGHtrunc were 
analyzed by analytical GPC as described in chapter 2.7.6 (135). The respective 
chromatogram indicating a monomeric protein with a relative molecular mass of 
28’000 is presented in figure 31. 
 
 
 
 
 
 
 
 
 
 
Figure 31: A-PGHtrunc elution profile of GPC analysis 
50 µl of a 9.8 mg/ml A-PGHtrunc sample was loaded onto a Superdex™ 200 Increase 
5/150 GL chromatography column. Protein elution was performed at a flow rate of 
0.45 ml/min with washing buffer A, simultaneously monitoring the absorption at 
280 nm. Employed standard proteins for calibration (data not shown): cytochrome c 
(Mr = 12’400), carbonic anhydrase (Mr = 29’000), BSA (Mr = 66’000), yeast alcohol 
dehydrogenase (Mr = 150’000) and β-amylase (Mr = 200’000).  
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7.2  Localization of AcvB and VirJ in A. tumefaciens – malate 
dehydrogenase activity assay 
Impurities of the periplasmic fractions with cytoplasmic proteins were detected 
via the MD activity assay performed as described in chapter 2.12.1.5 (142). A 
representative activity measurement with the isolated periplasmic and 
cytoplasmic fractions, indicating almost no impurities of cytoplasmic proteins in 
the periplasmic fractions, is shown in figure 32. 
 
 
 
 
 
 
 
 
 
 
Figure 32: MD activity assay using the isolated periplasmic and cytoplasmic 
fractions of the different localization strains. 
To determine the MD activity 50 µl of the respective periplasmic or cytoplasmic fraction 
was mixed with 500 µl of the test solution MD (50 mM HEPES-NaOH pH 7.2, 0.3 mM 
NADH). 25 µl of a 10 mM oxaloacetate solution were added and the absorption at a 
wavelength of 340 nm, corresponding to NADH+H+, was monitored (2.12.1.5). In the 
diagram the determined absorption at 340 nm was plotted against the time and it 
clearly shows a decrease of NADH+H+ in the cytoplasmic fractions of all localization 
strains, whereas no change in the NADH+H+ content is visible for the periplasmic 
fractions. In the adjacent legend the abbreviations P and C stand for the periplasmic 
and cytoplasmic fraction, respectively. 
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7.3 Sequence alignment of homologous proteins A-PGH, AcvB and VirJ 
The sequences of proteins A-PGH, AcvB and VirJ were aligned using Clustal 
Omega (2.15) and the alignment is presented in figure 33. 
 
 
 
Figure 33: Sequence alignment of proteins A-PGH, AcvB and VirJ 
The alignment was generated with Clustal Omega using the protein sequences A-PGH 
from P. aeruginosa PAO1, AcvB from A. tumefaciens C58 and VirJ from the 
octopine-type Ti-plasmid pTiA6 (2.15). The key catalytic serine and histidine residues 
are depicted in bold letters and amino acids mutated by site-directed mutagenesis are 
highlighted with a grey background. Conservation degrees are indicated: 
semi-conserved (.), conserved (:), identical (*). 
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